MiRNA for Treating Diseases and Conditions Associated with Neo-angiogenesis

ABSTRACT

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.

This application is a continuation of international applicationPCT/NL2012/050011, filed Jan. 10, 2012, which claims priority toEuropean application No. 11150645.7, filed Jan. 11, 2011, and U.S.provisional applications 61/431,656 and 61/431,667, filed Jan. 11, 2011,and 61/521/917 and 61/521,931, filed Aug. 10, 2011, and 61/522,346,filed Aug. 11, 2011, and 61/540,640, filed Sep. 29, 2011.

FIELD OF THE INVENTION

The invention relates to a diagnostic use of a miRNA molecule,equivalent or source thereof and therapeutic use of said miRNA molecule,equivalent or source thereof in diseases and conditions associated withneo-angiogenesis.

BACKGROUND OF THE INVENTION

Angiogenesis is defined as the growth of new microvessels out ofpre-existing capillaries. It may be distinguished from vasculogenesis,which refers to neovascularization during embryonal growth in which alsolarger vessels are formed and where endothelial precursor cells (EPCs)cells participate. However, there is evidence that EPCs can play a(minor) role in tumor angiogenesis as well. It can also be distinguishedfrom arteriogenesis which mainly involves the maturation and growth ofcollateral blood vessels (Asahara S. et al 1999, Carmeliet P. 2000, andHelisch A. et al 2003). Angiogenesis is the main mechanism by which newblood vessels are formed during physiological processes like woundhealing, inflammation, and the female reproductive cycle. In addition,angiogenesis is involved in various disorders including age-relatedmacular degeneration, rheumatoid arthritis, endometriosis, and cancer(Carmeliet P. et al 2005, and Griffioen A. W. et al 2000). A centuryago, it was observed that angiogenesis occurs around tumors and furtherresearch led to the hypothesis that tumors produce pro-angiogenesisfactors to stimulate neovascularisation (Carmeliet P. et al 2000,Folkman J. et al 1971). The importance of angiogenesis in tumor growthwas initially hypothesized in 1971, when Judah Folkman theorized thatsolid tumors possess limited resources that the many activelyproliferating cancer cells fight for. Ever since, tumor angiogenesisresearch has focused on understanding of and interfering with theprocesses by which tumor cells promote the growth of new blood vessels(Folkman J. et al 2007, and Ribatti D. et al 2000). The process of tumorangiogenesis is primarily activated when a growing tumor mass surpassesthe maximal volume that can be maintained by diffusion of oxygen andnutrients (Carmeliet P. 2000). The hypoxic environment will cause thetumor cells to undergo the angiogenic switch leading to increasedproduction of pro-angiogenesis proteins like the vascular endothelialgrowth factor (VEGF) (Folkman J. et al 1995, Folkman J. et al 2002, andHanahan D. et al 1996). These pro-angiogenic proteins activateendothelial cells in nearby vessels. At the same time, an increasedactivity of different proteolytic enzymes results in degradation of thebasal membrane and detachment of cell-cell contacts, which facilitatemigration and invasion of EC (endothelial cells) into the surroundingmatrix and towards the tumor (Carmeliet P. 2000, and Griffioen A. W. etal 2000). The proteolytic cleavage of the extracellular matrix alsoallows migration of the activated endothelial cells towards chemotacticsignals that originate from the tumor tissue. These signals are sensedby endothelial cells and the subsequent migration and proliferation ofendothelial cells results in the formation of vessel-like structures(Adams R. H. et al 2007, and Carmeliet P. 2000). Despite its irregularand disorganized structure, this network is capable of providing thegrowing tumor mass with all the required metabolites. In addition, thevascular bed provides the tumor cells with the opportunity to enter thecirculation and form distant metastases (Folkman J. et al, 2002). Whiledifferent cell types contribute to neovascularization, the endothelialcell is generally acknowledged to be the central player in theangiogenesis process. In response to different triggers, these cellsdisplay a variety of functions, including extracellular matrixremodeling, proliferation, and migration. All these functions requirethe expression of specific molecules, and proper execution of thiscomplex process relies on endothelial cell flexibility to readily adjustthe transcriptome and proteome to comply with the functional demands.Besides the more classical mechanisms, like regulation of gene promoteractivity and altered protein turn-over, it has now become evident thatcells also use small non-coding RNA molecules to govern gene expression.One class of these RNA molecules, microRNAs (miRNAs), acts as molecularswitches that can redirect the expression profile of a cell. Evidence isincreasing that these miRNAs fulfill an important role in endothelialgene expression regulation during tumor angiogenesis (Heusschen R, et al2010). Many miRNAs show organ-specific expression patterns suggestingcell type-specific functions (Chen C. Z. et al 2004, Poy M. N. et al2004, and van Rooij E. et al 2007). Consequently, dysregulation of miRNAexpression and function may lead to human diseases (Chang T. C. et al2007). The first large-scale analysis of miRNA expression in endothelialcells (ECs) was carried out in HUVECs (Human Umbilical Venal EndothelialCells) and identified 15 highly expressed miRNAs with receptors ofangiogenic factors (e.g. Flt-1, Nrp-2, Fgf-R, c-Met, and c-kit) asputative mRNA targets, according to prediction algorithms (Polisenol L.et al 2006). Additional studies also profiled the expression of miRNAsin ECs (Kuehbacher A. et al 2007, and Suarez Y. et al 2007). The highlyexpressed miRNAs that were common in at least 2 of the 3 studies,included miRNA-15b, -16, -20, -21, -23a, -23b, -24, -29a and -b, -31,-99a, -100, -103, -106, -125a, -125b, -126, -130a, -181a, -191, -221,-222, -320, let-7, let-7b, let-7c, and let-7d (Kuehbacher A. et al 2007,Polisenol L. et al 2006, and Suarez Y. et al 2007). However, theirspecific targets and functions in ECs related to angiogenesis have onlybeen characterized for a few of them.

A study showed that transfection of HUVECs with miRNA-221/222 inhibitstube formation, migration, and wound healing in response to stem cellfactor (Polisenol L. et al 2006). This and other studies suggest anantiangiogenic action for these miRNAs and they might be a potentialtool to block angiogenesis. However, it is important to note thatmiR221/222 can also promote cancer cell proliferation through theregulation of p27(Kip1) tumor suppressor (Le Sage C. et al 2007)indicating that the regulation of proliferation by these miRNAs appearscell type specific. Therefore, cell specific targeting with miRNAs is animportant area of investigation to be developed. Other miRNAs expressedin ECs, let-7f and miRNA-27b, have been shown to exert proangiogeniceffects, as revealed by the blockade of in vitro angiogenesis with2′-O-methyl oligonucleotides inhibitors (Kuehbacher A. et al 2007)although their targets in ECs have not yet been characterized.

The best-characterized EC-specific miRNA is miRNA-126 (Fish J. E. et al2008, Harris T. A. et al 2008, and Wang S. et al 2008). It promotesgrowth factor (VEGF/FGF Vascular Endothelial Growth Factor/FibroblastGrowth Factor) signaling, angiogenesis, and vascular integrity byinhibiting endogenous repressors of growth factors within ECs (Fish J.E. et al 2008, and Wang S. et al 2008). These findings illustrate that asingle miRNA can regulate vascular integrity and angiogenesis, providinga new target for either pro- or antiangiogenic therapies.

A very recent study (Anand S. et al 2010) concludes that miRNA-132 actsas an angiogenic switch by suppressing endothelial p120RasGAP (p120RasGTPase Activating Protein) expression, leading to Ras activation and theinduction of neovascularization, whereas the application of antimiRNA-132 inhibits neovascularization by maintaining vessels in theresting state.

Additionally, several other findings which are not described hereprovide proof-of-concept for miRNAs as a powerful and highly specificanti-angiogenic therapeutic modality.

There are currently several angiostatic compounds in the market and manyare in mid- and late stage clinical testing. Since approximately 5years, medication based on anti-angiogenesis (e.g. Avastin) has beenapproved for the clinic. More recently, small molecule RTKI's (ReceptorTyrosine Kinase Inhibitor) are used, e.g. Sunitinib. However, by theirnature—targeting essentially tumor driven processes—they evoke clinicalresistance. Although there is definitely some prolongation of survivalin patient cohorts for some cancer types, the benefit can be consideredmoderate. In addition to the cancer treatment, three anti-angiogenesistherapies are currently used for the treatment of patients with eyediseases such as wet age-related macular degeneration (AMD): pegaptanib(Macugen, Pfizer), ranibizumab (Lucentis, Novartis), and bevacizumab(Avastin, Roche). Here also, although there is definitely some visualacuity improvement, the benefit is still considered as limited.

Therefore, there is a clear need for better diagnostic markers forneo-angiogenesis, as well as better strategies of therapeuticangiogenesis inhibition.

DESCRIPTION OF THE INVENTION

The invention encompasses several uses of a miRNA molecule, equivalent,mimic, isomiR or antagomir or source thereof as identified herein. Theinvention also encompasses each of the newly identified miRNA moleculesequivalent, mimic, isomiR or antagomir per se.

In a first aspect, there is provided a miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule, an equivalent, mimic, isomiR, or asource thereof or a composition comprising said miRNA molecule miRNA-9,miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142, said equivalent or saidsource thereof, preferably for use as a medicament for preventing,treating, reverting, curing and/or delaying neo-angiogenesis or adisease or a condition associated with neo-angiogenesis. MicroRNAs(miRNAs) are small RNAs of 17-25 nucleotides, which function asregulators of gene expression in eukaryotes. miRNAs are initiallyexpressed in the nucleus as part of long primary transcripts calledprimary miRNAs (pri-miRNAs). Inside the nucleus, pri-miRNAs arepartially digested by the enzyme Drosha, to form 65-120 nucleotide-longhairpin precursor miRNAs (pre-miRNAs) that are exported to the cytoplasmfor further processing by Dicer into shorter, mature miRNAs, which arethe active molecules. In animals, these short RNAs comprise a 5′proximal “seed” region (nucleotides 2 to 8) which appears to be theprimary determinant of the pairing specificity of the miRNA to the 3′untranslated region (3′-UTR) of a target mRNA. A more detailedexplanation is given in the part dedicated to general definitions.

Each of the definitions given below concerning a miRNA molecule, a miRNAequivalent, a miRNA mimic or a miRNA isomiR, or a mimic or an isomiR ora miRNA source is to be used for each of the identified miRNAs or miRNAequivalent or miRNA sources of this application: miRNA-574, miRNA-7,miRNA-26b, miRNA-27a, miRNA-92a, miRNA-221, miRNA-222, miRNA-145,let7a1, miRNA-190b, miRNA-142, miRNA-9 and sources thereof. Preferredmature or mimic sequences (as identified in Table 5 as SEQ ID NO:22-52), seed sequences (as identified in Tables 5 and 7 as SEQ ID NO:348-378, 61-115 and 379-381), isomiR sequences (as identified in Table 7as SEQ ID NO: 116-304 and 382-396) or source sequences (as identified inTables 4 (RNA precursor as SEQ ID NO: 1-21) or 6 (DNA encoding a RNAprecursor as SEQ ID NO: 53-60)) of said miRNA molecule or equivalentthereof respectively are identified in corresponding tables.

Within the whole text of the application unless otherwise indicated, amiRNA may also be named a miRNA molecule, a miR, or an equivalentthereof or a source or a precursor thereof. A preferred equivalent is anisomiR or a mimic. Each sequence identified herein may be identified asbeing SEQ ID NO as used in the text of the application or ascorresponding SEQ ID NO in the sequence listing.

MiRNA-132, miRNA-126 and miRNA-21 are also referred to in the presentinvention. They are the only miRNA molecules of this invention whoseexpression is not to be up-regulated/over-expressed/increased and/orwhose activity is not to be increased in order to be used in therapeuticapplications as identified herein. In contrast, the endogenousexpression of these miRNA molecules needs to be down-regulated/decreasedand/or an activity of such miRNA molecule needs to be decreased orreduced or inhibited to obtain a therapeutically desirable effect. Thisis preferably carried out as explained later herein using an antagomir.Therefore, in the invention when reference is made to any of these miRNAmolecules in a therapeutic use, one always refers to a use of anantagomir of a miRNA-132, miRNA-126 or miRNA-21 molecule or of anequivalent of an antagomir of these miRNAs or a source of an antagomirof these miRNAs. Accordingly, when one refers to an antagomir, onealways refers to a use of an antagomir of a miRNA-132, miRNA-126 andmiRNA-21 molecule or an equivalent or a source thereof as indicatedherein. Each of the definitions given herein concerning a miRNA moleculeor a miRNA equivalent or a miRNA source may also apply for any of themiRNA molecule to be used as an antagomir as identified in thisparagraph. Each definition given herein concerning q given antagomir ofa miRNA molecule also holds for other antagomir of a distinct miRNAmolecule, each as defined herein.

In the context of the invention, a miRNA molecule or an equivalent or amimic or an antagomir or an isomiR thereof may be a synthetic or naturalor recombinant or mature or part of a mature miRNA or a human miRNA orderived from a human miRNA as further defined in the part dedicated tothe general definitions. A human miRNA molecule is a miRNA moleculewhich is found in a human cell, tissue, organ or body fluids (i.e.endogenous human miRNA molecule). A human miRNA molecule may also be ahuman miRNA molecule derived from an endogenous human miRNA molecule bysubstitution, deletion and/or addition of a nucleotide. A miRNA moleculeor an equivalent or a mimic or an antagomir thereof may be a singlestranded or double stranded RNA molecule.

Preferably a miRNA molecule or an equivalent, or a mimic thereof is from6 to 30 nucleotides in length, preferably 12 to 30 nucleotides inlength, preferably 15 to 28 nucleotides in length, more preferably saidmolecule has a length of at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotidesor more.

Preferably an antagomir of a miRNA molecule is from 8 to 30 nucleotidesin length, preferably 10 to 30 nucleotides in length, preferably 12 to28 nucleotides in length, more preferably said molecule has a length ofat least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, 30 nucleotides or more.

In a preferred embodiment, a miRNA molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence of said miRNA molecule or equivalent or mimic or isomiRthereof (Tables 5 and 7 show preferred seed sequence of each of themiRNAs molecule identified herein as SEQ ID NO: 348-378, 61-115 and379-381). Preferably in this embodiment, a miRNA molecule or anequivalent or a mimic or isomiR thereof is from 6 to 30 nucleotides inlength and more preferably comprises at least 6 of the 7 nucleotidespresent in the seed sequence of said miRNA molecule or equivalentthereof. Even more preferably a miRNA molecule or an equivalent or amimic or isomiR thereof is from 15 to 28 nucleotides in length and morepreferably comprises at least 6 of the 7 nucleotides present in the seedsequence, even more preferably a miRNA molecule has a length of at least6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30 nucleotides or more.

Accordingly a preferred miRNA-574 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 353, 354, 78, 79, 80, 82, 83,and/or 84 and more preferably has a length of at least 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30 nucleotides or more.

Accordingly a preferred miRNA-7 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 348, 349, 350, 62, 63, 64, 65,66, 67, 68, 69, 71, 72, 73, and/or 74 and more preferably has a lengthof at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides or more.

Accordingly a preferred miRNA-190b molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 374 and/or 96 and more preferablyhas a length of at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides or more.

Accordingly a preferred miRNA-142 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 375, 376, 97, 99, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, and/or 110 and more preferably has alength of at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides or more.

Accordingly a preferred miRNA-9 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 377, 378, 114, 115, 379, 380and/or 381 and more preferably has a length of at least 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30 nucleotides or more.

In a more preferred embodiment, a miRNA-9 molecule or equivalent ormimic or isomiR thereof is identified as a miRNA-9* molecule orequivalent or mimic or isomiR thereof and comprises at least 6 of the 7nucleotides present in the seed sequence identified as SEQ ID NO: 378,114 and/or 115 and more preferably has a length of at least 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30 nucleotides or more.

In another preferred embodiment, a miRNA molecule or an equivalent ormimic or isomiR thereof comprises at least 6 of the 7 nucleotidespresent in a given seed sequence as identified in Tables 5 and 7 as SEQID NO: 348-378, 61-115 and 379-381 and has at least 70% identity overthe whole mature sequence as identified in Table 5 (Table 5 showspreferred mature or mimic sequences of each of the miRNAs identifiedherein as SEQ ID NO: 22-52). Preferably, identity is at least 75%, 80%,85%, 90%, 95%, 97%, 98%, 99% or 100%.

Accordingly a preferred miRNA-574 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 353, 354, 78, 79, 80, 82, 83,and/or 84 and/or has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%,99% or 100% identity over SEQ ID NO: 27, 28, 181, 182, 183, 184, 185,186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199,200, 201, 202, 203, 204 and/or 205.

Accordingly a preferred miRNA-7 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 348, 349, 350, 62, 63, 64, 65,66, 67, 68, 69, 71, 72, 73 and/or 74 and/or has at least 70%, 75%, 80%,85%, 90%, 95%, 97%, 98%, 99% or 100% identity over SEQ ID NO: 22, 23,24, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128,129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142,143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156,157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170,171, 172, 173, 174, 175, 176, and/or 177.

Accordingly a preferred miRNA-190b molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 374 and/or 96 and/or has at least70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity over SEQ IDNO: 48, 234, 235, 236, 237, 238, 239 and/or 240.

Accordingly a preferred miRNA-142 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 375, 376, 97, 99, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, and/or 110 and/or has at least 70%,75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity over SEQ ID NO:49, 50, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253,254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267,268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281,282, 283, 284, 285, 286, 287, 288 and/or 289.

Accordingly a preferred miRNA-9 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 377, 378, 114, 115, 379, 380and/or 381 has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or100% identity over SEQ ID NO: 51, 52, 290, 291, 291, 293, 294, 295, 296,297, 298, 299, 300, 301, 302, 303, 304, 382, 383, 384, 385, 386, 387,388, 389, 390, 391, 392, 393, 394, 395 and/or 396.

In a more preferred embodiment, a miRNA-9 molecule or equivalent ormimic or isomiR thereof is identified as a miRNA-9* molecule orequivalent or mimic or isomiR thereof and comprises at least 6 of the 7nucleotides present in the seed sequence identified as SEQ ID NO: 378,114 and/or 115 has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%or 100% identity over SEQ ID NO: 52, 293, 294, 295, 296, 297, 298, 299,300, 301, 302, 303 and/or 304.

Preferably in this embodiment, a miRNA molecule or an equivalent or amimic or an isomiR thereof has a length of at least 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,30 nucleotides or more, comprises at least 6 of the 7 nucleotidespresent in a given seed sequence as identified in Tables 5 and 7 as SEQID NO: 348-378, 61-115 and 379-381 and has at least 70% identity overthe whole mature sequence as identified in Table 5 as SEQ ID NO: 22-52.Preferably, identity is at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%or 100%.

Alternatively, preferably in this embodiment, a miRNA molecule or anequivalent or a mimic or an isomiR thereof has a length of not more than6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40nucleotides, comprises at least 6 of the 7 nucleotides present in agiven seed sequence as identified in Tables 5 and 7 as SEQ ID NO:348-378, 61-115 and 379-381 and has at least 70% identity over the wholemature sequence as identified in Table 5 as SEQ ID NO: 22-52.Preferably, identity is at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%or 100%.

In another preferred embodiment, an isomiR of a miRNA molecule has atleast 70% identity over the whole isomiR sequence (Table 7 showspreferred isomiR of each of the mature miRNAs identified as SEQ ID NO:116-304 and 382-396. Preferably, identity is at least 75%, 80%, 85%,90%, 95% or higher. Preferably in this embodiment, an isomiR of a miRNAmolecule or an equivalent or a mimic thereof has a length of at least 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30 nucleotides or more.

Accordingly a preferred miRNA-574 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 353, 354, 78, 79, 80, 82, 83,and/or 84 and/or has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%,99% or 100% identity over SEQ ID NO: 27, 28, 181, 182, 183, 184, 185,186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199,200, 201, 202, 203, 204 and/or 205 and/or has a length of at least 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleotidesor more.

Accordingly a preferred miRNA-7 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 348, 349, 350, 62, 63, 64, 65,66, 67, 68, 69, 71, 72, 73 and/or 74 and/or has at least 70%, 75%, 80%,85%, 90%, 95%, 97%, 98%, 99% or 100% identity over SEQ ID NO: 22, 23,24, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128,129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142,143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156,157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170,171, 172, 173, 174, 175, 176 and/or 177 and/or has a length of at least6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40nucleotides or more.

Accordingly a preferred miRNA-190b molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 374 and/or 96 and/or has at least70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity over SEQ IDNO: 48, 234, 235, 236, 237, 238, 239 and/or 240 and/or has a length ofat least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40nucleotides or more.

Accordingly a preferred miRNA-142 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 375, 376, 97, 99, 100, 101, 102,103, 104, 105, 106, 107, 108, 109 and/or 110 and/or has at least 70%,75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity over SEQ ID NO:49, 50, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253,254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267,268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281,282, 283, 284, 285, 286, 287, 288 and/or 289 and/or has a length of atleast 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40nucleotides or more.

Accordingly a preferred miRNA-9 molecule or equivalent or mimic orisomiR thereof comprises at least 6 of the 7 nucleotides present in theseed sequence identified as SEQ ID NO: 377, 378, 114, 115, 379, 380and/or 381 has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or100% identity over SEQ ID NO: 51, 52, 290, 291, 292, 293, 294, 295, 296,297, 298, 299, 300, 301, 302, 303, 304, 382, 383, 384, 385, 386, 387,388, 389, 390, 391, 392, 393, 394, 395 and/or 396 and/or has a length ofat least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40nucleotides or more.

In a more preferred embodiment, a miRNA-9 molecule or equivalent ormimic or isomiR thereof is identified as a miRNA-9* molecule orequivalent or mimic or isomiR thereof and comprises at least 6 of the 7nucleotides present in the seed sequence identified as SEQ ID NO: 378,114 and/or 115 has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%or 100% identity over SEQ ID NO: 52, 293, 294, 295, 296, 297, 298, 299,300, 301, 302, 303 and/or 304 and/or has a length of at least 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleotides ormore.

Another preferred miRNA molecule or equivalent or mimic or an isomiRthereof has at least 60% identity with a seed sequence (as identified inTables 5 and 7 as SEQ ID NO: 348-378, 61-115 and 379-381 or with amature sequence (as identified in Table 5 as SEQ ID NO: 22-52 or with aprecursor sequence (as identified in Table 4 as SEQ ID NO: 1-21 or witha DNA encoding an RNA precursor (as identified in Table 6 as SEQ ID NO:53-60 or with an isomiR sequence (as identified in Table 7 as SEQ ID NO:116-304 and 382-396. Identity may be at least 65%, 70%, 75%, 80%, 85%,90%, 95%, 99% or 100%. Identity is preferably assessed on the whole SEQID NO as identified in a given table. However, identity may also beassessed on part of a given SEQ ID NO. Part may mean at least 50% of thelength of the SEQ ID NO, at least 60%, at least 70%, at least 80%, atleast 90% or 100%.

An equivalent of a miRNA molecule may be an isomiR or a mimic. Aprecursor sequence may result in more than one isomiR sequencesdepending on the maturation process (see for example miRNA-26b,miRNA-132, miRNA-126, or miRNA-142 wherein certain tissues multipleisomiRs have been identified (Table 7). A mimic is a molecule which hasa similar or identical activity with a miRNA molecule. In this context asimilar activity is given the same meaning as an acceptable level of anactivity. A mimic is, in a functional determination, opposed to anantagomir. An antagomir of a miRNA molecule or equivalent or sourcethereof is therefore a molecule which has an activity which is oppositeor reverse to the one of the corresponding miRNA molecule it derivesfrom. An antagomir of a miRNA molecule or equivalent thereof may also bedefined as a molecule which is able to antagonize or silence or decreasean activity of said miRNA molecule or equivalent thereof. An activitywhich is opposite or reverse to the one of the corresponding miRNAmolecule it derives from or an activity which is able to antagonize anactivity of said miRNA molecule it derives from is preferably anactivity which is able to decrease an activity of said miRNA molecule,equivalent or source thereof. In this context, decrease means at least5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95° A or 100% decreaseof the activity of said miRNA molecule or equivalent or source thereof.

An antagomir of a miRNA molecule or equivalent or source thereof may bea nucleic acid, preferably a RNA which is complementary to a part of thecorresponding miRNA molecule or equivalent thereof. Preferred antagomirare complementary to a part of sequences of mature miRNAs or isomiRidentified in Table 5 as SEQ ID NO: 22-52 or Table 7 as SEQ ID NO:116-304 and 382-396. A part may mean at least 50% of the length of theSEQ ID NO, at least 60%, at least 70%, at least 80%, at least 90% or100%. In a preferred embodiment; an antagomir or an equivalent thereofis complementary to a seed sequence or a part of said seed sequence of amiRNA molecule or equivalent thereof A part may mean at least 50% of thelength of the seed sequence, at least 60%, at least 70%, at least 80%,at least 90% or 100%.

Preferably, an antagomir is from 8 to 30 nucleotides in length,preferably 10 to 30 nucleotides in length, preferably 12 to 28nucleotides in length, more preferably said molecule has a length of atleast 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30 nucleotides or more and is complementary to apart of sequences of mature miRNAs or isomiR identified in Table 5 (asSEQ ID NO: 22-52) or Table 7 (as SEQ ID NO: 116-304 and 382-396). A partmay mean at least 50% of the length of a given sequence, at least 60%,at least 70%, at least 80%, at least 90% or 100%.

Preferably, an antagomir is from 8 to 30 nucleotides in length,preferably 10 to 30 nucleotides in length, preferably 12 to 28nucleotides in length, more preferably said molecule has a length of atleast 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30 nucleotides or more and is complementary to apart of a seed sequence (as identified in Tables 5 and 7 as SEQ ID NO:348-378, 61-115 and 379-381). A part may mean at least 50% of the lengthof the seed sequence, at least 60%, at least 70%, at least 80%, at least90% or 100%.

Preferably an antagomir or equivalent thereof has at least 60% identitywith an antagomir sequence (as identified in Table 8 as SEQ ID NO:305-310). Identity may be at least 65%, 70%, 75%, 80%, 85%, 90%, 95%,99% or 100%. Identity is preferably assessed on the whole SEQ ID NO asidentified in Table 8. However, identity may also be assessed on a partof a given SEQ ID NO. A part may mean at least 50% of the length of theSEQ ID NO, at least 60%, at least 70%, at least 80%, at least 90% or100%.

Preferably, an antagomir is from 8 to 30 nucleotides in length,preferably 12 to 28 nucleotides in length, more preferably said moleculehas a length of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides or more and hasat least 60% identity with an antagomir sequence (as identified in Table8 as SEQ ID NO: 305-310). Identity may be at least 65%, 70%, 75%, 80%,85%, 90%, 95%, 99% or 100%. Identity is preferably assessed on the wholeSEQ ID NO as identified in Table 8. However, identity may also beassessed on a part of a given SEQ ID NO. A part may mean at least 50% ofthe length of the SEQ ID NO, at least 60%, at least 70%, at least 80%,at least 90% or 100%.

The chemical structure of the nucleotides of an antagomir of a miRNAmolecule or equivalent or source thereof may be modified to increasestability, binding affinity and/or specificity. Said antagomir maycomprise or consists of a RNA molecule or preferably a modified RNAmolecule. A preferred modified RNA molecule comprises a modified sugar.One example of such modification is the introduction of a 2′-O-methyl or2′-O-methoxyethyl group or 2′ fluoride group on the nucleic acid toimprove nuclease resistance and binding affinity to RNA. Another exampleof such modification is the introduction of a methylene bridgeconnecting the 2′-O atom and the 4′-C atom of the nucleic acid to lockthe conformation (Locked Nucleic Acid (LNA)) to improve affinity towardscomplementary single-stranded RNA. A third example is the introductionof a phosphorothioate group as linker between nucleic acid in theRNA-strand to improve stability against a nuclease attack. A fourthmodification is conjugation of a lipophilic moiety on the 3′ end of themolecule, such as cholesterol to improve stability and cellulardelivery. In a preferred embodiment, an antagomir of miRNA moleculeconsists of a fully LNA-modified phosphorotioate oligonucleotide, termedtiny LNA as described in Obad et al. An antagomir as defined herein maycomprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more sugar modifications. Itis also encompassed by the invention to introduce more than one distinctsugar modification in one antagomir.

Each of the miRNA molecules or equivalents or mimics or isomiRs thereofas identified herein has an acceptable level of an activity of a givenmiRNA they derive from. An acceptable level of an activity is preferablythat said miRNA or equivalent or mimics or isomiRs thereof is still ableto exhibit an acceptable level of said activity of said miRNA. Anactivity of a given miRNA or an equivalent thereof is for example theability to exhibit a detectable anti-angiogenesis activity and/or inducea decrease of neo-angiogenesis as later defined herein. An acceptablelevel of an activity is preferably at least 30%, 40%, 50%, 60%, 70%,80%, 90%, 95% or 100% of the activity of the miRNA they derive from.

A preferred activity of any of the miRNA molecule or equivalent orisomiR or mimic thereof as identified herein (i.e. miRNA-574, miRNA-7,miRNA-26b, miRNA-27a, miRNA-92a, miRNA-221, miRNA-222, miRNA-145,let7a1, miRNA-190b, miRNA-142, miRNA-9) is to exhibit a detectableanti-angiogenesis activity and/or induce a decrease of neo-angiogenesisin a subject as later defined herein.

A preferred activity of any of the antagomir miRNA molecule orequivalent or source thereof as identified herein (i.e. antagomir ofmiRNA-132, miRNA-126 and miRNA-21) is to exhibit a detectableanti-angiogenesis activity and/or induce a decrease of neo-angiogenesisin a subject as later defined herein.

A source of a miRNA molecule or a source of an equivalent of a miRNAmolecule, mimic, isomiR may be any molecule which is able to induce theproduction of a miRNA molecule or of an equivalent thereof such as amimic or isomiR as identified herein and which comprises a hairpin-likestructure and/or a double stranded nucleic acid molecule. The presenceof a hairpin-like structure, may be assessed using the RNAshapes program(Steffen P. et al 2006) using sliding windows of 80, 100 and 120 nt ormore. The hairpin-like structure is usually present in a natural orendogenous source of a miRNA molecule whereas a double-stranded nucleicacid molecule is usually present in a recombinant or synthetic source ofa miRNA molecule or of an equivalent thereof.

A source of an antagomir of a miRNA molecule or a source of anequivalent of an antagomir of a miRNA molecule may be any molecule whichis able to induce the production of said antagomir.

A source of a miRNA molecule or of an equivalent or a mimic or an isomiRor an antagomir thereof may be a single stranded, a double stranded RNAor a partially double stranded RNA or may comprise three strands, anexample of which is described in WO2008/10558. As used herein partiallydouble stranded refers to double stranded structures that also comprisesingle stranded structures at the 5′ and/or at the 3′ end. It may occurwhen each strand of a miRNA molecule does not have the same length. Ingeneral, such partial double stranded miRNA molecule may have less than75% double stranded structure and more than 25% single strandedstructure, or less than 50% double stranded structure and more than 50%single stranded structure, or more preferably less than 25%, 20% or 15%double stranded structure and more than 75%, 80%, 85% single strandedstructure.

Alternatively, a source of a miRNA molecule or of an equivalent or amimic or an isomiR thereof is a DNA molecule encoding a precursor of amiRNA molecule or of an equivalent or a mimic or an isomiR thereof.Preferred DNA molecules in this context are identified in Table 6 as SEQID NO: 53-60. The invention encompasses the use of a DNA moleculeencoding a precursor of a miRNA molecule that has at least 70% identitywith said sequence as identified in Table 6. Preferably, the identity isat least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%. Preferably inthis embodiment, a DNA molecule has a length of at least 50, 55, 60, 70,75, 80, 85, 90, 95, 100, 130, 150, 200, 250, 300, 350, 400 nucleotidesor more and has at least 70% identity with a DNA sequence as identifiedin Table 6 as SEQ ID NO: 53-60.

The induction of the production of a given miRNA molecule or of anequivalent thereof or of a mimic or an isomiR or of an antagomiR thereofis preferably obtained when said source is introduced into a cell usingone assay as defined below. Cells encompassed by the present inventionare later on defined.

A preferred source of a miRNA molecule or of an equivalent thereof or ofa mimic or an isomiR thereof is a precursor thereof, more preferably anucleic acid encoding said miRNA molecule or an equivalent thereof or ofa mimic or an isomiR thereof A preferred precursor is anaturally-occurring precursor. A precursor may be a synthetic orrecombinant precursor.

A preferred precursor of a given miRNA molecule is identified in Table 4as SEQ ID NO: 1-21. The invention encompasses the use of a precursor ofa miRNA molecule or of an equivalent thereof that has at least 70%identity with said sequence. Preferably, identity is at least 75%, 80%,85%, 90%, 95%, 97%, 98%, 99% or 100%. Preferably in this embodiment, aDNA molecule has a length of at least 50, 55, 60, 70, 75, 80, 85, 90,95, 100, 130, 150, 200, 250, 300, 350, 400 nucleotides or more and hasat least 70% identity with a sequence as identified in Table 4 as SEQ IDNO: 1-21.

Accordingly, a preferred source of a miRNA-574 molecule has at least70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity with SEQ IDNO: 5 and/or 55 and/or has a length of at least 50, 55, 60, 70, 75, 80,85, 90, 95, 100, 130, 150, 200, 250, 300, 350, 400 nucleotides or more.

Accordingly, a preferred source of a miRNA-7 molecule has at least 70%,75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity with SEQ ID NO:1, 2, 3 and/or 53 and/or has a length of at least 50, 55, 60, 70, 75,80, 85, 90, 95, 100, 130, 150, 200, 250, 300, 350, 400 nucleotides ormore.

Accordingly, a preferred source of a miRNA-190b molecule has at least70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity with SEQ IDNO: 17 and/or 58 and/or has a length of at least 50, 55, 60, 70, 75, 80,85, 90, 95, 100, 130, 150, 200, 250, 300, 350, 400 nucleotides or more.

Accordingly, a preferred source of a miRNA-142 molecule has at least70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity with SEQ IDNO: 18 and/or 59 and/or has a length of at least 50, 55, 60, 70, 75, 80,85, 90, 95, 100, 130, 150, 200, 250, 300, 350, 400 nucleotides or more.

Accordingly, a preferred source of a miRNA-9 molecule has at least 70%,75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identity with SEQ ID NO:19, 20, 21, and/or 60 and/or has a length of at least 50, 55, 60, 70,75, 80, 85, 90, 95, 100, 130, 150, 200, 250, 300, 350, 400 nucleotidesor more.

In this context, it is pointed that several precursors of a given maturemiRNA molecule may lead to an identical miRNA molecule. For example,miRNA-7 may originate from precursor miRNA-7-1, mi-RNA7-2 or miRNA-7-3(preferably identified as being SEQ ID NO: 1, 2 or 3). In a preferredembodiment, a miRNA-7-3 or a molecule having at least 70%, 75%, 80%,85%, 90%, 95%, 97%, 98%, 99% or 100% identity with miRNA-7-3 or SEQ IDNO:3 is used as a precursor of a miRNA-7 molecule. Preferred sources orprecursors have been defined later herein. A preferred source includesor comprises an expression construct comprising a nucleic acid, i.e. DNAencoding said precursor of said miRNA, more preferably said expressionconstruct is a viral gene therapy vector selected from gene therapyvectors based on an adenovirus, an adeno-associated virus (AAV), aherpes virus, a pox virus and a retrovirus. A preferred viral genetherapy vector is an AAV or Lentiviral vector. Other preferred vectorsare oncolytic viral vectors. Such vectors are further described hereinbelow. Alternatively, a source may be a synthetic miRNA molecule or achemical mimic as further defined in the part dedicated to generaldefinitions.

The detection of the presence of a miRNA molecule or of an equivalentthereof such as a mimic or an isomiR or the presence of an antagomir ofa miRNA molecule or equivalent thereof may be carried out using anytechnique known to the skilled person. The assessment of the expressionlevel or of the presence of such molecule is preferably performed usingclassical molecular biology techniques such as (real time PolymeraseChain Reaction) qPCR, microarrays, bead arrays, RNAse protectionanalysis or Northern blot analysis or cloning and sequencing. Theskilled person will understand that alternatively or in combination withthe quantification of a miRNA molecule or of an equivalent thereof, thequantification of a substrate of a corresponding miRNA molecule or of anequivalent thereof of any compound known to be associated with afunction of said miRNA molecule or of said equivalent thereof or thequantification of a function or activity of said miRNA molecule or ofsaid equivalent thereof using a specific assay is encompassed within thescope of the invention. The same holds for an antagomir of a miRNAmolecule.

Preferred compositions and formulations are all defined later herein. AmiRNA molecule or an equivalent thereof or a mimic or an isomiR or anantagomir thereof may be used as such as a naked molecule, with orwithout chemical modifications, or encapsulated into a particle orconjugated to a moiety. A preferred composition comprises a miRNAmolecule or an equivalent thereof or a mimic or an isomiR or anantagomir thereof encapsulated into a nanoparticle or a liposomalstructure. A miRNA molecule or equivalent thereof or a mimic or anisomiR or an antagomir thereof may be an aptamer-miRNA hybrid. Anaptamer-miRNA is defined as a miRNA linked to an RNA (or DNA)oligonucleotide, the latter adopting a conformation that targets theaptamer-miRNA hybrid molecule to a cell-surface protein (e.g. cyclic RGDpeptide (cyclic arginine(R)-glycine(G)-aspartic acid(D) peptide). Theaptamer-tagged miRNA can be linked to e.g. polyethylene glycol, whichincreases the chimera's circulating half-life (Dassie, J. P., et al.2009).

An activity of a given miRNA or an equivalent thereof such as a mimic,isomiR or a corresponding source thereof or an activity of a givenantagomir of a miRNA molecule or an equivalent thereof or acorresponding source thereof all as defined herein is preferably theability to exhibit a detectable anti-angiogenesis activity and/or inducea decrease of neo-angiogenesis. Within the context of the invention, ananti-angiogenic activity may comprise or comprises at least one of thefollowing:

-   -   Reduction or decrease of neo-angiogenesis,    -   Normalization of vessels and    -   Reduce number of vessels in the pathogenic area.

Exhibiting such a detectable anti-angiogenesis activity and/or inducingsuch a reduction or decrease of neo-angiogenesis is crucial in thepresent invention in order to be able to prevent, delay, cure and/ortreat neo-angiogenesis and/or any disease or condition associated withneo-angiogenesis. Any disease or condition wherein neo-angiogenesis isinvolved or associated may be prevented, delayed, cured and/or treatedwith a molecule as defined herein. In a disease or condition of theinvention, neo-angiogenesis may be detectable before the onset of thedisease or condition i.e. before the appearance of a symptom of saiddisease or condition. It is further encompassed by the present inventionthat neo-angiogenesis is detectable during the development of saiddisease or condition, i.e. after the apparition of a symptom of saiddisease or condition. Angiogenesis is defined as the growth of newmicrovessels out of pre-existing capillaries. It may be distinguishedfrom vasculogenesis, which refers to neovascularization during embryonalgrowth in which also larger vessels are formed and where EPCs cellsparticipate. However, there is evidence that EPCs can play a role intumor angiogenesis as well. It can also be distinguished fromarteriogenesis which mainly involves the maturation and growth ofcollateral blood vessels (Asahara S. et al 1999, Carmeliet P. 2000, andHelisch A. et al 2003). Angiogenesis is the main mechanism by which newblood vessels are formed during physiological processes like woundhealing, inflammation, and the female reproductive cycle. In the contextof the invention, neo-angiogenesis is defined as angiogenesis when it isinvolved in a disease or condition which is not physiological or ispathological.

Neo-angiogenesis may be detected using any technique known to theskilled person. Neo-angiogenesis may be assessed in situ in a patient orin a tumor by non-invasive techniques such as PET (Positron emissiontomography), MRI (Magnetic Resonance Imaging) (Dynamic ContrastEnhanced, DCE-MRI) or CT (Computer Tomography) imaging. These techniquesmay be used to monitor tumor burden, based on increased leakage of thevasculature in tumors. Using MRI or PET, you could follow the presenceof angiogenesis markers such as a5β3-integrin, plasma VEGF or bFGF.

Alternatively neo-angiogenesis may be assessed using a tumor biopsy orsection and subsequent immune-histochemical analyses on endothelialcells to assess their activity and compare it to the activity of normalendothelial cells from a healthy subject or from endothelial cells fromthe patient but isolated at a different place in the body. Suchimmune-histochemical analyses may be done using pan-endothelial cellantibodies such as anti-CD31 and anti-CD34 to assess microvesseldensity. Tissue sections could be stained with markers for endothelialcells, combined with proliferation markers, to explore the ratio betweentumor endothelial cells and tumor proliferating cells in the tissue. Anexample of an endothelial marker is CD31 or CD34. An example of aproliferation marker is Ki67. Ki-67 is an excellent marker to determinethe growth fraction of a given cell population.

The fraction of Ki-67-positive tumor cells (the Ki-67 labelling index)is often correlated with the clinical course of cancer. The microvesseldensity (MVD) is preferably assessed in a tumor section as in example 13(FIG. 13) stained with an anti-CD31 and using the intensity of thestaining to quantify MVD.

Quantification of MVD is preferably done by counting the positivelystained luminal structures in four to five representative images pertumor section. A decrease, preferably a significant decrease of the MVDassessed in at least four to five representative images per tumorsection is preferably seen as in indication that the moleculeadministered has an anti-angiogenesis activity or is able to induce adecrease of neo-angiogenesis.

Neo-angiogenesis may also be assessed using cells, preferablyendothelial cells from a tumor, a healthy subject or endothelial celllines. Endothelial cells from a tumor are preferably designated as tumorendothelium. Tumor endothelium may be isolated by FACS (FluoresenceActivated Cell Sorting) of tumor tissue using CD31 as an endothelialmarker. This could be carried out as described in van Beijnum et al2008. Preferred endothelial cell to assess neo-angiogenesis in vitro areHUVEC and RF24 as used in the experimental part. The assessment ofneo-angiogenesis activity in vitro may be carried out using a MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)assay: assessment of the proliferative activity of endothelial cells.Preferably the MTS assay is carried out and results of this MTS assayare analyzed as described in the experimental part. However, otherviability assays known to the skilled person may be used such as MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), CrystalViolet and WST-1 (Water Soluble Tetrazolium).

In addition, other types of assays could be used such as spheroidsprouting assay and matrigel tube formation assay as second lineactivity assays. In the matrigel tube formation assay, cells, especiallyendothelial cells, are seeded on a synthetic semi-natural gel matrix(such as Matrigel from BD Biosciencesor collagen-gel, in some casesfibrin gels). In both assays, endothelial cells, preferably HUVECs arebeing used. After a certain period of time, depending on cell cultureconditions, cells begin to form tube-like structures. The formation oftube-like structures is regarded as a first step towards the generationof new vessels. The read-out parameter is the number of vessel-knots perarea unit. For the spheroid sprouting assay, cell spheroids (e.g.endothelial cells) are placed on a gel (e.g. matrigel and collagengels). After a certain period of time sprout formation can be observed.The extend of sprouting is considered as a criteria for the evaluationof the angiogenic potential of cells. The read-out parameter is thenumber of sprouts per spheroid. An anti-angiogenic activity may bepresent when the number of vesselknot per area unit, respectively numberof sprouts per spheroid is reduced or decreased for a given period oftime by comparison to the corresponding number of vesselknot per areaunit, respectively number of sprouts per spheroid in untreated cellsversus the number of sprouts per spheroid in treated cells. A decreaseor a reduction may be a decrease of 5%, 10%, 20%, 30%, 40%, 50%, 60%,70%, 80%, 90% or 100%. Preferably, no vesselknot per area unit,respectively no sprout per sheroid is detectable in a given period oftime.

An anti-angiogenic activity in a tumor tissue may also be present when anormalization of vessels is visualized and/or when the number of vesselsin the pathogenic area is reduced.

In a preferred embodiment, as soon as the number of vessel in thepathogenic area is found to be decreased by comparison to the number ofvessel at the onset of the treatment, there is a detectableanti-angiogenic activity. A decrease may be a detectable decrease of thenumber of vessels in the pathogenic area or a decrease of 5%, 10%, 20%,30%, 40%, 50%, 60%, 70%, 80% of the vessel in the pathogenic area.Pathogenic area is the area of the tumor including the surroundingtissue, located close to the tumor area. Close in this context may meanup to a few centimetres.

A normalization of vessels is preferably a change in the 3 dimensionalstructure of a vessel or microvessel. For example, a pathological vesselor microvessel associated with neo-angiogenesis activity in a tumorendothelium may be less regular and/or appears more tortuous and/orappears more leaky than a control vessel or microvessel. A controlvessel may be a vessel from a healthy individual or a vessel from thepatient but not located in the pathogenic area from said patient. In apreferred embodiment, as soon as the 3 dimensional structure of a vesselappears more regular, less tortuous and/or less leaky than a controlvessel, an anti-angiogenic activity is said to have been detected.Preferably, less irregular, tortuous and/or leaky vessels are detectedin the pathogenic area than at the onset of the treatment. Morepreferably, less means 5% less, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,90% or 100% less. Most preferably, no irregular, tortuous and/or leakyvessels are detected in the pathogenic area. A normalization of vesselsand/or the number of vessels in the pathogenic area may be assessedusing a non-invasive imaging technique such as PET, MRI or CT imaging.

In the case of an eye disease or condition associated withneo-angiogenesis, several assays have been developed for assessing adetectable anti-angiogenesis activity and/or a reduction or decrease ofneo-angiogenesis induced by a drug to be tested. In these differentdisease models, the angiogenesis can be triggered by different stimulisuch a mechanical stimulus (laser induced rupture of Bruch's membrane)(Shen et al, 2006 Gene therapy. 13, 225-234) or by the overexpression ofspecific blood vessel growth such as vEGF in transgenic mice (Miki etal, 2009, Ophthalmology. 2009 September 116(9): 1748-1754). If adetectable anti-angiogenesis activity and/or a reduction or decrease ofangiogenesis is assessed using a miRNA molecule, equivalent or sourcethereof as identified herein, such miRNA molecule, equivalent or sourcethereof is said to be used as a medicament for preventing, treating,reverting, curing and/or delaying neo-angiogenesis or a disease or acondition associated with neo-angiogenesis.

The assessment of neo-angiogenesis and/or anti-angiogenic activity maybe carried out periodically, e.g. each week, each month. Theincrease/decrease of neo-angiogenesis and/or presence of ananti-angiogenic activity may therefore be assessed periodically, e.g.each week, month. This assessment is preferably carried out at severaltime points for a given subject or at one or several time points for agiven subject and a healthy control. The assessment may be carried outat regular time intervals, e.g. each week, each month. The assessmentmay therefore be assessed regularly, e.g. each week, each month. Whenone assessment of neo-angiogenesis or angiogenic activity has led to thefinding of a decrease of neo-angiogenesis or to the presence of ananti-angiogenic activity, a miRNA molecule, an equivalent, a mimic, anisomiR thereof a or a source thereof or an antagomiR or an equivalent ora source thereof is said is exhibit a detectable anti-angiogenesisactivity and/or inducing a reduction or decrease of neo-angiogenesis.

A detectable decrease of neo-angiogenesis activity and/or the presenceof an anti-angiogenic activity has been preferably detected when for atleast one time point, a decrease of neo-angiogenesis and/or the presenceof an anti-angiogenic activity has been detected. Preferably, a decreaseof neo-angiogenesis and/or the presence of an anti-angiogenic activityhas been detected for at least two, three, four, five time points.

The invention provides a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/ormiRNA-142 molecule, an equivalent or a source thereof or a compositioncomprising said miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142molecule said equivalent or said source thereof, preferably, for use asa medicament for preventing, treating, reverting, curing and/or delayingneo-angiogenesis or a disease or a condition associated withneo-angiogenesis.

It has been surprisingly found that a miRNA-190b molecule or equivalentor mimic or isomiR thereof is able to exhibit a detectableanti-angiogenesis activity and/or to induce a decrease ofneo-angiogenesis as demonstrated in example 7 and example 8.

It has been surprisingly found that a miRNA-142 molecule or equivalentor mimic or isomiR thereof is able to exhibit a detectableanti-angiogenesis activity and/or to induce a decrease ofneo-angiogenesis as demonstrated in example 7 and example 8.

It has been surprisingly found that a miRNA-9* molecule or equivalent ormimic or isomiR thereof is able to exhibit a detectableanti-angiogenesis activity and/or to induce a decrease ofneo-angiogenesis as demonstrated in example 9, example 10 and example12.

It has been surprisingly found that a miRNA-7 molecule or equivalent ormimic or isomiR thereof is able to exhibit a detectableanti-angiogenesis activity and/or to induce a decrease ofneo-angiogenesis as demonstrated in example 7, example 11 and example12.

It has been surprisingly found that a miRNA-574 molecule or equivalentor mimic or isomiR thereof is able to exhibit a detectableanti-angiogenesis activity and/or to induce a decrease ofneo-angiogenesis as demonstrated in example 7, example 11 and example12.

Preferably, a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142molecule or an equivalent or a source thereof is able to prevent, treat,revert, cure and/or delay neo-angiogenesis or a disease or a conditionassociated with neo-angiogenesis when said molecule exhibits adetectable anti-angiogenesis activity or induces a decrease ofneo-angiogenesis. Throughout the invention, a molecule exhibiting adetectable anti-angiogenesis activity is synonymous with a molecule thatinduces a decrease of neo-angiogenesis. Preferably, a decrease ofneo-angiogenesis means a significant decrease, preferably a decrease ofat least 5% of neo-angiogenesis. The decrease of neo-angiogenesis may beassessed using any of the assays mentioned earlier herein. The presenceof a neo-angiogenesis activity in a subject may be assessed inendothelial cells from a tumor, a healthy subject. Endothelial cellsfrom a tumor may also be designated as the tumor endothelium. Theassessment of the activity may be carried out immune-histochemicalanalyses using pan-endothelial cell antibodies such as anti-CD31 andanti-CD34 to assess microvessel density as earlier defined herein. Suchdecrease of neo-angiogenesis activity may be measured by comparing saidneo-angiogenesis activity in an endothelial cell from a subject at agiven time point after start of treatment with the correspondingactivity from an endothelial cell from the same subject before the onsetof the treatment.

More preferably, a decrease means a decrease of at least 10%, even morepreferably at least 20%, at least 30%, at least 40%, at least 50%, atleast 70%, at least 90%, or 100%. In this case, no neo-angiogenesisactivity is detectable.

Neo-angiogenesis or a disease or condition wherein neo-angiogenesis isinvolved or associated is any disease or condition wherein an abnormalor excessive or unwanted neo-vascularization occurs. For exampleabnormal or excessive neo-angiogenesis occurs in various eye diseases,where it may result in hemorrhage and functional disorders of the eye,contributing to the loss of vision associated with retinopathy ofprematurity, diabetic retinopathy, retinal vein occlusion, age-relatedmacular degeneration, and other eye diseases (see, for example, Yoshidaet al., 1999, Histol Histopathol. 14(4): 1287-94). These conditions areleading causes of blindness (Aiello, 1997, Ophthalmic Res.29(5):354-62). Excessive angiogenesis also plays a role in other diseaseconditions such as rheumatoid arthritis, and psoriasis.

Furthermore, neo-angiogenesis plays an important role in the growth andmetastasis of tumors. Indeed several angiogenesis inhibitors are usedclinically in the treatment of cancer. Therefore, a condition or diseasewherein neo-angiogenesis is involved or associated may be a cancer.

In a preferred embodiment, a disease or condition whereinneo-angiogenesis is involved or associated is a cancer (e.g., malignant,metastatic), an eye disease as a disorder including age-related maculardegeneration, a diabetic retinopathy, a retinal vein occlusion, orrheumatoid arthritis, psoriasis, endometriosis or any other disease orcondition wherein inflammation is present (Carmeliet P. et al 2005 andGriffioen A. W. et al, 2000). Cancers of a preferred embodiment of theinvention include a cancer of epithelial origin or neuronal origin or acarcinoma or a solid tumor or a sarcoma or a liquid tumor such aleukemia or a lymphoma. Cancer cells may be from the bladder; brain;breast; colon; esophagus; gastrointestine; head; kidney; liver; lung;nasopharynx; neck; ovary; prostate; skin; stomach; testis; tongue;neuron or uterus. In addition, the cancer may specifically be of thefollowing histological type, though it is not limited to these:neoplasm; malignant; carcinoma; carcinoma undifferentiated; giant andspindle cell carcinoma; small cell carcinoma; pilomatrix carcinoma;transitional cell carcinoma; papillary transitional cell carcinoma;adenocarcinoma; gastrinoma; malignant; cholangiocarcinoma;hepatocellular carcinoma; combined hepatocellular carcinoma andcholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma;adenocarcinoma in adenomatous polyp; adenocarcinoma; familial polyposiscoli; solid carcinoma; carcinoid tumor; malignant; branchiolo-alveolarcarcinoma; papillary carcinoma; squamous cell carcinoma; basaladenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma;acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clearcell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma;papillary and follicular adenocarcinoma; nonencapsulating sclerosingcarcinoma; adrenal cortical carcinoma; endometroid carcinoma; skinappendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma;ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma;papillary cystadenocarcinoma; papillary serous cystadenocarcinoma;mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cellcarcinoma; infiltrating duct carcinoma; medullary carcinoma; lobularcarcinoma; inflammatory carcinoma; paget's disease of the breast; acinarcell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamousmetaplasia; ovarian stromal tumor, malignant; and roblastoma, malignant;Sertoli cell carcinoma. A cancer may be neuroblastoma.

In this context a leukemia includes any of: Acute lymphoblastic leukemia(ALL) such as precursor B acute lymphoblastic leukemia, precursor Tacute lymphoblastic leukemia, Burkitt's leukemia, and acute biphenotypicleukemia, Chronic lymphocytic leukemia (CLL) such as B-cellprolymphocytic leukemia, a more aggressive disease, Acute myelogenousleukemia (AML) such as acute promyelocytic leukemia, acute myeloblasticleukemia, and acute megakaryoblastic leukemia, Chronic myelogenousleukemia (CML) such as chronic monocytic leukemia, Hairy cell leukemia(HCL), T-cell prolymphocytic leukemia (T-PLL), Large granularlymphocytic leukemia and Adult T-cell leukemia.

In this context a Lymphoma includes any of: Small lymphocytic lymphoma,Lymphoplasmacytic lymphoma (such as Waldenström macroglobulinemia),Splenic marginal zone lymphoma, Plasma cell myeloma, Plasmacytoma,Extranodal marginal zone B cell lymphoma (MALT lymphoma), Nodal marginalzone B cell lymphoma (NMZL), Follicular lymphoma, Mantle cell lymphomaDiffuse large B cell lymphoma, Mediastinal (thymic) large B celllymphoma, Intravascular large B cell lymphoma, Primary effusionlymphoma, Burkitt lymphoma/leukemia, T cell prolymphocytic leukemia, Tcell large granular lymphocytic leukemia, Aggressive NK cell leukemia,Adult T cell leukemia/lymphoma, Extranodal NK/T cell lymphoma—nasaltype, Enteropathy-type T cell lymphoma, Hepatosplenic T cell lymphoma,Blastic NK cell lymphoma, Mycosis fungoides/Sezary syndrome, Primarycutaneous CD30-positive T cell lymphoproliferative disorders, Primarycutaneous anaplastic large cell lymphoma, Lymphomatoid papulosis,Angioimmunoblastic T cell lymphoma, Peripheral T cell lymphoma,unspecified Anaplastic large cell lymphoma, Hodgkin lymphoma,Immunodeficiency-associated lymphoproliferative disorders.

Any cancer that is already known to be treated with an angiostaticcompound is encompassed within the scope of the invention. Preferredcancers in this context are: carcinoma, sarcomas, leukemias andlymphomas. More preferred cancers in this context are: colon, breast,lung carcinoma's and renal carcinoma's and glioma's. There are currentlyknown medicaments (angiostatic compounds) that may be used forspecifically preventing, treating, reverting, curing and/or delayingneo-angiogenesis or a disease or condition associated withneo-angiogenesis in a subject. However, each of these treatments islikely to display a therapeutic activity which is not sufficient to beused in patients and/or induce resistance. Such a therapeutic activityis not sufficient to be used in patients preferably when such knownmedicaments (angiostatic compounds) are not able to exhibit a detectableanti-angiogenesis activity and/or not able to induce a decrease ofneoangiogenesis. Each of these features has been defined earlier herein.The invention provides a new medicament which is expected not to havesuch drawbacks. The invention encompasses to use a miRNA-9, miRNA-574,miRNA-7, miRNA-190b and/or miRNA-142 molecule, an equivalent or a sourcethereof or a composition comprising said miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule or equivalent thereof or a sourcethereof. This use includes increasing, preferably pharmacologicallyincreasing an activity or the steady-state level of said miRNA-9,miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 or equivalent thereof orof said source thereof in a subject, in a cell of said subject, in atissue of said subject or in body fluid of said subject.

Within the context of the invention, “increasing an activity or thesteady-state level of an antagomir or equivalent thereof or of saidsource thereof” could be replaced by “decreasing an activity or thesteady-state level of a miRNA molecule or equivalent thereof”. The sameholds for other antagomir identified herein.

In this use, an activity or steady-state level of said miRNA-9,miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 or equivalent thereof orsource thereof is increased in order to exhibit a detectableanti-angiogenesis activity and/or induce a detectable decrease ofneo-angiogenesis. The assessment of an anti-angiogenesis activity and ofneo-angiogenesis in a subject had been earlier defined herein.

An activity or steady-state level of said miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule, equivalent thereof such as a mimicor isomiR thereof or source thereof may be increased at the level ofsaid miRNA molecule (or equivalent thereof) itself, e.g. by providingsaid miRNA molecule or equivalent thereof to a subject, preferably to acell of a subject, or to a tissue of said subject, or to an organ ofsaid subject or to said subject said miRNA molecule or equivalentthereof being from an exogenous source. For provision of a miRNAmolecule or equivalent thereof from an exogenous source, said miRNAmolecule or equivalent thereof may conveniently be produced byexpression of a nucleic acid encoding said miRNA molecule or equivalentthereof or encoding a source of said miRNA molecule or equivalentthereof in a suitable host cell as described below or as completelysynthetic molecule by chemical synthesis.

Preferably, however, an activity or steady-state level of a miRNAmolecule or equivalent thereof is increased by regulating the expressionlevel of a nucleotide sequence encoding said miRNA molecule orequivalent thereof or encoding a source of said miRNA molecule orequivalent thereof. Preferably, the expression level of a nucleotidesequence is regulated in a cell of said subject or in a tissue of saidsubject or in the subject. The expression level of a miRNA molecule orequivalent thereof or a source of said miRNA molecule or equivalentthereof may be increased by introduction of a miRNA, and equivalent, ora source thereof, or an expression construct (or vector) into a cell,tissue, organ or body fluid of said subject, or in the subject wherebyan expression vector comprises a nucleotide sequence comprising a miRNAmolecule or equivalent thereof or comprising a source of said miRNAmolecule or equivalent thereof, and whereby a nucleotide sequence isunder control of a promoter capable of driving expression of anucleotide sequence in said cell, tissue, organ, subject. The expressionlevel of a miRNA molecule or equivalent thereof or source thereof mayalso be increased by introduction of an expression construct into acell, tissue, organ, subject, whereby a construct comprises a nucleotidesequence encoding a factor capable of trans-activation of an endogenousnucleotide sequence encoding a miRNA molecule or equivalent thereof.

A use of the invention preferably comprises the step of administering toa subject a therapeutically effective amount of a pharmaceuticalcomposition comprising a nucleic acid construct for increasing theactivity or steady state level of miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule or equivalent as defined herein. Anucleic acid construct may be an expression construct as furtherspecified herein. Preferably, an expression construct is a viral genetherapy vector selected from gene therapy vectors based on anadenovirus, an adeno-associated virus (AAV), a herpes virus, a poxvirus, an oncolytic virus vector and a retrovirus. A preferred viralgene therapy vector is an AAV or Lentiviral vector. Alternatively, a useof the invention preferably comprises the step of administering to asubject a therapeutically effective amount of a pharmaceuticalcomposition comprising a miRNA-9 molecule, an equivalent or a sourcethereof as defined herein.

In a use of the invention, a cell, a tissue, an organ or body fluid ispreferably from a subject suspected to have a high risk of exhibitingneo-angiogenesis or of having a disease or condition associated withneo-angiogenesis due for example to its age or its genetic background orto its diet. Alternatively, in another preferred embodiment, use of theinvention is applied on a cell, tissue, organ or body fluid from asubject diagnosed as either having a predictive risk for developinglater a disease or condition associated with neo-angiogenesis. Adiagnostic method used is preferably one of the inventions as describedherein. Alternatively, a cell, a tissue or organ to be treated may beselected based on risk of progression of the disease or conditionassociated with neo-angiogenesis. Such risk of progression may beassessed using classical clinic-pathological criteria or biomarker-basedprognosis known to the skilled person. It is also encompassed by theinvention to administer a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/ormiRNA-142 molecule or equivalent thereof or a precursor thereof or acomposition comprising said miRNA-9, miRNA-574, miRNA-7, miRNA-190band/or miRNA-142 molecule or equivalent thereof or source thereof into atissue or organ of said subject. The organ or tissue may correspond tothe organ or tissue wherein neo-angiogenesis or a disease or conditionassociated with neo-angiogenesis had been diagnosed. In the invention, apreferred tissue is a tissue comprising or containing or consisting of atumor endothelium. In the invention, a preferred organ is colon, breast,lung, kidney or brain in case of a colon, breast, lung or a renalcarcinoma or glioma, or any tumor endothelium derived from said organmentioned above. A tumor endothelium is a tissue comprising orconsisting of endothelial cells that are associated with tumor cells,either located within the boundaries of the tumor tissue or in thevicinity thereof, and that are activated by the action of tumor derivedmolecular signals such as growth factors, cytokines and/or hormones. Avicinity of a tumor in this context may mean up to a few centimetres.Within a tumor usually 0.1-5% of cells are of endothelial origin. Sometumors, such as endothelioma, haemangioma and Kaposi sarcoma, areoriginating from endothelial cells, through which the number ofendothelial cells can be as high as 99%.

A tumor endothelium is a tissue comprising 30%, 40%, 50%, 60%, 70%, 80%,90%, 100% endothelial cells, preferably these cells are activated asdefined earlier herein and wherein said cells are associated with tumorcells, either located within the boundaries of the tumor tissue or inthe vicinity thereof. The assessment of the identity of endothelial cellis preferably carried out using FACS staining cells with endothelialmarkers as CD31 and CD34 on a tumor tissue obtained from a biopsy. Theassessment of the activation of endothelial cell is preferably carriedout using FACS staining cells with a marker as Ki-67 on a tumor tissueobtained from a biopsy. Preferred tissues comprise colon, breast, lungor kidney in case of a colon, breast, lung carcinoma or a renalcarcinoma or glioma. In the invention, a preferred cell is a cellderived from a colon, breast, lung or kidney in case of a colon, breast,lung carcinoma or a renal carcinoma or glioma. This cell may be orcomprise a tumor cell or an endothelial cell. In each case, a miRNA-9,miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalentor source thereof is preferably administered to an endothelial cellpresent in said organ, tissue. Said miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule or equivalent or source thereof ispreferably administered to a tissue comprising 30%, 40%, 50%, 60%, 70%,80%, 90%, 100% endothelial cells. Said miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule or equivalent or source thereof maybe targeted to endothelial cells. A treatment of a disease or conditionassociated with neo-angiogenesis may include a treatment that preventsneo-angiogenesis in a tumor tissue that contains tumor cell that has notyet metastasized or decreases neo-angiogenesis around tumor cell thathas already formed metastases and/or is migrating from the primary tumorto distant sites in the body. Alternatively or in combination withpreferred definition, a treatment of a disease or condition associatedwith neo-angiogenesis may include a treatment that preventsneo-angiogenesis in a tumor tissue that contains endothelial cells. Inthis preferred embodiment, endothelial cells are specifically targetedby linking or conjugating said miRNA-9, miRNA-574, miRNA-7, miRNA-190band/or miRNA-142 or equivalent or source thereof to a targeting part. Apreferred targeting part is a cRGD as identified herein or any moleculeknown to recognize or bind a molecule which is expressed on endothelialcells. A preferred molecule expressed on endothelial cells is CD31 andCD34.

In another use, the invention mentioned herein may be combined withstandard treatments of disease or condition associated withneo-angiogenesis such as chemotherapy, radiotherapy or surgery. Examplesof chemotherapeutic agents are later identified herein.

Although gene therapy is a possibility for preventing, treating,reverting and/or delaying neo-angiogenesis or a condition or a diseaseassociated with neo-angiogenesis, other possible treatments may also beenvisaged. For example, treatment by “small molecule” drugs to steercertain molecular pathways in the desired direction, is also preferred.These small molecules are preferably identified by the screening methodof the invention as defined later herein.

In the context of the invention, preventing, treating, reverting, curingand/or delaying a disease or condition associated with neo-angiogenesismay mean that:

-   -   The severity of at least one symptom of this disease or        condition has been reduced, and/or    -   At least a parameter associated with this disease or condition        has been improved: preferably such parameter is associated with        neo-angiogenesis and/or an angiogenic activity.

A symptom may be endothelial sprouts. The presence of endothelialsprouts may be assessed in situ in a patient or in a tumor bynon-invasive techniques such as PET, MRI (Dynamic Contrast Enhanced,DCE-MRI) or CT imaging as for assessing neo-angiogenesis. The severityof the symptom endothelial sprouts is preferably said to have beenreduced when the number of endothelial sprouts originating from a tumoris decreased of at least 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 55%, 60%,65%, 70% or 75%, or more. Endothelial sprouts may be assessed ordetected after at least one week, two weeks, three weeks, fours weeks,one month, two months, three months, four months, five months, sixmonths or more of treatment in a subject and compared to the number ofendothelial sprouts at the onset of the treatment.

A parameter may be the assessment of neo-angiogenesis and/oranti-angiogenic activity as explained earlier herein. In the context ofthe invention, preventing, treating, reverting, curing and/or delayingneo-angiogenesis or a disease or condition associated withneo-angiogenesis may be replaced by achieving an anti-tumor effect.Unless otherwise indicated, an anti-tumor effect is preferably assessedor detected after at least one week, two weeks, three weeks, foursweeks, one month, two months, three months, four months, five months,six months or more in a treated subject. An anti-tumor effect ispreferably identified in a subject as:

-   -   an inhibition of proliferation of tumor cells and/or    -   an induction or increased induction of tumor cells death and/or    -   a delay in occurrence of metastases and/or of tumor cell        migration and/or    -   an inhibition or prevention or delay of the increase of a tumor        weight or growth and/or    -   a prolongation of patient survival of at least one month,        several months or more (compared to those not treated or treated        with a control or compared with the subject at the onset of the        treatment) and/or    -   improvement of the quality of life and observed pain relief

In the context of the invention, a patient may survive and/or may beconsidered as being disease free. Alternatively, the disease orcondition may have been stopped or delayed. In the context of theinvention, an improvement of quality of life and observed pain reliefmay mean that a patient may need less pain relief drugs than at theonset of the treatment. Alternatively or in combination with theconsumption of less pain relief drugs, a patient may be less constipatedthan at the ontset of the treatment. “Less” in this context may mean 5%less, 10% less, 20% less, 30% less, 40% less, 50% less, 60% less, 70%less, 80% less, 90% less. A patient may no longer need any pain reliefdrug. This improvement of quality of life and observed pain relief maybe seen, detected or assessed after at least one week, two weeks, threeweeks, fours weeks, one month, two months, three months, four months,five months, six months or more of treatment in a patient and comparedto the quality of life and observed pain relief at the onset of thetreatment of said patient.

An inhibition of the proliferation of tumor cells, preferablyendothelial cells from the tumor endothelium may be at least 20%, 30%,40%, 50%, 55%, 60%, 65%, 70% or 75%, or more. Proliferation of cells maybe assessed using known techniques. An induction of tumor cell death maybe at least 1%, 5%, 10%, 15%, 20%, 25%, or more. Tumor growth may beinhibited at least 5%, 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70% or75%, or more. Tumor cell death may be assessed using techniques known tothe skilled person. Tumor cell death may be assessed using MRI or CT. Incertain embodiments, tumor weight increase or tumor growth may beinhibited at least 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70% or 75%, ormore. Tumor weight or tumor growth may be assessed using techniquesknown to the skilled person.

The detection of tumor growth or the detection of the proliferation oftumor cells may be assessed in vivo by measuring changes in glucoseutilization by positron emission tomography with the glucose analogue2-[18F]-fluor-2-deoxy-D-glucose (FDG-PET) or[18F]-′3-fluoro-′3-deoxy-L-thymidine PET. An ex vivo alternative may bestaining of a tumor biopsy with Ki67.

To test the effect of a miRNA molecule on tumour growth in an animalmodel in vivo, an experimental system as described in example 12 may beused. A delay in occurrence of metastases and/or of tumor cell migrationmay be a delay of at least one week, one month, several months, one yearor longer. The presence of metastases may be assessed using MRI, CT orEchography or techniques allowing the detection of circulating tumourcells (CTC). Examples of the latter tests are CellSearch CTC test(Veridex), an EpCam-based magnetic sorting of CTCs from peripheralblood. In certain embodiments, tumor growth may be delayed at least oneweek, one month, two months or more. In a certain embodiment, anoccurrence of metastases is delayed at least one week, two weeks, threeweeks, fours weeks, one months, two months, three months, four months,five months, six months or more.

In a further preferred embodiment, there is provided a compositionfurther comprising another miRNA molecule and/or an antagomir of a miRNAmolecule selected from:

-   -   a) a miRNA-9, a miRNA-190b, miRNA-7, a miRNA-574 and/or a        miRNA-142 molecule, an equivalent such as a mimic and/or an        isomiR and/or a source thereof,    -   b) optionally at least one of miRNA-26b, miRNA-27a, miRNA-92a,        miRNA-221, miRNA-222, miRNA-145 and a let7a1 molecule an        equivalent such as a mimic or an isomiR or a source thereof,    -   c) and optionally at least one antagomir of a miRNA-132,        miRNA-126 and miRNA-21 or an equivalent or a source thereof.

Since not each of the identified miRNAs molecules or equivalents thereofis expected to have the same target genes, it is assumed that the use ofa miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule orequivalent thereof or source thereof optionally combined with at leastone of the miRNAs molecule, or equivalent thereof or source thereofidentified above under a) and/or b) and/or at least one antagomir orequivalent or source thereof as identified above under c) allows a moreeffective treatment of a disease or condition associated withneo-angiogenesis. A tumor treated by a composition or a cocktail of atleast a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142molecule, or equivalent or source thereof is expected to have fewerpossibilities to escape or to resist said treatment. In a furtherpreferred embodiment, it is encompassed to diagnose the expression ofeach of the miRNA molecules or of their target genes as identifiedherein and depending on the outcome to adapt the identity of the miRNAmolecules used for the treatment.

When the invention relates to a composition comprising more than onemiRNA molecule or equivalent thereof or source thereof or antagomirthereof it is encompassed that each miRNA molecule or equivalent thereofor source thereof or antagomir thereof may be present each in a separatecomposition, each composition being sequentially or simultaneouslyadministered to a subject. Alternatively, it is also encompassed thatmore than one miRNA molecules or equivalents thereof or sources thereofor antagomir thereof is present in a composition as defined herein.

Therefore the invention further encompasses to use a miRNA molecule, anequivalent or a source thereof or a composition comprising said miRNAmolecule or equivalent thereof or a source thereof as identified undera) and/or b) and/or an additional antagomir of a miRNA molecule or anequivalent therefore as identified under c). This preferred use:

includes increasing, preferably pharmacologically increasing an activityor the steady-state level of said miRNA molecule or equivalent thereofor of said source thereof as identified under a) and/or b) in a subject,in a cell of said subject, in a tissue of said subject or in body fluidof said subject and/or

includes decreasing, preferably pharmacologically decreasing an activityor the steady-state level of said miRNA molecule or equivalent thereofor of said source thereof as identified under c) in a subject, in a cellof said subject, in a tissue of said subject or in body fluid of saidsubject.

In this preferred use:

an activity or steady-state level of a miRNA molecule as defined undera) and/or b) may be increased in order to exhibit a detectableanti-angiogenesis activity and/or induce a detectable decrease ofneo-angiogenesis and/or

an activity or steady-state level of an antagomir as defined under c)may be increased in order to exhibit a detectable anti-angiogenesisactivity and/or induce a detectable decrease of neo-angiogenesis.

Ways of increasing an activity or steady state level of an antagomirhave already been defined earlier herein. The assessment of ananti-angiogenesis activity and of neo-angiogenesis in a subject had beenearlier defined herein.

In a further aspect, there is provided the use of a miRNA-9, miRNA-574,miRNA-7, miRNA-190b and/or miRNA-142 molecule, an equivalent or a sourcethereof or a composition comprising said miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 an equivalent or a source thereof preferablyfor the manufacture of a medicament for preventing, treating, reverting,curing and/or delaying neo-angiogenesis or a disease or a conditionassociated with neo-angiogenesis. Each feature of this further aspecthas already been described herein.

In a further aspect, there is provided a method for preventingpreventing, treating, reverting, curing and/or delaying neo-angiogenesisor a condition or disease associated with neo-angiogenesis byadministering a miRNA molecule or equivalent thereof or source thereofor an antagomir thereof or a composition as earlier defined herein to asubject in the need thereof. Each feature of this further aspect hasalready been described herein.

In a further aspect, there is provided a method for diagnosingneo-angiogenesis or a disease or condition associated withneo-angiogenesis in a subject, the method comprising the steps of:

-   -   (a) determining the expression level of a miRNA-9, miRNA-574,        miRNA-7, miRNA-190b and/or miRNA-142 molecule, an equivalent or        a source thereof in a subject, and optionally    -   (b) comparing the expression level of said molecule or        equivalent thereof or source thereof as defined in (a) with a        reference value for the expression level of said molecule,        equivalent or source thereof, the reference value preferably        being the average value for the expression level of said        molecule, equivalent or source thereof in a healthy subject.

In the context of the invention, diagnosis means either a predictiverisk assessment of a subject for developing neo-angiogenesis or fordeveloping a disease or a condition associated with neo-angiogenesis. Inthe context of the invention, a subject may be an animal or a humanbeing. Preferably, a subject is a human being. In the context of theinvention, the reference value assessed in (b) and the expression levelof a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule,an equivalent or a source thereof assessed in (a) are assessed in acorresponding or similar tissue of both subjects.

Since the expression levels of these nucleotide sequences and/or amountsof corresponding miRNA molecule or equivalent thereof or source thereofmay be difficult to be measured in a subject, a sample from a subject ispreferably used. According to another preferred embodiment, theexpression level (of a nucleotide sequence or miRNA molecule orequivalent or source thereof) is determined ex vivo in a sample obtainedfrom a subject. The sample preferably comprises a body fluid of asubject. A sample may be a tissue biopsy or a tumor biopsy or a cancertissue of epithelial origin of a subject. A preferred tissue is eitherprimary tumor tissue or metastasized tissue. A body fluid may compriseor be derived from blood, serum, sputum, plasma, CSF (CerebrospinalFluid), stool, urine. It is specifically contemplated that the inventioncan be used to evaluate or diagnose differences between stages ofdisease or condition associated with neo-angiogenesis, such as betweenpre-cancer and cancer, or between a primary tumor and a metastasizedtumor.

An increase or decrease of the expression level of a nucleotide sequence(or steady state level of the encoded miRNA molecule or equivalent orsource thereof) is preferably defined as being a detectable change ofthe expression level of a nucleotide (or steady state level of anencoded miRNA molecule or equivalent or source thereof or any detectablechange in a biological activity of a miRNA molecule or equivalent orsource thereof) using a method as defined earlier on as compared to theexpression level of a corresponding nucleotide sequence (or steady statelevel of a corresponding encoded miRNA molecule or equivalent or sourcethereof) in a healthy subject. A preferred nucleotide sequence is asequence encoding a precursor of a miRNA molecule or equivalent thereof.According to a preferred embodiment, an increase or decrease of a miRNAactivity is quantified using a specific assay for a miRNA activity. Apreferred assay is the assessment of neo-angiogenesis as earlier definedherein.

Preferably, a decrease of the expression level of a nucleotide sequencemeans a decrease of at least 10% of the expression level of thenucleotide sequence using arrays. More preferably, a decrease of theexpression level of a nucleotide sequence means an decrease of at least15%, even more preferably at least 20%, at least 30%, at least 40%, atleast 50%, at least 70%, at least 90%, or 100%. In this case, there isno detectable expression.

Preferably, a decrease of the expression level of a miRNA molecule orequivalent or source thereof means a decrease of at least 10% of theexpression level of the miRNA using qPCR, microarrays or Northern blotanalysis. Preferably qPCR is stem-loop RT qPCR. More preferably, adecrease of the expression level of a miRNA molecule or equivalent orsource thereof means a decrease of at least 15%, even more preferably atleast 20%, at least 30%, at least 40%, at least 50%, at least 70%, atleast 90%, or 100%. In this case, there is no detectable expression.

Preferably, a decrease of a miRNA activity means a decrease of at least5% of a miRNA activity using a suitable assay. More preferably, adecrease of a miRNA activity means a decrease of at least 10%, even morepreferably at least 20%, at least 30%, at least 40%, at least 50%, atleast 70%, at least 90%, or 100%. In this case, there is no detectableactivity.

Preferably, an increase of the expression level of a nucleotide sequencemeans an increase of at least 10% of the expression level of thenucleotide sequence using any of the techniques mentioned herein. Morepreferably, an increase of the expression level of a nucleotide sequencemeans an increase of at least 15%, even more preferably at least 20%, atleast 30%, at least 40%, at least 50%, at least 70%, at least 90%, atleast 150% or more.

Preferably, an increase of the expression level of a miRNA molecule orequivalent or source thereof means an increase of at least 10% of theexpression level of the miRNA molecule or equivalent or source thereofusing RT-qPCR, preferably stem-loop RT qPCR. More preferably, anincrease of the expression level of a miRNA molecule or equivalent orsource thereof means an increase of at least 15%, even more preferablyat least 20%, at least 30%, at least 40%, at least 50%, at least 70%, atleast 90%, at least 150% or more.

Preferably, an increase of a miRNA activity means an increase of atleast 5% of a miRNA activity using a suitable assay. More preferably, anincrease of a miRNA activity means an increase of at least 10%, evenmore preferably at least 20%, at least 30%, at least 40%, at least 50%,at least 70%, at least 90%, at least 150% or more.

Preferably, an expression level is determined ex vivo in a sampleobtained from a subject. More preferably, the sample is as earlierdefined herein and wherein subsequently, a given nucleotide sequenceand/or miRNA molecule or equivalent or source thereof is extracted andpurified using known methods to the skilled person. More preferably, thesample is or comprises or is derived from a tumor biopsy, blood, sputum,stool or urine.

In a diagnostic method of the invention preferably the expression levelof more than one, more preferably of at least 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15 miRNAs molecule or equivalent or source thereofand/or the steady state levels of the corresponding miRNAs molecule orequivalent or source thereof are determined

Accordingly in a preferred method, in step (a) one determines theexpression level of another miRNA molecule or equivalent or sourcethereof selected from:

-   -   a) a miRNA-9, a miRNA-190b, miRNA-7, a miRNA-574 and/or a        miRNA-142 molecule, an equivalent and/or a source thereof,    -   b) optionally at least one of miRNA-26b, miRNA-27a, miRNA-92a,        miRNA-221, miRNA-222, miRNA-145, let7a1, miRNA-132, miRNA-126        and miRNA-21 molecule an equivalent or a source thereof.

In a further preferred method, neo-angiogenesis or a disease orcondition associated with neo-angiogenesis is diagnosed when thecomparison leads to the finding of a decrease of the expression level ofsaid miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule,equivalent or a source thereof.

In a further preferred method, neo-angiogenesis or a disease orcondition associated with neo-angiogenesis is diagnosed when thecomparison leads to the finding of a decrease of the expression level ofsaid miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule,equivalent or a source thereof and a decrease of the expression level ofat least one of another miRNA selected from:

-   -   a) a miRNA-9, a miRNA-190b, miRNA-7, miRNA-574 and/or a        miRNA-142 molecule, and/or an equivalent and/or a source        thereof,    -   b) optionally at least one of a miRNA-26b, miRNA-27a, miRNA-92a,        miRNA-221, miRNA-222, miRNA-145 and a let7a1 molecule an        equivalent or a source thereof.

In a further preferred embodiment, neo-angiogenesis or a disease orcondition associated with neo-angiogenesis is diagnosed when thecomparison leads to the finding of a decrease of the expression level ofsaid miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule,equivalent or a source thereof and/or a decrease of the expression levelof at an increase of the expression level of at least one of anothermiRNA as identified above and/or an increase of the expression level ofat least one of another miRNA selected from:

-   -   a) a miRNA-132, miRNA-126 and/or a miRNA-21 or an equivalent or        a source thereof.

In a further aspect, there is provided a method for identification of asubstance or a molecule capable of preventing, treating, reverting,curing and/or delaying neo-angiogenesis or a condition or diseaseassociated with neo-angiogenesis in a subject, the method comprising thesteps of:

-   (a) providing a test cell population capable of expressing a    miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or    equivalent thereof or source thereof, preferably the test population    comprises cancer cells and/or the test cell population comprises    mammalian cells, and/or the test cell population comprises human    cells;-   (b) contacting the test cell population with the substance;-   (c) determining the expression level of said miRNA-9, miRNA-574,    miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent thereof    or source thereof or the activity or steady state level of said    miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or    equivalent thereof or source thereof in the test cell population    contacted with the substance;-   (d) comparing the expression, activity or steady state level    determined in (c) with the expression, activity or steady state    level of said miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or    miRNA-142 molecule or equivalent thereof or source thereof in a test    cell population that is not contacted with the substance; and,-   (e) identifying a substance that produces a difference in expression    level, activity or steady state level of said miRNA-9, miRNA-574,    miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent thereof    or source thereof, between the test cell population that is    contacted with the substance and the test cell population that is    not contacted with the substance.

Preferably, in step a), a test cell comprises a nucleic acid constructcomprising a source or a precursor of a miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule or equivalent thereof or aprecursor of said miRNA as identified earlier herein. Preferably, in amethod the expression levels, an activity or steady state levels of morethan one nucleotide sequence or more than one miRNA molecule, equivalentor source thereof are compared. Preferably, in a method, a test cellpopulation comprises mammalian cells, more preferably human cells. Morepreferably, a test cell is an endothelial cell. A cell line may also beused as RF24. HUVEC cells may also be used. A preferred test cellpopulation does not express a miRNA-9, miRNA-574, miRNA-7, miRNA-190band/or miRNA-142 molecule or equivalent thereof or source thereof or hasa reduced expression compared to a normal counterpart. More preferably,a test cell population comprises an endothelial cell. More preferably, atest cell population comprises 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or100% of endothelial cells. Endothelial cells may be identified by theirexpression of CD31 and CD34 markers. Alternatively or in addition toprevious mentioned cells, in one aspect the invention also pertains to asubstance that is identified in the aforementioned methods.

In a preferred method, the expression levels, activities or steady statelevels of at least another one miRNA molecule or equivalent or sourcethereof is compared, preferably wherein the other miRNA molecule orequivalent or source thereof is selected from:

-   -   a) a miRNA-9, a miRNA-190b, a miRNA-7, a miRNA-574 and/or a        miRNA-142 molecule, and/an equivalent and/or a source thereof,    -   b) optionally at least one of miRNA-26b, miRNA-27a, miRNA-92a,        miRNA-221, miRNA-222, miRNA-145, let7a1, miRNA-132, miRNA-126        and miRNA-21 molecule an equivalent or a source thereof.

GENERAL DEFINITIONS AND GENERAL TECHNOLOGIES REFERRED TO HEREIN

MicroRNA molecules (“miRNAs”) are generally 21 to 22 nucleotides inlength, though lengths of 17 and up to 25 nucleotides have beenreported. Any length of 17, 18, 19, 20, 21, 22, 23, 24, 25 is thereforeencompassed within the present invention. The miRNAs are each processedfrom a longer precursor RNA molecule (“precursor miRNA”). PrecursormiRNAs are transcribed from non-protein-encoding genes. A precursor mayhave a length of at least 50, 70, 75, 80, 85, 100, 150, 200 nucleotidesore more. The precursor miRNAs have two regions of complementarity thatenables them to form a stem-loop- or fold-back-like structure, which iscleaved by enzymes called Dicer and Drosha in animals. Dicer and Droshaare ribonuclease Ill-like nucleases. The processed miRNA is typically aportion of the stem.

The processed miRNA (also referred to as “mature miRNA”) becomes part ofa large complex, known as the RNA-Induced Silencing Complex (RISC)complex, to (down)-regulate a particular target gene. Examples of animalmiRNAs include those that perfectly or imperfectly basepair with themRNA target, resulting in either mRNA degradation or inhibition oftranslation respectively (Olsen et al, 1999; Seggerson et al, 2002).SiRNA molecules also are processed by Dicer, but from a long,double-stranded RNA molecule. SiRNAs are not naturally found in animalcells, but they can function in such cells in a RNA-induced silencingcomplex (RISC) to direct the sequence-specific cleavage of an mRNAtarget (Denli et al, 2003).

The study of endogenous miRNA molecules is described in U.S. PatentApplication 60/575,743, which is hereby incorporated by reference in itsentirety. A miRNA is apparently active in the cell when the mature,single-stranded RNA is bound by a protein complex that regulates thetranslation of mRNAs that hybridize to the miRNA. Introducing exogenousRNA molecules that affect cells in the same way as endogenouslyexpressed miRNAs requires that a single-stranded RNA molecule of thesame sequence as the endogenous mature miRNA be taken up by the proteincomplex that facilitates translational control. A variety of RNAmolecule designs have been evaluated. Three general designs thatmaximize uptake of the desired single-stranded miRNA by the miRNApathway have been identified. An RNA molecule with a miRNA sequencehaving at least one of the three designs may be referred to as asynthetic miRNA.

miRNA molecules of the invention can replace or supplement the genesilencing activity of an endogenous miRNA. An example of such molecules,preferred characteristics and modifications of such molecules andcompositions comprising such molecules is described in WO2009/091982,which is hereby incorporated by reference in its entirety.

miRNA molecules of the invention or equivalents or source thereofcomprise, in some embodiments, two RNA molecules wherein one RNA isidentical to a naturally occurring, mature miRNA. The RNA molecule thatis identical to a mature miRNA is referred to as the active strand. Thesecond RNA molecule, referred to as the complementary strand, is atleast partially complementary to the active strand. The active andcomplementary strands are hybridized to create a double-stranded RNA,that is similar to the naturally occurring miRNA precursor that is boundby the protein complex immediately prior to miRNA activation in thecell. Maximizing activity of said miRNA requires maximizing uptake ofthe active strand and minimizing uptake of the complementary strand bythe miRNA protein complex that regulates gene expression at the level oftranslation. The molecular designs that provide optimal miRNA activityinvolve modifications of the complementary strand.

Two designs incorporate chemical modifications of the complementarystrand. The first modification involves creating a complementary RNAwith a group other than a phosphate or hydroxyl at its 5′ terminus. Thepresence of the 5′ modification apparently eliminates uptake of thecomplementary strand and subsequently favors uptake of the active strandby the miRNA protein complex. The 5′ modification can be any of avariety of molecules including NH2, NHCOCH3, biotin, and others. Thesecond chemical modification strategy that significantly reduces uptakeof the complementary strand by the miRNA pathway is incorporatingnucleotides with sugar modifications in the first 2-6 nucleotides of thecomplementary strand. It should be noted that the sugar modificationsconsistent with the second design strategy can be coupled with 5′terminal modifications consistent with the first design strategy tofurther enhance miRNA activities.

The third miRNA design involves incorporating nucleotides in the 3′ endof the complementary strand that are not complementary to the activestrand. Hybrids of the resulting active and complementary RNAs are verystable at the 3′ end of the active strand but relatively unstable at the5′ end of the active strand. Studies with siRNAs indicate that 5′ hybridstability is a key indicator of RNA uptake by the protein complex thatsupports RNA interference, which is at least related to the miRNApathway in cells. The inventors have found that the judicious use ofmismatches in the complementary RNA strand significantly enhances theactivity of said miRNA.

MiRNA Libraries

A key application for the miRNAs as identified herein is the assessmentor diagnosis of the presence of one individual or groups of miRNAs in asample. Cell populations with each of the different miRNAs can then beassayed to identify miRNAs whose presence affects a cellular phenotype(i.e. neo-angiogenesis). The number of different miRNAs in the librariesis variable. It is contemplated that there may be, be at least, or be atmost 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20 or more, or any range derivable therein, different miRNA-specificmolecules in the library. In specific embodiments, libraries have 1 to20 different miRNA-specific molecules, or 5 to 20 differentmiRNA-specific molecules. “Different” miRNA-specific molecules refers tonucleic acids that specifically encode miRNAs with different sequences.

miRNAs are contemplated to be made primarily of RNA, though in someembodiments, they may be RNA, nucleotide analogs, such as Locked nucleicacids (LNA) or Unlocked nucleic acids (UNA), DNA, or any combination ofDNA, RNA, nucleotide analogs, and PNAs (Peptide Nucleic Acids).Accordingly, it is understood that the library contains one or morenucleic acids for these different miRNAs. In specific embodiments, thelibrary is specific to human miRNAs, though libraries for multipleorganisms are contemplated.

An RNA molecule of the invention has or comprises or consists of a miRNAregion. In specific embodiments, a miRNA molecule or equivalent thereofhas a sequence that derives from any of SEQ ID NOs: 22-52 (Table 5). Itis particularly contemplated that nucleic acid molecules of theinvention may be derived from any of the mature miRNA sequences in SEQID NOs: 22-52.

A miRNA molecule or equivalent thereof will include a sequence thatextends at least 1 to 5 nucleotides of coding sequence upstream and/ordownstream of the predicted miRNA sequence. In some embodiments,molecules have up to 1, 2, 3, 4, 5, 6, 7, or more contiguousnucleotides, or any range derivable therein, that flank the sequenceencoding the predominant processed miRNA on one or both sides (5′ and/or3′ end).

Libraries of the invention can contain miRNA sequences from any organismhaving miRNAs, specifically including but not limited to, mammals suchas humans, non human primates, rats and mice. Specifically contemplatedare libraries having, having at least, or having at most 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or more differentmiRNAs (that is, miRNA-specific molecules having different sequencesderived from different miRNA genes). Specifically contemplated are suchlibraries described in the previous sentence with respect to any of SEQID NOs: 22-52 particularly those corresponding to miRNA sequences(mature sequence).

Nucleic Acids

The present invention concerns nucleic acid molecules also calledsources or precursors of miRNAs that can introduce miRNAs in culturedcells or into a subject. The nucleic acids may have been produced incells or in vitro by purified enzymes though they are preferentiallyproduced by chemical synthesis. They may be crude or purified. The term“miRNA,” unless otherwise indicated, refers to the processed miRNA,after it has been cleaved from its precursor. Table 4 indicates whichSEQ ID NO corresponds to a particular precursor sequence of a miRNA (SEQID NO: 1-21) and Table 5 indicates which SEQ ID NO corresponds to themature or mimic sequence of a miRNA (SEQ ID NO: 22-52. Table 6identifies the cloned DNA sequences into the lentiviral vector (SEQ IDNO: 53-60 which were used in the functional screen as described in theexamples. Tables 5 and 7 identify the preferred seed sequences (as SEQID NO: 348-378, 61-115 and 379-381) of each of the mature miRNAs ofTable 5. The name of the miRNA is often abbreviated and referred towithout the prefix and will be understood as such, depending on thecontext. Unless otherwise indicated, miRNAs referred to in theapplication are human sequences identified as mir-X or let-X, where X isa number and/or letter.

It is understood that a miRNA is derived from genomic sequences or anon-coding gene. In this respect, the term “gene” is used for simplicityto refer to the genomic sequence encoding the precursor miRNA for agiven miRNA. However, embodiments of the invention may involve genomicsequences of a miRNA that are involved in its expression, such as apromoter or other regulatory sequences.

The term “recombinant” may be used and this generally refers to amolecule that has been manipulated in vitro or that is the replicated orexpressed product of such a molecule.

The term “nucleic acid” is well known in the art. A “nucleic acid” asused herein will generally refer to a molecule (one or more strands) ofDNA, RNA or a derivative or analog thereof, comprising a nucleobase. Anucleobase includes, for example, a naturally occurring purine orpyrimidine base found in DNA (e.g., an adenine “A,” a guanine “G,” athymine “T” or a cytosine “C”) or RNA (e.g., an A, a G, an uracil “U” ora C). The term “nucleic acid” encompasses the terms “oligonucleotide”and “polynucleotide,” each as a subgenus of the term “nucleic acid.”

The term “miRNA” generally refers to a single-stranded molecule, but inspecific embodiments, molecules implemented in the invention will alsoencompass a region or an additional strand that is partially (between 10and 50% complementary across length of strand), substantially (greaterthan 50% but less than 100% complementary across length of strand) orfully complementary to another region of the same single-strandedmolecule or to another nucleic acid. Thus, nucleic acids may encompass amolecule that comprises one or more complementary or self-complementarystrand(s) or “complement(s)” of a particular sequence comprising amolecule. For example, precursor miRNA may have a self-complementaryregion, which is up to 100% complementary.

As used herein, “hybridization”, “hybridizes” or “capable ofhybridizing” is understood to mean the forming of a double or triplestranded molecule or a molecule with partial double or triple strandednature using techniques known to the skilled person such as southernblotting procedures. The term “anneal” as used herein is synonymous with“hybridize.” The term “hybridization”, “hybridize(s)” or “capable ofhybridizing” may mean “low”, “medium” or “high” hybridization conditionsas defined below.

Low to medium to high stringency conditions means prehybridization andhybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 pg/ml sheared anddenatured salmon sperm DNA, and either 25% 35% or 50% formamide for lowto medium to high stringencies respectively. Subsequently, thehybridization reaction is washed three times for 30 minutes each using2×SSC, 0.2% SDS and either 55° C., 65° C., or 75° C. for low to mediumto high stringencies.

Nucleic acids or derivatives thereof of the invention will comprise, insome embodiments the miRNA sequence of any miRNA described in SEQ IDNOs: 22-52 or are described in SEQ ID NOs: 116-304 and 382-396. It iscontemplated that nucleic acids sequences of the invention derived fromSEQ ID NO: 22-52 and/or 116-304 and/or 382-396 can have, have at least,or have at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, contiguous nucleotides from SEQ ID NOs: 22-52 or 116-304or 382-396 (or any range derivable therein). In other embodiments,nucleic acids are, are at least, or are at most 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% identicalto the miRNA sequence of SEQ ID NOs: 22-52 or 116-304 or 382-396 or tothe precursor sequence of any of SEQ ID NO: 1-21 or 53-60 or anycombination or range derivable therein.

Nucleobases

As used herein a “nucleobase” refers to a heterocyclic base, such as forexample a naturally occurring nucleobase (i.e., an A, T, G, C or U)found in at least one naturally occurring nucleic acid (i.e., DNA andRNA), and naturally or non-naturally occurring derivative(s) and analogsof such a nucleobase. A nucleobase generally can form one or morehydrogen bonds (“anneal” or “hybridize”) with at least one naturallyoccurring nucleobase in a manner that may substitute for naturallyoccurring nucleobase pairing (e.g., the hydrogen bonding between A andT, G and C, and A and U).

“Purine” and/or “pyrimidine” nucleobase(s) encompass naturally occurringpurine and/or pyrimidine nucleobases and also derivative(s) andanalog(s) thereof, including but not limited to, those a purine orpyrimidine substituted by one or more of an alkyl, caboxyalkyl, amino,hydroxyl, halogen (i.e., fluoro, chloro, bromo, or iodo), thiol oralkylthiol moeity. Preferred alkyl (e.g., alkyl, caboxyalkyl, etc.)moieties comprise of from about 1, about 2, about 3, about 4, about 5,to about 6 carbon atoms. Other non-limiting examples of a purine orpyrimidine include a deazapurine, a 2,6-diaminopurine, a 5-fluorouracil,a xanthine, a hypoxanthine, a 8-bromoguanine, a 8-chloroguanine, abromothymine, a 8-aminoguanine, a 8-hydroxyguanine, a 8-methylguanine, a8-thioguanine, an azaguanine, a 2-aminopurine, a 5-ethylcytosine, a5-methylcyosine, a 5-bromouracil, a 5-ethyluracil, a 5-iodouracil, a5-chlorouracil, a 5-propyluracil, a thiouracil, a 2-methyladenine, amethylthioadenine, a N,N-diemethyladenine, an azaadenines, a8-bromoadenine, a 8-hydroxyadenine, a 6-hydroxyaminopurine, a6-thiopurine, a 4-(6-aminohexyl/cytosine), and the like. Other examplesare well known to those of skill in the art.

A nucleobase may be comprised in a nucleoside or nucleotide, using anychemical or natural synthesis method described herein or known to one ofordinary skill in the art. Such nucleobase may be labeled or it may bepart of a molecule that is labeled and contains the nucleobase.

Nucleosides

As used herein, a “nucleoside” refers to an individual chemical unitcomprising a nucleobase covalently attached to a nucleobase linkermoiety. A non-limiting example of a “nucleobase linker moiety” is asugar comprising 5-carbon atoms (i.e., a “5-carbon sugar”), includingbut not limited to a deoxyribose, a ribose, an arabinose, or aderivative or an analog of a 5-carbon sugar. Non-limiting examples of aderivative or an analog of a 5-carbon sugar include a2′-fluoro-2′-deoxyribose or a carbocyclic sugar where a carbon issubstituted for an oxygen atom in the sugar ring.

Different types of covalent attachment(s) of a nucleobase to anucleobase linker moiety are known in the art. By way of non-limitingexample, a nucleoside comprising a purine (i.e., A or G) or a7-deazapurine nucleobase typically covalently attaches the 9 position ofa purine or a 7-deazapurine to the l′-position of a 5-carbon sugar. Inanother non-limiting example, a nucleoside comprising a pyrimidinenucleobase (i.e., C, T or U) typically covalently attaches a 1 positionof a pyrimidine to a l′-position of a 5-carbon sugar (Kornberg andBaker, 1992).

Nucleotides

As used herein, a “nucleotide” refers to a nucleoside further comprisinga “backbone moiety”. A backbone moiety generally covalently attaches anucleotide to another molecule comprising a nucleotide, or to anothernucleotide to form a nucleic acid. The “backbone moiety” in naturallyoccurring nucleotides typically comprises a phosphorus moiety, which iscovalently attached to a 5-carbon sugar. The attachment of the backbonemoiety typically occurs at either the 3′- or 5′-position of the 5-carbonsugar. However, other types of attachments are known in the art,particularly when a nucleotide comprises derivatives or analogs of anaturally occurring 5-carbon sugar or phosphorus moiety.

Nucleic Acid Analogs

A nucleic acid may comprise, or be composed entirely of, a derivative oranalog of a nucleobase, a nucleobase linker moiety and/or backbonemoiety that may be present in a naturally occurring nucleic acid. RNAwith nucleic acid analogs may also be labeled according to methods ofthe invention. As used herein a “derivative” refers to a chemicallymodified or altered form of a naturally occurring molecule, while theterms “mimic” or “analog” refer to a molecule that may or may notstructurally resemble a naturally occurring molecule or moiety, butpossesses similar functions. As used herein, a “moiety” generally refersto a smaller chemical or molecular component of a larger chemical ormolecular structure. Nucleobase, nucleoside and nucleotide analogs orderivatives are well known in the art, and have been described (see forexample, Scheit, 1980, incorporated herein by reference).

Additional non-limiting examples of nucleosides, nucleotides or nucleicacids comprising 5-carbon sugar and/or backbone moiety derivatives oranalogs, include those in: U.S. Pat. No. 5,681,947, which describesoligonucleotides comprising purine derivatives that form triple helixeswith and/or prevent expression of dsDNA; U.S. Pat. Nos. 5,652,099 and5,763,167, which describe nucleic acids incorporating fluorescentanalogs of nucleosides found in DNA or RNA, particularly for use asfluorescent nucleic acids probes; U.S. Pat. No. 5,614,617, whichdescribes oligonucleotide analogs with substitutions on pyrimidine ringsthat possess enhanced nuclease stability; U.S. Pat. Nos. 5,670,663,5,872,232 and 5,859,221, which describe oligonucleotide analogs withmodified 5-carbon sugars (i.e., modified T-deoxyfuranosyl moieties) usedin nucleic acid detection; U.S. Pat. No. 5,446,137, which describesoligonucleotides comprising at least one 5-carbon sugar moietysubstituted at the 4′ position with a substituent other than hydrogenthat can be used in hybridization assays; U.S. Pat. No. 5,886,165, whichdescribes oligonucleotides with both deoxyribonucleotides with 3′-5′internucleotide linkages and ribonucleotides with 2′-5′ internucleotidelinkages; U.S. Pat. No. 5,714,606, which describes a modifiedinternucleotide linkage wherein a 3′-position oxygen of theinternucleotide linkage is replaced by a carbon to enhance the nucleaseresistance of nucleic acids; U.S. Pat. No. 5,672,697, which describesoligonucleotides containing one or more 5′ methylene phosphonateinternucleotide linkages that enhance nuclease resistance; U.S. Pat.Nos. 5,466,786 and 5,792,847, which describe the linkage of asubstituent moiety which may comprise a drug or label to the 2′ carbonof an oligonucleotide to provide enhanced nuclease stability and abilityto deliver drugs or detection moieties; U.S. Pat. No. 5,223,618, whichdescribes oligonucleotide analogs with a 2′ or 3′ carbon backbonelinkage attaching the 4′ position and 3′ position of adjacent 5-carbonsugar moiety to enhanced cellular uptake, resistance to nucleases andhybridization to target RNA; U.S. Pat. No. 5,470,967, which describesoligonucleotides comprising at least one sulfamate or sulfamideinternucleotide linkage that are useful as nucleic acid hybridizationprobe; U.S. Pat. Nos. 5,378,825, 5,777,092, 5,623,070, 5,610,289 and5,602,240, which describe oligonucleotides with three or four atomlinker moiety replacing phosphodiester backbone moiety used for improvednuclease resistance, cellular uptake and regulating RNA expression; U.S.Pat. No. 5,858,988, which describes hydrophobic carrier agent attachedto the 2′-0 position of oligonucleotides to enhanced their membranepermeability and stability; U.S. Pat. No. 5,214,136, which describesoligonucleotides conjugated to anthraquinone at the 5′ terminus thatpossess enhanced hybridization to DNA or RNA; enhanced stability tonucleases; U.S. Pat. No. 5,700,922, which describes PNA-DNA-PNA chimeraswherein the DNA comprises 2′-deoxy-erythro-pentofuranosyl nucleotidesfor enhanced nuclease resistance, binding affinity, and ability toactivate RNase H; and WO98/39352, WO99/14226, WO2003/95467 andWO2007/085485, which describe modified RNA nucleotides of which theribose moiety is modified with an extra bridge connecting the 2′ oxygenand 4′ carbon. The locked ribose significantly increases the bindingaffinity and specificity; and WO2008/147824, which describes modifiedRNA nucleotides termed UNA (unlocked nucleic acid). UNA are acyclicanalogues of RNA in which the bond between the C2′ and C3′ atoms hasbeen cleaved, decreasing binding affinity towards a complementarystrand. UNA are compatible with RNase H recognition and RNA cleavage andimproves siRNA mediated gene silencing; WO2008/036127 which describesMorpholino nucleic acid analogues, which contain both uncharged andcationic intersubunit linkages; WO/2007/069092 and EP2075342 whichdescribe Zip Nucleic Acids (ZNA), containing conjugating sperminederivatives as cationic moieties (Z units) to an oligonucleotide; U.S.Pat. No. 5,708,154, which describes RNA linked to a DNA to form aDNA-RNA hybrid; U.S. Pat. No. 5,728,525, which describes the labeling ofnucleoside analogs with a universal fluorescent label.

Additional teachings for nucleoside analogs and nucleic acid analogs areU.S. Pat. No. 5,728,525, which describes nucleoside analogs that areend-labeled; U.S. Pat. Nos. 5,637,683, 6,251,666 (L-nucleotidesubstitutions), and 5,480,980 (7-deaza-2′-deoxyguanosine nucleotides andnucleic acid analogs thereof).

The use of other analogs is specifically contemplated for use in thecontext of the present invention. Such analogs may be used in syntheticnucleic acid molecules of the invention, both throughout the molecule orat selected nucleotides. They include, but are not limited to,

-   1) ribose modifications (such as 2′F, 2′ NH2, 2′N3,4′ thio, or 2′    O—CH3) and-   2) phosphate modifications (such as those found in    phosphorothioates, methyl phosphonates, and phosphoroborates).

Such analogs have been created to confer stability on RNAs by reducingor eliminating their capacity to be cleaved by ribonucleases. When thesenucleotide analogs are present in RNAs, they can have profoundlypositive effects on the stability of the RNAs in animals. It iscontemplated that the use of nucleotide analogs can be used alone or inconjunction with any of the design modifications of a synthetic miRNAfor any nucleic acid of the invention.

Modified Nucleotides

miRNAs of the invention specifically contemplate the use of nucleotidesthat are modified to enhance their activities. Such nucleotides includethose that are at the 5′ or 3′ terminus of the RNA as well as those thatare internal within the molecule. Modified nucleotides used in thecomplementary strands of said miRNAs either block the 5′OH or phosphateof the RNA or introduce internal sugar modifications that enhance uptakeof the active strand of the miRNA. Modifications for the miRNAs includeinternal sugar modifications that enhance hybridization as well asstabilize the molecules in cells and terminal modifications that furtherstabilize the nucleic acids in cells. Further contemplated aremodifications that can be detected by microscopy or other methods toidentify cells that contain the synthetic miRNAs.

Preparation of Nucleic Acids

A nucleic acid may be made by any technique known to one of ordinaryskill in the art, such as for example, chemical synthesis, enzymaticproduction or biological production. Though miRNAs according to theinvention could be produced using recombinant methods, it is preferredto produce miRNAs by chemical synthesis or enzymatic production. miRNAscan be produced by a number of methods, including methods involvingrecombinant DNA technology.

Nucleic acid synthesis is performed according to standard methods. See,for example, Itakura and Riggs (1980). Additionally, U.S. Pat. No.4,704,362, U.S. Pat. No. 5,221,619, and U.S. Pat. No. 5,583,013 eachdescribe various methods of preparing nucleic acids. Non-limitingexamples of a nucleic acid (e.g., a oligonucleotide), include a nucleicacid made by in vitro chemically synthesis using phosphotriester,phosphite or phosphoramidite chemistry and solid phase techniques suchas described in EP 266,032, incorporated herein by reference, or viadeoxynucleoside H-phosphonate intermediates as described by Froehler etal., 1986 and U.S. Pat. No. 5,705,629, each incorporated herein byreference. In the methods of the present invention, one or moreoligonucleotide may be used. Various different mechanisms ofoligonucleotide synthesis have been disclosed in for example, U.S. Pat.Nos. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148,5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein byreference.

A non-limiting example of an enzymatically produced nucleic acid includeone produced by enzymes in amplification reactions such as PCR™ (see forexample, U.S. Pat. No. 4,683,202 and U.S. Pat. No. 4,682,195, eachincorporated herein by reference), or the synthesis of anoligonucleotide described in U.S. Pat. No. 5,645,897, incorporatedherein by reference.

Oligonucleotide synthesis is well known to those of skill in the art.Various different mechanisms of oligonucleotide synthesis have beendisclosed in for example, U.S. Pat. Nos. 4,659,774, 4,816,571,5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146,5,602,244, each of which is incorporated herein by reference.

Basically, chemical synthesis can be achieved by the diester method, thetriester method polynucleotides phosphorylase method and by solid-phasechemistry. These methods are discussed in further detail below.

Diester Method

The diester method was the first to be developed to a usable state,primarily by Khorana and co-workers. (Khorana, 1979). The basic step isthe joining of two suitably protected deoxynucleotides to form adideoxynucleotide containing a phosphodiester bond. The diester methodis well established and has been used to synthesize DNA molecules(Khorana, 1979).

Triester Method

The main difference between the diester and triester methods is thepresence in the latter of an extra protecting group on the phosphateatoms of the reactants and products (Itakura et al., 1975). Thephosphate protecting group is usually a chlorophenyl group, whichrenders the nucleotides and polynucleotide intermediates soluble inorganic solvents. Therefore purifications are done in chloroformsolutions. Other improvements in the method include (i) the blockcoupling of trimers and larger oligomers, (ii) the extensive use ofhigh-performance liquid chromatography for the purification of bothintermediate and final products, and (iii) solid-phase synthesis.

Polynucleotide Phosphorylase Method.

This is an enzymatic method of DNA synthesis that can be used tosynthesize many useful oligonucleotides (Gillam et al., 1978; Gillam etal, 1979). Under controlled conditions, polynucleotide phosphorylaseadds predominantly a single nucleotide to a short oligonucleotide.

Chromatographic purification allows the desired single adduct to beobtained. At least a trimer is required to start the procedure, and thisprimer must be obtained by some other method. The polynucleotidephosphorylase method works and has the advantage that the proceduresinvolved are familiar to most biochemists.

Solid-Phase Methods.

Drawing on the technology developed for the solid-phase synthesis ofpolypeptides, it has been possible to attach the initial nucleotide tosolid support material and proceed with the stepwise addition ofnucleotides. All mixing and washing steps are simplified, and theprocedure becomes amenable to automation. These syntheses are nowroutinely carried out using automatic nucleic acid synthesizers.

Phosphoramidite chemistry (Beaucage and Lyer, 1992) has become by farthe most widely used coupling chemistry for the synthesis ofoligonucleotides. As is well known to those skilled in the art,phosphoramidite synthesis of oligonucleotides involves activation ofnucleoside phosphoramidite monomer precursors by reaction with anactivating agent to form activated intermediates, followed by sequentialaddition of the activated intermediates to the growing oligonucleotidechain (generally anchored at one end to a suitable solid support) toform the oligonucleotide product.

Recombinant Methods.

Recombinant methods for producing nucleic acids in a cell are well knownto those of skill in the art. These include the use of vectors,plasmids, cosmids, and other vehicles for delivery a nucleic acid to acell, which may be the target cell or simply a host cell (to producelarge quantities of the desired RNA molecule). Alternatively, suchvehicles can be used in the context of a cell free system so long as thereagents for generating the RNA molecule are present. Such methodsinclude those described in Sambrook, 2003, Sambrook, 2001 and Sambrook,1989, which are hereby incorporated by reference. In certainembodiments, the present invention concerns nucleic acid molecules thatare not synthetic. In some embodiments, the nucleic acid molecule has achemical structure of a naturally occurring nucleic acid and a sequenceof a naturally occurring nucleic acid, such as the exact and entiresequence of a single stranded primary miRNA (see Lee 2002), asingle-stranded precursor miRNA, or a single-stranded mature miRNA. Inaddition to the use of recombinant technology, such non-syntheticnucleic acids may be generated chemically, such as by employingtechnology used for creating oligonucleotides.

Design of miRNAs

miRNAs typically comprise two strands, an active strand that isidentical in sequence to the mature miRNA that is being studied and acomplementary strand that is at least partially complementary to theactive strand. The active strand is the biologically relevant moleculeand should be preferentially taken up by the complex in cells thatmodulates translation either through mRNA degradation or translationalcontrol. Preferential uptake of the active strand has two profoundresults: (1) the observed activity of said miRNA increases dramaticallyand (2) non-intended effects induced by uptake and activation of thecomplementary strand are essentially eliminated. According to theinvention, several miRNA designs can be used to ensure the preferentialuptake of the active strand.

5′ Blocking Agent.

The introduction of a stable moiety other than phosphate or hydroxyl atthe 5′ end of the complementary strand impairs its activity in the miRNApathway. This ensures that only the active strand of the miRNA will beused to regulate translation in the cell. 5′ modifications include, butare not limited to, NH2, biotin, an amine group, a lower alkylaminegroup, an acetyl group, 2′ O-Me, DMTO, fluoroscein, a thiol, or acridineor any other group with this type of functionality.

Other sense strand modifications. The introduction of nucleotidemodifications like 2′-O Me, 2′-deoxy, T-deoxy-2′-fluoro, 2′-O-methyl,2′-O-methoxyethyl (2′-O-MOE), 2′-β-aminopropyl (2′-O-AP),2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-β-dimethylaminopropyl(2′-O-DMAP), 2′-O— dimethylaminoethyloxyethyl (2′-β-DMAEOE), or2′-O—N-methylacetamido (2′-0-NMA), NH2, biotin, an amine group, a loweralkylamine group, an acetyl group, DMTO, fluoroscein, a thiol, oracridine or any other group with this type of functionality in thecomplementary strand of the miRNA can eliminate the activity of thecomplementary strand and enhance uptake of the active strand of themiRNA.

Base mismatches in the sense strand. As with siRNAs (Schwarz 2003), therelative stability of the 5′ and 3′ ends of the active strand of themiRNA apparently determines the uptake and activation of the active bythe miRNA pathway. Destabilizing the 5′ end of the active strand of themiRNA by the strategic placement of base mismatches in the 3′ end of thecomplementary strand of the synthetic miRNA enhances the activity of theactive strand and essentially eliminates the activity of thecomplementary strand.

Host Cells and Target Cells

The cells wherein a miRNA or source thereof is introduced or wherein thepresence of a miRNA is assessed may be derived from or contained in anyorganism. Preferably, the cell is a vertebrate cell. More preferably,the cell is a mammalian cell. Even more preferably, the cell is a humancell.

A mammalian cell may be from the germ line or somatic, totipotent orpluripotent, dividing or non-dividing, epithelium, immortalized ortransformed, or the like. The cell may be an undifferentiated cell, suchas a stem cell, or a differentiated cell, such as from a cell of anorgan or tissue. Alternatively, cells may be qualified as epithelial orendothelial cells, stromal cells, brain, breast, cervix, colon,gastrointestinal tract, heart, kidney, large intestine, liver, lung,ovary, pancreas, heart, prostate, bladder, small intestine, stomach,testes or uterus.

As used herein, the terms “cell,” “cell line,” and “cell culture” may beused interchangeably. All of these terms also include their progeny,which is any and all subsequent generations formed by cell division. Itis understood that all progeny may not be identical due to deliberate orinadvertent mutations. A host cell may be “transfected” or“transformed,” which refers to a process by which exogenous nucleic acidis transferred or introduced into the host cell. A transformed cellincludes the primary subject cell and its progeny. As used herein, theterms “engineered” and “recombinant” cells or host cells are intended torefer to a cell into which an exogenous nucleic acid sequence, such as,for example, a small, interfering RNA or a template construct encoding areporter gene has been introduced. Therefore, recombinant cells aredistinguishable from naturally occurring cells that do not contain arecombinantly introduced nucleic acid.

A tissue may comprise a host cell or cells to be transformed orcontacted with a nucleic acid delivery composition and/or an additionalagent. The tissue may be part or separated from an organism. In certainembodiments, a tissue and its constituent cells may comprise, but is notlimited to brain, stem cells, liver, lung, bone, breast, cervix, colon,endometrium, epithelial, esophagus, goblet cells, kidney, ovaries,pancreas, prostate, bladder, skin, small intestine, stomach, testes,heart, blood vessel.

In certain embodiments, the host cell or tissue may be comprised in atleast one organism. In certain embodiments, the organism may be amammal, a human, a primate or murine. One of skill in the art wouldfurther understand the conditions under which to incubate all of theabove described host cells to maintain them and to permit their divisionto form progeny.

Delivery Methods

The present invention involves in some embodiments delivering a nucleicacid into a cell. This may be done as part of a screening method, or itmay be related to a therapeutic or diagnostic application.

RNA molecules may be encoded by a nucleic acid molecule comprised in avector. The term “vector” is used to refer to a carrier nucleic acidmolecule into which a nucleic acid sequence can be inserted forintroduction into a cell where it can be replicated. A nucleic acidsequence can be “exogenous,” which means that it is foreign to the cellinto which the vector is being introduced or that the sequence ishomologous to a sequence in the cell but in a position within the hostcell nucleic acid in which the sequence is ordinarily not found. Vectorsinclude plasmids, cosmids, viruses (bacteriophage, animal viruses,lentivirus, and plant viruses), and artificial chromosomes (e.g., YACs).One of skill in the art would be well equipped to construct a vectorthrough standard recombinant techniques, which are described in Sambrooket al, 1989 and Ausubel et al, 1996, both incorporated herein byreference. In addition to encoding a modified polypeptide such asmodified gelonin, a vector may encode non-modified polypeptide sequencessuch as a tag or targeting molecule. A targeting molecule is one thatdirects the desired nucleic acid to a particular organ, tissue, cell, orother location in a subject's body.

The term “expression vector” refers to a vector containing a nucleicacid sequence coding for at least part of a gene product capable ofbeing transcribed. Expression vectors can contain a variety of “controlsequences,” which refer to nucleic acid sequences necessary for thetranscription and possibly translation of an operably linked codingsequence in a particular host organism. In addition to control sequencesthat govern transcription and translation, vectors and expressionvectors may contain nucleic acid sequences that serve other functions aswell and are described

There are a number of ways in which expression vectors may be introducedinto cells. In certain embodiments of the invention, the expressionvector comprises a virus or engineered vector derived from a viralgenome. The ability of certain viruses to enter cells viareceptor-mediated endocytosis, to integrate into host cell genome andexpress viral genes stably and efficiently have made them attractivecandidates for the transfer of foreign genes into mammalian cells(Ridgeway, 1988; Nicolas and Rubenstein, 1988; Baichwal and Sugden,1986; Temin, 1986). The first viruses used as gene vectors were DNAviruses including the papovaviruses (simian virus 40, bovine papillomavirus, and polyoma) (Ridgeway, 1988; Baichwal and Sugden, 1986) andadenoviruses (Ridgeway, 1988; Baichwal and Sugden, 1986). These have arelatively low capacity for foreign DNA sequences and have a restrictedhost spectrum. Furthermore, their oncogenic potential and cytopathiceffects in permissive cells raise safety concerns. They can accommodateonly up to 8 kb of foreign genetic material but can be readilyintroduced in a variety of cell lines and laboratory animals (Nicolasand Rubenstein, 1988; Temin, 1986). The expression vectors may containan RNAi expression cassette comprising one promoter and one or morestem-loop structures separated by one or more spacer regions(WO2006/084209).

Another way of introducing expression vectors into cells, using avidinfusion proteins is described in U.S. Pat. No. 6,287,792.

The retroviruses are a group of single-stranded RNA virusescharacterized by an ability to convert their RNA to double-stranded DNAin infected cells; they can also be used as vectors. Other viral vectorsmay be employed as expression constructs in the present invention.Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988;Baichwal and Sugden, 1986; Coupar et al, 1988) adeno-associated virus(AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska,1984), lentivirus (WO2008/071959, WO2004/054512), Hemaglutinating Virusof Japan (WO2004/035779), Baculovirus (WO2006/048662) and herpesvirusesmay be employed. They offer several attractive features for variousmammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden,1986; Coupar et al, 1988; Horwich et al, 1990).

Other suitable methods for nucleic acid delivery to affect expression ofcompositions of the present invention are believed to include virtuallyany method by which a nucleic acid (e.g., DNA, including viral andnonviral vectors) can be introduced into an organelle, a cell, a tissueor an organism, as described herein or as would be known to one ofordinary skill in the art. Such methods include, but are not limited to,direct delivery of DNA such as by injection (U.S. Pat. Nos. 5,994,624,5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610,5,589,466 and 5,580,859, each incorporated herein by reference),including microinjection (Harlan and Weintraub, 1985; U.S. Pat. No.5,789,215, incorporated herein by reference); by electroporation (U.S.Pat. No. 5,384,253, incorporated herein by reference); by calciumphosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama,1987; Rippe et al., 1990); by using DEAE-dextran followed bypolyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimeret al, 1987); by liposome mediated transfection (Nicolau and Sene, 1982;Fraley et al., 1979; Nicolau et al, 1987; Wong et al, 1980; Kaneda etal., 1989; Kato et al., 1991); by photochemical internalization(WO2008/007073); by microprojectile bombardment (PCT Application Nos. WO94/09699 and 95/06128; U.S. Pat. Nos. 5,610,042; 5,322,783 5,563,055,5,550,318, 5,538,877 and 5,538,880, and each incorporated herein byreference); by agitation with silicon carbide fibers (Kaeppler et al,1990; U.S. Pat. Nos. 5,302,523 and 5,464,765, each incorporated hereinby reference); by Agrobacterium-mediated transformation (U.S. Pat. Nos.5,591,616 and 5,563,055, each incorporated herein by reference); or byPEG-mediated transformation of protoplasts (Omirulleh et al., 1993; U.S.Pat. Nos. 4,684,611 and 4,952,500, each incorporated herein byreference); by desiccation/inhibition-mediated DNA uptake (Potrykus etal., 1985). Through the application of techniques such as these,organelle(s), cell(s), tissue(s) or organism(s) may be stably ortransiently transformed.

A review provides several ways of formulating a RNA molecule in order tooptimize its internalisation into a cell (Kim S S., et al, Trends Mol.Med., 2009, 15: 491-500). The following other publications disclosesalternative ways of formulating a RNA molecule in order to improve itsinternalisation into a cell, each incorporated herein by reference: WO2007/095152, describing the use of PTD-DRBD (Peptide transductiondomains linked to double stranded binding domain) for delivery ofoligonculeotides, WO 2009/086558, describing the use of SNALP (StableNucleic Acid Lipid Particles) particles, comprising a mixture ofcationic and fusogenic lipids that enable the cellular uptake andendosomal release of the particle's nucleic acid payload, WO2009/149418, describing neutral phospholipid-oil-RNAi emulsions, WO2007/121947, describing the use of a delivery vehicle based on lipoplex,WO 2009/132131, describing the use of novel lipids and nucleicacid-lipid particles that provide efficient encapsulation and efficientdelivery of the encapsulated nucleic acid to cells, WO2004/091578 andWO2004/064805 describing cochleate technology of alternating layers oflipids that spiral around a nucleic acid molecule, WO2003/047494 andWO2003/047493 describing reverse micelles incorporating nucleic acidsfor oral and mucosal delivery, WO 2008/156702, describing bacteria andbacterial therapeutic particle (BTP), including oligonucleotides for asdelivery vehicle to cells. Each of the formulations referred to ordisclosed in these publications is encompassed by the present invention.

A variety of compounds have been attached to the ends ofoligonucleotides to facilitate their transport across cell membranes.Short signal peptides found in the HIV TAT, HSV VP22, Drosphilaantennapedia, and other proteins have been found to enable the rapidtransfer of biomolecules across membranes (reviewed by Schwarze 2000).These signal peptides, referred to as Protein Transduction Domains(PTDs), have been attached to oligonucleotides to facilitate theirdelivery into cultured cells (Eguchi A, Dowdy S F, Trends PharmacolSci., 2009, 7:341-5). Cholesterols have been conjugated tooligonucleotides to improve their uptake into cells in animals(MacKellar 1992). The terminal cholesterol groups apparently interactwith receptors or lipids on the surfaces of cells and facilitate theinternalization of the modified oligonucleotides. Likewise,poly-L-lysine has been conjugated to oligonucleotides to decrease thenet negative charge and improve uptake into cells (Leonetti 1990).

A variety of compounds have been developed that complex with nucleicacids, deliver them to surfaces of cells, and facilitate their uptake inand release from endosomes. Among these are: (1) a variety of lipidssuch as DOTAP (or other cationic lipid), DDAB, DHDEAB, and DOPE and (2)non-lipid-based polymers like polyethylenimine, polyamidoamine, anddendrimers of these and other polymers. In certain of these embodimentsa combination of lipids is employed such as DOTAP and cholesterol or acholesterol derivative (U.S. Pat. No. 6,770,291, which is herebyincorporated by reference). Several of these reagents have been shown tofacilitate nucleic acid uptake in animals.

The cellular components involved in the miRNA pathway are becomingknown. Proteins that stabilize and/or transport miRNAs within cellsmight enhance the stability and activity of miRNAs because they shouldprotect and guide the bound miRNAs once they are in cells. Mixtures ofmiRNA-transporter proteins and miRNAs could enhance the efficacy ofmiRNA-based therapeutics. RNAs are hydrophilic molecules by virtue oftheir anionic phosphate and sugar backbone. Although the nucleobases arehydrophobic, hydrophilicity dominates owing to the extensive hydrogenbonding resulting from the phosphate and sugar residues. The hydrophiliccharacter and anionic backbone reduces cellular permeation. Conjugationof lipophilic groups like cholesterol (Manoharan, 2002) and lauric andlithocholic acid derivatives with C32 functionality (Lorenz et al,2004), have been shown to improve cellular uptake. Moreover binding ofsteroid conjugated oligonucleotides to different lipoproteins in thebloodstream, such as LDL, protect their integrity and govern theirbiodistribution (Rump et al, 2000). Cholesterol attached to anti-sensemolecules (Bijsterbosch et al., 2001) and aptamers (Rusconi et al.,2004) has also been shown to stabilize oligonucleotides by allowingbinding to lipoproteins. Cholesterol has been demonstrated to enhanceuptake and serum stability of siRNAs in vitro (Lorenz et al., 2004) andin vivo (Soutschek et al., 2004). Additionally, a number of smallmolecules like SB-435495 (Blackie et al, (2002), Isradipine (Oravcova etal, 1994), amlodipine (Oravcova et al, 1994) and2,2′,4,4′,5,5′-hexachlorobiphenyl (Borlakoglu et al, 1990) could enhancecellular uptake, and improve nuclease resistance by promotinglipoprotein association.

Screening with miRNA Libraries

As used in the patent application, screening is a process whereinmultiple miRNA-specific reagents are delivered separately intoindividual cell populations or animals. At one or more designated timesafter delivery, the cell populations or animals are assayed for one ormore phenotypes. Those cells or animals that have a significantlydifferent phenotype than cells or animals in the negative control groupare classified as positives. The miRNA that was being manipulated in thesample is defined as a hit. Hits represent targets for additionalresearch and potential therapeutic development.

In some embodiments, there is a multi-step process for screening, incertain embodiments, there are four general steps:

-   (1) Develop Quantitative Assay to Monitor Cellular Process being    Studied.

Assays that measure the intensity of a cellular phenotype range frommicroscopic assays that monitor cell size, cell cycle status, orantibody staining to enzymatic assays that assess the turnover of aspecific substrate in a cell lysate to direct measurements ofbiomolecules or small molecules in lysates, on cells, or in medium.

Critical to the success of a screen is creating an assay that trulymeasures the cellular phenotype and maximizing the signal-to-noise ratioof the assay. Maximizing signal-to-noise involves testing variables likeassay time, assay components, cell type, and length of time betweentransfection and assay. The greater the difference in the assay resultsbetween a positive phenotype and a negative control phenotype, thegreater the spread will be in the screening results and the better theopportunity will be to identify interesting genes. Alternative screeningmethods exist using batch infection.

-   (2) Optimize Transfection Conditions for the Desired Cells.

The first step in this process is identifying a transfection reagent andplating conditions that maximize the uptake of synthetic miRNAs whilemaintaining high cell viability. We find it useful to test 2-5 differenttransfection reagents when using cell lines or 5-10 electroporationconditions when using primary or suspension cells. Transfection can beoptimized for the reagent or electroporation condition that worked bestamong the conditions tested. Screening miRNA-specific libraries requiresconditions for high-throughput transfection. In this type of screen,lentiviral introduction rather than transfection was used. This mayrequire alternative optimization techniques.

-   (3) Screen

Once the assay and transfection process have been developed, a libraryof synthetic miRNAs or miRNAs expressed by viruses can be introducedsequentially into cells in a 24- or 96-well plate. Duplicate orTriplicate transfections for each reagent provide enough data forreasonable statistical analysis. MTS assay as carried out in theexperimental part is an example of such a screen.

-   (4) Validate Hits

Validating a hit involves showing that the observed phenotype is due tothe miRNA being targeted. Hits are typically confirmed by delivering adilution series of the miRNA inhibitor or synthetic miRNA thatregistered as a hit into the cell that was originally assayed.Confirmation is slightly different from validation. Confirmation is arepeat of the miRNA-induced phenotype, whereas validation can alsoinclude reversal of the phenotype by antagonizing miRNA mediatedphenotype.

Labeling and Labeling Techniques

In some embodiments, the present invention concerns miRNAs that arelabeled, such as for screening assays to evaluate the therapeutic ordiagnostic relevance of a particular miRNA species. It is contemplatedthat miRNA may first be isolated (either from a cell in which the miRNAis endogenous to the cell or from a cell in which miRNA is exogenous tothe cell) and/or purified prior to labeling. This may achieve a reactionthat more efficiently labels the miRNA, as opposed to other RNA in asample in which the miRNA is not isolated or purified prior to labeling.In many embodiments of the invention, the label is non-radioactive.Generally, nucleic acids may be labeled by adding labeled nucleotides(one-step process) or adding nucleotides and labeling the addednucleotides (two-step process).

Moreover, miRNAs may be labeled as is described in U.S. PatentApplication Ser. No. 60/649,584, which is hereby incorporated byreference. Such nucleotides include those that can be labeled with adye, including a fluorescent dye, or with a molecule such as biotin.Labeled nucleotides are readily available; they can be acquiredcommercially or they can be synthesized by reactions known to those ofskill in the art.

Nucleotides for Labeling

Nucleotides for labelling are not naturally occurring nucleotides, butinstead, refer to prepared nucleotides that have a reactive moiety onthem. Specific reactive functionalities of interest include: amino,sulfhydryl, sulfoxyl, aminosulfhydryl, azido, epoxide, isothiocyanate,isocyanate, anhydride, monochlorotriazine, dichlorotriazine, mono- ordihalogen substituted pyridine, mono- or disubstituted diazine,maleimide, epoxide, aziridine, sulfonyl halide, acid halide, alkylhalide, aryl halide, alkylsulfonate, N-hydroxysuccinimide ester, imidoester, hydrazine, azidonitrophenyl, azide, 3-(2-pyridyldithio)-propionamide, glyoxal, aldehyde, iodoacetyl, cyanomethyl ester,p-nitrophenyl ester, o-nitrophenyl ester, hydroxypyridine ester,carbonyl imidazole, and the other such chemical groups. In someembodiments, the reactive functionality may be bonded directly to anucleotide, or it may be bonded to the nucleotide through a linkinggroup. The functional moiety and any linker cannot substantially impairthe ability of the nucleotide to be added to the miRNA or to be labeled.Representative linking groups include carbon containing linking groups,typically ranging from about 2 to 18, usually from about 2 to 8 carbonatoms, where the carbon containing linking groups may or may not includeone or more heteroatoms, e.g. S, O, N etc., and may or may not includeone or more sites of unsaturation. Of particular interest in manyembodiments are alkyl linking groups, typically lower alkyl linkinggroups of 1 to 16, usually 1 to 4 carbon atoms, where the linking groupsmay include one or more sites of unsaturation. The functionalizednucleotides (or primers) used in the above methods of functionalizedtarget generation may be fabricated using known protocols or purchasedfrom commercial vendors, e.g., Sigma, Roche, Ambion, and IDT. Functionalgroups may be prepared according to ways known to those of skill in theart, including the representative information found in U.S. Pat. Nos.4,404,289; 4,405,711; 4,337,063 and 5,268,486, and Br. Pat. No.1,529,202, which are all incorporated by reference.

Amine-modified nucleotides are used in several embodiments of theinvention. The amine-modified nucleotide is a nucleotide that has areactive amine group for attachment of the label. It is contemplatedthat any ribonucleotide (G, A, U, or C) or deoxyribonucleotide (G, A, T,or C) can be modified for labeling. Examples include, but are notlimited to, the following modified ribo- and deoxyribo-nucleotides:5-(3-aminoallyl)-UTP; 8-[(4-amino)butyl]-amino-ATP and8-[(6-amino)butyl]-amino-ATP; N⁶-(4-amino)butyl-ATP,N⁶-(6-amino)butyl-ATP, N⁴-[2,2-oxy-bis-(ethylamine)]-CTP;N⁶-(6-Amino)hexyl-ATP; 8-[(6-Amino)hexyl]-amino-ATP;5-propargylamino-CTP, 5-propargylamino-UTP; 5-(3-aminoallyl)-dUTP;8-[(4-amino)butyl]-amino-dATP and 8-[(6-amino)butyl]-amino-dATP;N-(4-amino)butyl-dATP, N⁶-(6-amino)butyl-dATP,N⁴-[2,2-oxy-to-(ethylamine)]-dCTP; N⁶-(6-Amino)hexyl-dATP;8-[(6-Amino)hexyl]-amino-dATP; 5-propargylamino-dCTP, and5-propargylamino-dUTP. Such nucleotides can be prepared according tomethods known to those of skill in the art. Moreover, a person ofordinary skill in the art could prepare other nucleotide entities withthe same amine-modification, such as a 5-(3-aminoallyl)-CTP, GTP, ATP,dCTP, dGTP, dTTP, or dUTP in place of a 5-(3-aminoallyl)-UTP.

Labeling Techniques

In some embodiments, nucleic acids are labeled by catalytically addingto the nucleic acid an already labeled nucleotide or nucleotides. One ormore labeled nucleotides can be added to miRNA molecules. See U.S. Pat.No. 6,723,509, which is hereby incorporated by reference.

In other embodiments, an unlabeled nucleotide or nucleotides iscatalytically added to an miRNA, and the unlabeled nucleotide ismodified with a chemical moiety that enables it to be subsequentlylabeled, in embodiments of the invention, the chemical moiety is areactive amine such that the nucleotide is an amine-modified nucleotide.Examples of amine-modified nucleotides are well known to those of skillin the art, many being commercially available such as from Ambion,Sigma, Jena Bioscience, and TriLink.

In contrast to labeling of cDNA during its synthesis, the issue forlabeling miRNAs is how to label the already existing molecule. To thisend, we may use an enzyme capable of using a di- or tri-phosphateribonucleotide or deoxyribonucleotide as a substrate for its addition toan miRNA, a small RNA molecule. Moreover, in specific embodiments, itinvolves using a modified di- or triphosphate ribonucleotide, which isadded to the 3′ end of an miRNA. The source of the enzyme is notlimiting. Examples of sources for the enzymes include yeast,gram-negative bacteria such as E. coli, lactococcus lactis, and sheeppox virus.

Enzymes capable of adding such nucleotides include, but are not limitedto, poly(A) polymerase, terminal transferase, and polynucleotidephosphorylase. In specific embodiments of the invention, ligase iscontemplated as NOT being the enzyme used to add the label, and instead,a non-ligase enzyme is employed.

Poly(A) polymerase has been cloned from a number of organisms fromplants to humans. It has been shown to catalyze the addition ofhomopolymer tracts to RNA (Martin et al, RNA, 4(2):226-30, 1998).

Terminal transferase catalyzes the addition of nucleotides to the 3′terminus of a nucleic acid.

Polynucleotide phosphorylase can polymerize nucleotide diphosphateswithout the need for a primer.

Labels and Tags

miRNAs or miRNA probes may be labeled with a positron emitting(including radioactive), enzymatic, colorimetric (includes visible andUV spectrum, including fluorescent), luminescent or other label or tagfor detection or isolation purposes. The label may be detected directlyor indirectly. Radioactive labels include ¹²⁵I, ³²P, ³³P, and ³⁵S.Examples of enzymatic labels include alkaline phosphatase, luciferase,horseradish peroxidase, and β-galactosidase. Labels can also be proteinswith luminescent properties, e.g., green fluorescent protein andphicoerythrin.

The colorimetric and fluorescent labels contemplated for use asconjugates include, but are not limited to, AMCA, Alexa Fluor dyes,BODIPY dyes, such as BODIPY FL, BODIPY 630/650, BODIPY 650/665,BODIPY-R6G, BODIPY-TRX; Cascade Blue; Cascade Yellow; coumarin and itsderivatives, such as 7-amino-4-methylcoumarin, aminocoumarin andhydroxycoumarin; cyanine dyes, such as Cy3 and Cy5; eosins anderythrosins; fluorescein and its derivatives, such as fluoresceinisothiocyanate; macrocyclic chelates of lanthanide ions, such as QuantumDye™; Marina Blue; Oregon Green; rhodamine dyes, such as rhodamine red,tetramethylrhodamine and rhodamine 6G; Texas Red;

Specific examples of dyes include, but are not limited to, thoseidentified above and the following: Alexa Fluor 350, Alexa Fluor 405,Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500. Alexa Fluor 514,Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568,Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 647,Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, and, Alexa Fluor 750;amine-reactive BODIPY dyes, such as BODIPY 493/503, BODEPY 530/550,BODEPY 558/568, BODIPY 564/570, BODDPY 576/589, BODIPY 581/591, BODEPY630/650, BODIPY 650/655, BODIPY FL, BODIPY R6G, BODEPY TMR, and,BODIPY-TR; Cy3, Cy5, 6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE,Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG,Rhodamine Green, Rhodamine Red, Renographin, ROX, SYPRO, TAMRA,2′,4′,5′,7′-Tetrabromosulfonefluorescein, and TET.

Specific examples of fluorescently labeled ribonucleotides are availablefrom Molecular Probes, and these include, Alexa Fluor 488-5-UTP,Fluorescein-12-UTP, BODEPY FL-14-UTP, BODIPY TMR-14-UTP,Tetramethylrhodamine-6-UTP, Alexa Fluor 546-14-UTP, Texas Red-5-UTP, andBODIPY TR-14-UTP. Other fluorescent ribonucleotides are available fromAmersham Biosciences, such as Cy3-UTP and Cy5-UTP. Examples offluorescently labeled deoxyribonucleotides include Dinitrophenyl(DNP)-11-dUTP, Cascade Blue-7-dUTP, Alexa Fluor 488-5-dUTP,Fluorescein-12-dUTP, Oregon Green 488-5-dUTP, BODEPY FL-14-dUTP,Rhodamine Green-5-dUTP, Alexa Fluor 532-5-dUTP, BODEPY TMR-14-dUTP,Tetramethylrhodamine-6-dUTP, Alexa Fluor 546-14-dUTP, Alexa Fluor568-5-dUTP, Texas Red-12-dUTP, Texas Red-5-dUTP, BODEPY TR-14-dUTP,Alexa Fluor 594-5-dUTP, BODEPY 630/650-14-dUTP, BODIPY 650/665-14-dUTP;Alexa Fluor 488-7-OBEA-dCTP, Alexa Fluor 546-16-OBEA-dCTP, Alexa Fluor594-7-OBEA-dCTP, Alexa Fluor 647-12-OBEA-dCTP. It is contemplated thatnucleic acids may be labeled with two different labels. Furthermore,fluorescence resonance energy transfer (FRET) may be employed in methodsof the invention (e.g., Klostermeier et al., 2002; Emptage, 2001;Didenko, 2001, each incorporated by reference). Fluorescent energytransfer dyes, such as thiazole orange-ethidium heterodimer; and, TOTABmay be used.

Alternatively, the label may not be detectable per se, but indirectlydetectable or allowing for the isolation or separation of the targetednucleic acid. For example, the label could be biotin, digoxigenin,polyvalent cations, chelator groups and the other ligands, includeligands for an antibody.

Visualization Techniques

A number of techniques for visualizing or detecting labeled nucleicacids are readily available. The reference by Stanley T. Crooke, 2000has a discussion of such techniques (Chapter 6), which is incorporatedby reference. Such techniques include, microscopy, arrays, Fluorometry,Light cyclers or other real time PCR™ machines, FACS analysis,scintillation counters, Phosphoimagers, Geiger counters, MRI, CAT,antibody-based detection methods (Westerns, immunofluorescence,immunohistochemistry), histochemical techniques, HPLC (Griffey et al,1997, spectroscopy, capillary gel electrophoresis (Cummins et ah, 1996),spectroscopy; mass spectroscopy; radiological techniques; and massbalance techniques. Alternatively, nucleic acids may be labeled ortagged to allow for their efficient isolation. In other embodiments ofthe invention, nucleic acids are biotinylated.

When two or more differentially colored labels are employed, fluorescentresonance energy transfer (FRET) techniques may be employed tocharacterize the dsRNA. Furthermore, a person of ordinary skill in theart is well aware of ways of visualizing, identifying, andcharacterizing labeled nucleic acids, and accordingly, such protocolsmay be used as part of the invention. Examples of tools that may be usedalso include fluorescent microscopy, a BioAnalyzer, a plate reader,Storm (Molecular Dynamics), Array Scanner, FACS (fluorescent activatedcell sorter), or any instrument that has the ability to excite anddetect a fluorescent molecule (Acumen [TTP Labtech] plate cytometer forexample.

Array Preparation

The present invention can be employed with miRNA arrays, which areordered macroarrays or microarrays of nucleic acid molecules (probes)that are fully or nearly complementary or identical to a plurality ofmiRNA molecules or precursor miRNA molecules and that are positioned ona support material in a spatially separated organization. Macroarraysare typically sheets of nitrocellulose or nylon upon which probes havebeen spotted. Microarrays position the nucleic acid probes more denselysuch that up to 10,000 nucleic acid molecules can be fit into a regiontypically 1 to 4 square centimeters. Microarrays can be fabricated byspotting nucleic acid molecules, e.g., genes, oligonucleotides, etc.,onto substrates or fabricating oligonucleotide sequences in situ on asubstrate. Spotted or fabricated nucleic acid molecules can be appliedin a high density matrix pattern of up to about 30 non-identical nucleicacid molecules per square centimeter or higher, e.g. up to about 100 oreven 1000 per square centimeter. Microarrays typically use coated glassas the solid support, in contrast to the nitrocellulose-based materialof filter arrays. By having an ordered array of miRNA-complementingnucleic acid samples, the position of each sample can be tracked andlinked to the original sample. A variety of different array devices inwhich a plurality of distinct nucleic acid probes are stably associatedwith the surface of a solid support are known to those of skill in theart. Useful substrates for arrays include nylon, glass and silicon Sucharrays may vary in a number of different ways, including average probelength, sequence or types of probes, nature of bond between the probeand the array surface, e.g. covalent or non-covalent, and the like.

Representative methods and apparatus for preparing a microarray havebeen described, for example, in U.S. Pat. Nos. 5,143,854; 5,202,231;5,242,974; 5,288,644; 5,324,633; 5,384,261; 5,405,783; 5,412,087;5,424,186; 5,429,807; 5,432,049; 5,436,327; 5,445,934; 5,468,613;5,470,710; 5,472,672; 806; 5,525,464; 5,503,980; 5,510,270; 5,525,464;5,527,681; 5,529,756; 5,532,128; 5,545,531; 5,547,839; 5,554,501;5,556,752; 5,561,071; 5,571,639; 5,580,726; 5,580,732; 5,593,839;5,599,695; 5,599,672; 5,610,287; 5,624,711; 5,631,134; 5,639,603;5,654,413; 5,658,734; 5,661,028; 5,665,547; 5,667,972; 5,695,940;5,700,637; 5,744,305; 5,800,992; 5,807,522; 5,830,645; 5,837,196;5,871,928; 5,847,219; 5,876,932; 5,919,626; 6,004,755; 6,087,102;6,368,799; 6,383,749; 6,617,112; 6,638,717; 6,720,138, as well as WO93/17126; WO 95/11995; WO 95/21265; WO 95/21944; WO 95/35505; WO96/31622; WO 97/10365; WO 97/27317; WO 99/35505; WO 09923256; WO09936760; WO0138580; WO 0168255; WO 03020898; WO 03040410; WO 03053586;WO 03087297; WO 03091426; WO03100012; WO 04020085; WO 04027093; EP 373203; EP 785 280; EP 799 897 and UK 8 803 000; the disclosures of whichare all herein incorporated by reference. It is contemplated that thearrays can be high density arrays, such that they contain 100 or moredifferent probes. It is contemplated that they may contain 1000, 16,000,65,000, 250,000 or 1,000,000 or more different probes. The probes can bedirected to targets in one or more different organisms. Theoligonucleotide probes range from 5 to 50, 5 to 45, 10 to 40, or 15 to40 nucleotides in length in some embodiments, hi certain embodiments,the oligonucleotide probes are 20 to 25 nucleotides in length.

The location and sequence of each different probe sequence in the arrayare generally known. Moreover, the large number of different probes canoccupy a relatively small area providing a high density array having aprobe density of generally greater than about 60, 100, 600, 1000, 5,000,10,000, 40,000, 100,000, or 400,000 different oligonucleotide probes percm². The surface area of the array can be about or less than about 1,1.6, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm².

Moreover, a person of ordinary skill in the art could readily analyzedata generated using an array. Such protocols are disclosed above, andinclude information found in WO 9743450; WO 03023058; WO 03022421; WO03029485; WO03067217; WO 03066906; WO 03076928; WO 03093810; WO03100448A1, all of which are specifically incorporated by reference.

Recently, alternative profiling methods have become availables, based onsolution hybridization and subsequent immobiliztion and identificatione.g. Illumina platform.

Sample Preparation

It is contemplated that the miRNA of a wide variety of samples can beanalyzed using assays described herein. While endogenous miRNA iscontemplated for use with some embodiments, recombinant or syntheticmiRNA—including nucleic acids that are identical to endogenous miRNA orprecursor miRNA—can also be handled and analyzed as described herein.Samples may be biological samples, in which case, they can be fromblood, CSF, tissue, organs, tumor, semen, sputum, stool, urine, saliva,tears, other bodily fluid, hair follicles, skin, or any samplecontaining or constituting biological cells. Alternatively, the samplemay not be a biological sample, but be a chemical mixture, such as acell-free reaction mixture (which may contain one or more biologicalenzymes).

Cell Assays to Identify miRNAs with Ties to Disease

Specifically contemplated applications include identifying miRNAs thatcontribute to decrease neo-angiogenesis and/or induce anti-angiogenicactivity that are themselves parts of a disease or conditions or mightotherwise be associated with a particular disease state. Additionally, acontemplated application includes the identification of miRNAs that areable to decrease neo-angiogenesis and/or induce anti-angiogenicactivity. Also, miRNA functions may be compared between a samplebelieved to be susceptible to a particular disease or conditionassociated with neo-angiogenesis and one believed to be not susceptibleor resistant to that disease or condition. It is specificallycontemplated that RNA molecules of the present invention can be used totreat any of the diseases or conditions discussed in the previoussection or modulate any of the cellular pathways discussed in theprevious section. Specifically contemplated applications includeidentifying miRNAs that contribute to neo-angiogenesis cellularprocesses and/or induce an anti-angiogenic activity that are themselvesparts of a disease or might otherwise be associated with a particulardisease state. Also, miRNA functions may be compared between a samplebelieved to be susceptible to a particular disease or conditionassociated with neo-angiogenesis and one believed to be not susceptibleor resistant to that disease or condition.

The efficacy of different therapeutic drugs may be altered by miRNAs asdefined and used according to the present invention. MiRNA molecule,equivalent or source thereof that decrease neo-angiogenesis and/orinduce an anti-angiogenic activity may enhance susceptibility to e.g.chemo and immunotherapy. Such therapeutic drugs include, but are notlimited to, chemotherapeutic drugs. A “chemotherapeutic agent” is usedto connote a compound or composition that is administered in thetreatment of cancer. These agents or drugs are categorized by their modeof activity within a cell, for example, whether and at what stage theyaffect the cell cycle. Alternatively, an agent may be characterizedbased on its ability to directly cross-link DNA, to intercalate intoDNA, or to induce chromosomal and mitotic aberrations by affectingnucleic acid synthesis. Most chemotherapeutic agents fall into thefollowing categories: alkylating agents, antimetabolites, antitumorantibiotics, mitotic inhibitors, and nitrosoureas.

Examples of chemotherapeutic agents include 6-mercaptopurine,thiamiprine, thioguanine; pyrimidine analogs such as ancitabine,azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,doxifluridine, enocitabine, floxuridine; androgens such as calusterone,dromostanolone propionate, epitiostanol, mepitiostane, testolactone;anti-adrenals such as aminoglutethimide, mitotane, trilostane; folicacid replenisher such as frolinic acid; aceglatone; aldophosphamideglycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil;bisantrene; edatraxate; defofamine; demecolcine; diaziquone;elformithine; elliptinium acetate; an epothilone; etoglucid; galliumnitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such asmaytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharidecomplex; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid;triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especiallyT-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine;dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids,e.g., paclitaxel and doxetaxel; chlorambucil; gemcitabine;6-thioguanine; mercaptopurine; methotrexate; platinum coordinationcomplexes such as cisplatin, oxaliplatin and carboplatin; vinblastine;platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine;vinorelbine; novantrone; teniposide; edatrexate; daunomycin;aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-II);topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO);retinoids such as retinoic acid; capecitabine; and pharmaceuticallyacceptable salts, acids or derivatives of any of the above. Alsoincluded in this definition are anti-hormonal agents that act toregulate or inhibit hormone action on tumors such as anti-estrogens andselective estrogen receptor modulators (SERMs), including, for example,tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene,keoxifene, LY1 17018, onapristone, and toremifene; aromatase inhibitorsthat inhibit the enzyme aromatase, which regulates estrogen productionin the adrenal glands, such as, for example, 4(5)-imidazoles,aminoglutethimide, megestrol acetate, exemestane, formestanie,fadrozole, vorozole, letrozole, and anastrozole; and anti-androgens suchas flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; aswell as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog);antisense oligonucleotides, particularly those which inhibit expressionof genes in signaling pathways implicated in aberrant cellproliferation, such as, for example, PKC-α, Raf and H-Ras; ribozymessuch as a VEGF expression inhibitor and a HER2 expression inhibitor;vaccines such as gene therapy vaccines and pharmaceutically acceptablesalts, acids or derivatives of any of the above. A list of U.S. FDAapproved oncology drugs with their approved indications can be found onthe World Wide Web ataccessdata.fda.gov/scripts/cder/onctools/druglist.cfm. Moreover, it iscontemplated that samples that have differences in the activity ofcertain pathways may also be compared. Such cellular pathways includebut are not limited to the following: any adhesion or motility pathwayincluding but not limited to those involving cyclic AMP, protein kinaseA, G-protein couple receptors, adenylyl cyclase, L-selectin, E-selectin,PECAM, VCAM-1, α-actinin, paxillin, cadherins, AKT, integrin-α,integrin-β, RAF-I, ERK, PI-3 kinase, vinculin, matrixmetalloproteinases, Rho GTPases, p85, trefoil factors, profilin, FAK,MAP kinase, Ras, caveolin, calpain-1, calpain-2, epidermal growth factorreceptor, ICAM-1, ICAM-2, cofilin, actin, gelsolin, Rho A, Rac, myosinlight chain kinase, platelet-derived growth factor receptor or ezrin;any apoptosis pathway including but not limited to those involving AKT,Fas ligand, NFKB, caspase-9, PB kinase, caspase-3, caspase-7, ICAD, CAD,EndoG, Granzyme B, Bad, Bax, Bid, Bak, APAF-I, cytochrome C, p53, ATM,Bcl-2, PARP, Chk1, Chk2, Rho-21, c-Jun, Rho73, Rad51, Mdm2, Rad50,c-Abl, BRCA-I, perforin, caspase-4, caspase-8, caspase-6, caspase-1,caspase-2, caspase-10, Rho, Jun kinase, Jun kinase kinase, Rip2,lamin-A, lamin-B1, lamin-B2, Fas receptor, H2O2, Granzyme A, NADPHoxidase, HMG2, CD4, CD28, CD3, TRADD, IKK, FADD, GADD45, DR3 deathreceptor, DR4/5 death receptor, FLIPs, APO-3, GRB2, SHC, ERK, MEK,RAF-1, cyclic AMP, protein kinase A, E2F, retinoblastoma protein,Smac/Diablo, ACH receptor, 14-3-3, FAK, SODD, TNF receptor, RTP,cyclin-D1, PCNA, BcI-XL, PIP2, PIP3, PTEN, ATM, Cdc2, protein kinase C,calcineurin, IKKα, IKKβ, IKKγ, SOS-I, c-FOS, Traf-1, Traf-2, IKBβ or theproteasome; any cell activation pathway including but not limited tothose involving protein kinase A, nitric oxide, caveolin-1, actin,calcium, protein kinase C, Cdc2, cyclin B, Cdc25, GRB2, SRC proteinkinase, ADP-ribosylation factors (ARFs), phospholipase D, AKAP95, p68,Aurora B, CDK1, Eg7, histone H3, PKAc, CD80, PI3 kinase, WASP, Arp2,Arp3, p34, p20, PP2A, angiotensin, angiotensin-converting enzyme,protease-activated receptor-1, protease-activated receptor-4, Ras,RAF-I, PLCβ, PLCγ, COX-I, G-protein-coupled receptors, phospholipase A2,IP3, SUMO1, SUMO 2/3, ubiquitin, Ran, Ran-GAP, Ran-GEF, p53,glucocorticoids, glucocorticoid receptor, components of the SWI/SNFcomplex, RanBP1, RanBP2, importins, exportins, RCCl, CD40, CD40 ligand,p38, DCKα, IKKβ, NFKB, TRAF2, TRAF3, TRAF5, TRAF6, IL-4, IL-4 receptor,CDK5, AP-I transcription factor, CD45, CD4, T cell receptors, MAPkinase, nerve growth factor, nerve growth factor receptor, c-Jun, c-Fos,Jun kinase, GRB2, SOS-I, ERK-I, ERK, JAK2, STAT4, IL-12, IL-12 receptor,nitric oxide synthase, TYK2, IFNγ, elastase, IL-8, epithelins, IL-2,IL-2 receptor, CD28, SMAD3, SMAD4, TGFβ or TGFβ receptor; any cell cycleregulation, signaling or differentiation pathway including but notlimited to those involving TNFs, SRC protein kinase, Cdc2, cyclin B,Grb2, Sos-1, SHC, p68, Aurora kinases, protein kinase A, protein kinaseC, Eg7, p53, cyclins, cyclin-dependent kinases, neural growth factor,epidermal growth factor, retinoblastoma protein, ATF-2, ATM, ATR, AKT,CHK1, CHK2, 14-3-3, WEE1, CDC25 CDC6, Origin Recognition Complexproteins, p15, p16, p27, p21, ABL, c-ABL, SMADs, ubiquitin, SUMO, heatshock proteins, Wnt, GSK-3, angiotensin, p73 any PPAR, TGFα, TGFβ, p300,MDM2, GADD45, Notch, cdc34, BRCA-I, BRCA-2, SKP1, the proteasome, CUL1,E2F, pi 07, steroid hormones, steroid hormone receptors, IκBα, IκBβ,Sin3A, heat shock proteins, Ras, Rho, ERKs, IKKs, PI3 kinase, Bcl-2,Bax, PCNA, MAP kinases, dynein, RhoA, PKAc, cyclin AMP, FAK, PIP2, PIP3,integrins, thrombopoietin, Fas, Fas ligand, PLK3, MEKs, JAKs, STATs,acetylcholine, paxillin calcineurin, p38, importins, exportins, Ran,Rad50, Rad51, DNA polymerase, RNA polymerase, Ran-GAP, Ran-GEF, NuMA,Tpx2, RCCl, Sonic Hedgehog, Crml, Patched (Ptc-1), MPF, CaM kinases,tubulin, actin, kinetochore-associated proteins, centromere-bindingproteins, telomerase, TERT, PP2A, c-MYC, insulin, T cell receptors, Bcell receptors, CBP, 1 KB, NFKB, RACl, RAFl, EPO, diacylglycerol, c-Jun,c-Fos, Jun kinase, hypoxia-inducible factors, GATA4, β-catenin,α-catenin, calcium, arrestin, survivin, caspases, procaspases, CREB,CREM, cadherins, PECAMs, corticosteroids, colony-stimulating factors,calpains, adenylyl cyclase, growth factors, nitric oxide, transmembranereceptors, retinoids, G-proteins, ion channels, transcriptionalactivators, transcriptional coactivators, transcriptional repressors,interleukins, vitamins, interferons, transcriptional corepressors, thenuclear pore, nitrogen, toxins, proteolysis, or phosphorylation; or anymetabolic pathway including but not limited to those involving thebiosynthesis of amino acids, oxidation of fatty acids, biosynthesis ofneurotransmitters and other cell signaling molecules, biosynthesis ofpolyamines, biosynthesis of lipids and sphingolipids, catabolism ofamino acids and nutrients, nucleotide synthesis, eicosanoids, electrontransport reactions, ER-associated degradation, glycolysis,fibrinolysis, formation of ketone bodies, formation of phagosomes,cholesterol metabolism, regulation of food intake, energy homeostasis,prothrombin activation, synthesis of lactose and other sugars,multi-drug resistance, biosynthesis of phosphatidylcholine, theproteasome, amyloid precursor protein, Rab GTPases, starch synthesis,glycosylation, synthesis of phoshoglycerides, vitamins, the citric acidcycle, IGF-I receptor, the urea cycle, vesicular transport, or salvagepathways. It is further contemplated that nucleic acids molecules of theinvention can be employed in diagnostic and therapeutic methods withrespect to any of the above pathways or factors. Thus, in someembodiments of the invention, a miRNA molecule, equivalent, mimic orsource thereof inhibits, eliminate, activates, induces, increases, orotherwise modulates one or more of the above pathways or factors iscontemplated as part of methods of the invention. The nucleic acid canbe used to diagnosis a disease or condition based on the relation ofthat miRNA to any of the pathways described above.

Other Assays

In addition to the use of arrays and microarrays, it is contemplatedthat a number of difference assays could be employed to analyze miRNAs,their activities and their effects. Such assays include, but are notlimited to, RT-PCR, in situ hybridization, hybridization protectionassay (HPA)(GenProbe), branched DNA (bDNA) assay (Collins, M. L. et al.(1997). Nucleic Acids Research 25: 2979-2984), rolling circleamplification (RCA), single molecule hybridization detection (USGenomics), Invader assay (ThirdWave Technologies), and Bridge LitigationAssay (Qiagen). It is contemplated that such methods may be used in thecontext of arrays, as well as in the context of diagnostic assays.

Therapeutic and Diagnostic Applications

miRNAs that affect phenotypic traits provide intervention points fortherapeutic applications as well as diagnostic applications (byscreening for the presence or absence of a particular miRNA). It isspecifically contemplated that RNA molecules of the present inventioncan be used to treat any of the diseases or conditions discussed in theprevious section. Moreover, any of the methods described above can alsobe employed with respect to therapeutic and diagnostic aspects of theinvention. For example, methods with respect to detecting miRNAs orscreening for them can also be employed in a diagnostic context. Intherapeutic applications, an effective amount of the miRNAs of thepresent invention is administered to a cell, which may or may not be inan animal. In some embodiments, a therapeutically effective amount ofthe miRNAs of the present invention is administered to an individual forthe treatment of disease or condition. The term “effective amount” asused herein is defined as the amount of the molecules of the presentinvention that are necessary to result in the desired physiologicalchange in the cell or tissue to which it is administered. The term“therapeutically effective amount” as used herein is defined as theamount of the molecules of the present invention that achieves a desiredeffect with respect to a disease or condition associated withneo-angiogenesis as earlier defined herein. A skilled artisan readilyrecognizes that in many cases the molecules may not provide a cure butmay provide a partial benefit, such as alleviation or improvement of atleast one symptom. In some embodiments, a physiological change havingsome benefit is also considered therapeutically beneficial. Thus, insome embodiments, an amount of molecules that provides a physiologicalchange is considered an “effective amount” or a “therapeuticallyeffective amount.”

In some embodiments the molecule has a sequence that corresponds to themiRNA sequence from that particular animal, as opposed to from anotheranimal. Thus, in some embodiments, a human sequence is utilized in theRNA molecules of the present invention. In in vivo experiments, a miRNAsequence may differ in the test animal as compared to the humansequence. In that case, a miRNA that differs from the human sequencemight be used to demonstrate therapeutic effect in the animal. Resultsobtained with this sequence tested in an animal may be extrapolatedexpected results in human with a corresponding miRNA molecule.

Modes of Administration and Formulations

The nucleic acid molecules of the invention may be administered to asubject alone or in the form of a pharmaceutical composition for thetreatment of a condition or disease. Pharmaceutical compositions may beformulated in conventional manner using one or more physiologicallyacceptable carriers, diluents, excipients or auxiliaries whichfacilitate processing of the miRNA into preparations which can be usedpharmaceutically. Proper formulation is dependent upon the route ofadministration chosen. For topical administration the miRNAs of theinvention may be formulated as solutions, gels, ointments, creams,suspensions, etc. as are well-known in the art. Systemic formulationsinclude those designed for administration by injection, e.g.subcutaneous, intravenous, intramuscular, intrathecal or intraperitonealinjection, as well as those designed for transdermal, transmucosal,inhalation, oral or pulmonary administration. For injection, the nucleicacids of the invention may be formulated in aqueous solutions,preferably in physiologically compatible buffers such as Hanks'solution, Ringer's solution, or physiological saline buffer. Thesolution may contain formulatory agents such as suspending, stabilizingand/or dispersing agents. Alternatively, the nucleic acid molecules maybe in powder form for constitution with a suitable vehicle, e.g.,sterile pyrogen-free water, before use. For transmucosal administration,penetrants appropriate to the barrier to be permeated are used in theformulation. Such penetrants are generally known in the art. For oraladministration, the nucleic acids can be readily formulated by combiningthe molecules with pharmaceutically acceptable carriers well known inthe art. Such carriers enable the nucleic acids of the invention to beformulated as tablets, pills, dragees, capsules, liquids, gels, syrups,slurries, suspensions and the like, for oral ingestion by a patient tobe treated. For oral solid formulations such as, for example, powders,capsules and tablets, suitable excipients include fillers such assugars, e.g. lactose, sucrose, mannitol and sorbitol; cellulosepreparations such as maize starch, wheat starch, rice starch, potatostarch, gelatin, gum tragacanth, methyl cellulose,hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/orpolyvinylpyrrolidone (PVP); granulating agents; and binding agents. Ifdesired, disintegrating agents may be added, such as the cross-linkedpolyvinylpyrrolidone, agar, or alginic acid or a salt thereof such assodium alginate. If desired, solid dosage forms may be sugar-coated orenteric-coated using standard techniques. For oral liquid preparationssuch as, for example, suspensions, elixirs and solutions, suitablecarriers, excipients or diluents include water, glycols, oils, alcohols,etc. Additionally, flavoring agents, preservatives, coloring agents andthe like may be added. For buccal administration, the molecules may takethe form of tablets, lozenges, etc. formulated in conventional manner.For administration by inhalation, the molecules for use according to thepresent invention are conveniently delivered in the form of an aerosolspray from pressurized packs or a nebulizer, with the use of a suitablepropellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In thecase of a pressurized aerosol the dosage unit may be determined byproviding a valve to deliver a metered amount. Capsules and cartridgesof gelatin for use in an inhaler or insufflator may be formulatedcontaining a powder mix of the nucleic acids and a suitable powder basesuch as lactose or starch. The RNA molecules may also be formulated inrectal or vaginal compositions such as suppositories or retentionenemas, e.g., containing conventional suppository bases such as cocoabutter or other glycerides.

In addition to the formulations described previously, the molecules mayalso be formulated as a depot preparation. Such long acting formulationsmay be administered by implantation (for example subcutaneously orintramuscularly) or by intramuscular injection. Thus, for example, themolecules may be formulated with suitable polymeric or hydrophobicmaterials (for example as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives, for example, as asparingly soluble salt. Alternatively, other pharmaceutical deliverysystems may be employed.

Liposomes and emulsions are well-known examples of delivery vehiclesthat may be used to deliver nucleic acids of the invention.

A nucleic acid of the invention may be administered in combination witha carrier or lipid to increase cellular uptake. For example, theoligonucleotide may be administered in combination with a cationiclipid. Examples of cationic lipids include, but are not limited to,lipofectin, DOTMA, DOPE, and DOTAP. The publication of WO0071096, whichis specifically incorporated by reference, describes differentformulations, such as a DOTAP; cholesterol or cholesterol derivativeformulation that can effectively be used for gene therapy. Otherdisclosures also discuss different lipid or liposomal formulationsincluding nanoparticles and methods of administration; these include,but are not limited to, U.S. Patent Publication 20030203865,20020150626, 20030032615, and 20040048787, which are specificallyincorporated by reference to the extent they disclose formulations andother related aspects of administration and delivery of nucleic acids.Methods used for forming particles are also disclosed in U.S. Pat. Nos.5,844,107, 5,877,302, 6,008,336, 6,077,835, 5,972,901, 6,200,801, and5,972,900, which are incorporated by reference for those aspects. Thenucleic acids may also be administered in combination with a cationicamine such as poly-L-lysine. Nucleic acids may also be conjugated to achemical moiety, such as transferrin and cholesteryls. In addition,oligonucleotides may be targeted to certain organs or tissues by linkingspecific chemical groups to the oligonucleotide. For example, linkingthe oligonucleotide to a suitable array of mannose residues will targetthe oligonucleotide to the liver. Other targeting ligands are describedin Liu B., Brief Funct. Genomic Proteomic 6:112-119, 2007. Additionalexamples are carbohydrate sugars such as galactose,N-acetylgalactosamine, mannose; vitamins such as folates; smallmolecules including naproxen, ibuprofen or other known protein-bindingmolecules, cyclodextrin, which targets the transferrin receptor, alsocalled transferring modified cyclodextrin (Hu-Lieskovan et al., 2005),PEI (RGD-targeted PEG-PEI, Schiffelers et al. 2004), anisamide,RGD-peptide or RGD mimics, poly-arginin, anti-TfR single chain antibodyfragment/TfRscFv, Annexin A5 (targeting phophatidylserine exposingmembranes, Garnier B. et al., Bioconjug Chem., 2009, 11:2114-22), WO2009/126933 describing compositions and methods for site-specificdelivery of nucleic acids by combining them with targeting ligands andendosomolytic components. Targeting ligands that are preferentiallysuitable are endothelial-associated cell surface proteins. Targeting ofnucleic acids may also be accomplished by using aptamer technology asdescribed in WO2005/111238. Moreover, additional lipid moieties, such asPEG-lipids, cholesterol, endosomolytic helper lipids or peptides(WO2009/046220) or the overall morphology of the generated nanoparticles(characterized by charge and particle size) to the above mentioneddelivery vehicles may confer targeting specificity to either cancercells and/or tumor vasculature.

Additionally, the molecules may be delivered using a sustained-releasesystem, such as semipermeable matrices of solid polymers containing thetherapeutic agent. Various of sustained-release materials have beenestablished and are well known by those skilled in the art.Sustained-release capsules may, depending on their chemical nature,release the molecules for a few weeks up to over 100 days. Depending onthe chemical nature and the biological stability of the chimericmolecules, additional strategies for molecule stabilization may beemployed.

Alternatively, the molecules may be delivered using a coordinationchemistry based delivery system as described in WO2007011217, which isspecifically incorporated herein by reference.

In addition to the above, a molecule of the invention may be deliveredusing electroporation for local or targeted treatment. Electroporationmethods are known to the skilled person and are for example described inDaud et al (2008) or Bodles-Brakhop (2009). Each of these publicationsis incorporated by reference.

Nucleic acids may be included in any of the above-described formulationsas the free acids or bases or as pharmaceutically acceptable salts.Pharmaceutically acceptable salts are those salts that substantiallyretain the biological activity of the free bases and which are preparedby reaction with inorganic acids. Pharmaceutical salts tend to be moresoluble in aqueous and other protic solvents than are the correspondingfree base forms.

Pharmaceutical compositions of the present invention comprise aneffective amount of one or more miRNA molecules dissolved or dispersedin a pharmaceutically acceptable carrier. The phrases “pharmaceutical orpharmacologically acceptable” refers to molecular entities andcompositions that do not produce or produce acceptable adverse, allergicor other untoward reaction when administered to an animal, such as, forexample, a human, as appropriate. Whether certain adverse effects areacceptable is determined based on the severity of the disease. Thepreparation of an pharmaceutical composition that contains at least onechimeric polypeptide or additional active ingredient will be known tothose of skill in the art in light of the present disclosure, asexemplified by Remington's Pharmaceutical Sciences, 18th Ed. MackPrinting Company, 1990, incorporated herein by reference. Moreover, foranimal (e.g., human) administration, it will be understood thatpreparations should meet sterility, pyrogenicity, general safety andpurity standards as required by FDA Office of Biological Standards.

As used herein, “pharmaceutically acceptable carrier” includes any andall solvents, dispersion media, coatings, surfactants, antioxidants,preservatives (e.g., antibacterial agents, antifungal agents), isotonicagents, absorption delaying agents, salts, preservatives, drugs, drugstabilizers, gels, binders, excipients, disintegration agents,lubricants, sweetening agents, flavoring agents, dyes, such likematerials and combinations thereof, as would be known to one of ordinaryskill in the art (see, for example, Remington's Pharmaceutical Sciences,18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated hereinby reference). Except insofar as any conventional carrier isincompatible with the active ingredient, its use in the therapeutic orpharmaceutical compositions is contemplated.

The miRNAs may comprise different types of carriers depending on whetherit is to be administered in solid, liquid or aerosol form, and whetherit need to be sterile for such routes of administration as injection.The present invention can be administered intravenously, intradermally,intraarterially, intraperitoneally, intralesionally, intracranially,intraarticularly, intraprostaticaly, intrapleurally, intratracheally,intranasally, intravitreally, intravaginally, intrarectally, topically,intratumorally, intramuscularly, intraperitoneally, subcutaneously,subconjunctival, intravesicularlly, mucosally, intrapericardially,intraumbilically, intraocularally, orally, topically, locally,inhalation (e.g. aerosol inhalation), injection, infusion, continuousinfusion, localized perfusion bathing target cells directly, via acatheter, via a lavage, in cremes, in lipid compositions (e.g.,liposomes), or by other method or any combination of the forgoing aswould be known to one of ordinary skill in the art (see, for example,Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company,1990, incorporated herein by reference).

The actual dosage amount of a composition of the present inventionadministered to an animal or a patient can be determined by physical andphysiological factors such as body weight, severity of condition, thetype of disease being treated, previous or concurrent therapeuticinterventions, idiopathy of the patient and on the route ofadministration. The practitioner responsible for administration will, inany event, determine the concentration of active ingredient(s) in acomposition and appropriate dose(s) for the individual subject.

In certain embodiments, pharmaceutical compositions may comprise, forexample, at least about 0.1% of an active compound. In otherembodiments, an active compound may comprise 2% to 75% of the weight ofthe unit, or 25% to 60%, for example, and any range derivable therein.In other non-limiting examples, a dose may also comprise less than 1microgram/kg/body weight, or 1 microgram/kg/body weight, from 5microgram/kg/body weight, 10 microgram/kg/body weight, 50microgram/kg/body weight, 100 microgram/kg/body weight, 200microgram/kg/body weight, 350 microgram/kg/body weight, 500microgram/kg/body weight, 1 milligram/kg/body weight, 5milligram/kg/body weight, 10 milligram/kg/body weight, 50milligram/kg/body weight, 100 milligram/kg/body weight, 200milligram/kg/body weight, 350 milligram/kg/body weight, or 500milligram/kg/body weight, to 1000 mg/kg/body weight or more peradministration, and any range derivable therein. In non-limitingexamples of a derivable range from the numbers listed herein, a range of5 mg/kg/body weight to 100 mg/kg/body weight, 5 microgram/kg/body weightto 500 milligram/kg/body weight, etc., can be administered, based on thenumbers described above.

In any case, the composition may comprise various antioxidants to retardoxidation of one or more component. Additionally, the prevention of theaction of microorganisms can be brought about by preservatives such asvarious antibacterial and antifungal agents, including but not limitedto parabens (e.g., methylparabens, propylparabens), chlorobutanol,phenol, sorbic acid, thimerosal or combinations thereof.

The molecules may be formulated into a composition in a free base,neutral or salt form. Pharmaceutically acceptable salts, include theacid addition salts, e.g., those formed with the free amino groups of aproteinaceous composition, or which are formed with inorganic acids suchas for example, hydrochloric or phosphoric acids, or such organic acidsas acetic, oxalic, tartaric or mandelic acid. Salts formed with the freecarboxyl groups can also be derived from inorganic bases such as forexample, sodium, potassium, ammonium, calcium or ferric hydroxides; orsuch organic bases as isopropylamine, trimethylamine, histidine orprocaine.

In embodiments where the composition is in a liquid form, a carrier canbe a solvent or dispersion medium comprising but not limited to, water,ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethyleneglycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes)and combinations thereof. The proper fluidity can be maintained, forexample, by the use of a coating, such as lecithin; by the maintenanceof the required particle size by dispersion in carriers such as, forexample liquid polyol or lipids; by the use of surfactants such as, forexample hydroxypropylcellulose; or combinations thereof such methods. Inmany cases, it will be preferable to include isotonic agents, such as,for example, sugars, sodium chloride or combinations thereof.

In other embodiments, one may use eye drops, nasal solutions or sprays,aerosols or inhalants in the present invention. Such compositions aregenerally designed to be compatible with the target tissue type. In anon-limiting example, nasal solutions are usually aqueous solutionsdesigned to be administered to the nasal passages in drops or sprays.Nasal solutions are prepared so that they are similar in many respectsto nasal secretions, so that normal ciliary action is maintained. Thus,in preferred embodiments the aqueous nasal solutions usually areisotonic or slightly buffered to maintain a pH of about 5.5 to about6.5. In addition, antimicrobial preservatives, similar to those used inophthalmic preparations, drugs, or appropriate drug stabilizers, ifrequired, may be included in the formulation. For example, variouscommercial nasal preparations are known and include drugs such asantibiotics or antihistamines. In certain embodiments, the molecules areprepared for administration by such routes as oral ingestion. In theseembodiments, the solid composition may comprise, for example, solutions,suspensions, emulsions, tablets, pills, capsules (e.g., hard or softshelled gelatin capsules), sustained release formulations, buccalcompositions, troches, elixirs, suspensions, syrups, wafers, orcombinations thereof. Oral compositions may be incorporated directlywith the food of the diet. Preferred carriers for oral administrationcomprise inert diluents, assimilable edible carriers or combinationsthereof. In other aspects of the invention, the oral composition may beprepared as a syrup or elixir. A syrup or elixir, and may comprise, forexample, at least one active agent, a sweetening agent, a preservative,a flavoring agent, a dye, a preservative, or combinations thereof.

In certain preferred embodiments an oral composition may comprise one ormore binders, excipients, disintegration agents, lubricants, flavoringagents, and combinations thereof. In certain embodiments, a compositionmay comprise one or more of the following: a binder, such as, forexample, gum tragacanth, acacia, cornstarch, gelatin or combinationsthereof; an excipient, such as, for example, dicalcium phosphate,mannitol, lactose, starch, magnesium stearate, sodium saccharine,cellulose, magnesium carbonate or combinations thereof; a disintegratingagent, such as, for example, corn starch, potato starch, alginic acid orcombinations thereof; a lubricant, such as, for example, magnesiumstearate; a sweetening agent, such as, for example, sucrose, lactose,saccharin or combinations thereof; a flavoring agent, such as, forexample peppermint, oil of wintergreen, cherry flavoring, orangeflavoring, etc. or combinations of the foregoing. When the dosage unitform is a capsule, it may contain, in addition to materials of the abovetype, carriers such as a liquid carrier. Various other materials may bepresent as coatings or to otherwise modify the physical form of thedosage unit. For instance, tablets, pills, or capsules may be coatedwith shellac, sugar or both.

The composition must be stable under the conditions of manufacture andstorage, and preserved against the contaminating action ofmicroorganisms, such as bacteria and fungi. It will be appreciated thatendotoxin contamination should be kept minimally at a safe level, forexample, less that 0.5 ng/mg protein.

In particular embodiments, prolonged absorption of an injectablecomposition can be brought about by the use in the compositions ofagents delaying absorption, such as, for example, aluminum monostearate,gelatin or combinations thereof.

Any embodiment discussed above with respect to delivery or transport tocells can also be employed with respect to implementing delivery ofmedicinal compounds discussed in this section.

Effective Dosages

The molecules of the invention will generally be used in an amounteffective to achieve the intended purpose. For use to treat or prevent adisease condition, the molecules of the invention, or pharmaceuticalcompositions thereof, are administered or applied in a therapeuticallyeffective amount. A therapeutically effective amount is an amounteffective to ameliorate or prevent the symptoms, or prolong the survivalof the patient being treated. Determination of a therapeuticallyeffective amount is well within the capabilities of those skilled in theart, especially in light of the detailed disclosure provided herein.

For systemic administration, a therapeutically effective dose can beestimated initially from in vitro assays. For example, a dose can beformulated in animal models to achieve a circulating concentration rangethat includes the EC50 as determined in cell culture. Such informationcan be used to more accurately determine useful doses in humans.

Initial dosages can also be estimated from in vivo data, e.g., animalmodels, using techniques that are well known in the art. One havingordinary skill in the art could readily optimize administration tohumans based on animal data.

Dosage amount and interval may be adjusted individually to provideplasma levels of the molecules which are sufficient to maintaintherapeutic effect. Usual patient dosages for administration byinjection range from 0.01 to 0.1 mg/kg/day, or from 0.1 to 5 mg/kg/day,preferably from 0.5 to 1 mg/kg/day or more. Therapeutically effectiveserum levels may be achieved by administering multiple doses each day.

In cases of local administration or selective uptake, the effectivelocal concentration of the proteins may not be related to plasmaconcentration. One having skill in the art will be able to optimizetherapeutically effective local dosages without undue experimentation.

The amount of molecules administered will, of course, be dependent onthe subject being treated, on the subject's weight, the severity of theaffliction, the manner of administration and the judgment of theprescribing physician.

The therapy may be repeated intermittently while symptoms detectable oreven when they are not detectable. The therapy may be provided alone orin combination with other drugs or treatment (including surgery).

Toxicity

Preferably, a therapeutically effective dose of the molecules describedherein will provide therapeutic benefit without causing substantialtoxicity. Toxicity of the molecules described herein can be determinedby standard pharmaceutical procedures in cell cultures or experimentalanimals, e.g., by determining the LD50 (the dose lethal to 50% of thepopulation) or the LD100 (the dose lethal to 100% of the population).The dose ratio between toxic and therapeutic effect is the therapeuticindex. Proteins which exhibit high therapeutic indices are preferred.The data obtained from these cell culture assays and animal studies canbe used in formulating a dosage range that is not toxic for use inhuman. The dosage of the proteins described herein lies preferablywithin a range of circulating concentrations that include the effectivedose with little or no toxicity. The dosage may vary within this rangedepending upon the dosage form employed and the route of administrationutilized. The exact formulation, route of administration and dosage canbe chosen by the individual physician in view of the patient'scondition. (See, e.g., Fingl et al, 1975, In: The Pharmacological Basisof Therapeutics, Ch. 1, p. 1).

Pendant Groups

A “pendant group” may be attached or conjugated to the nucleic acid.Pendant groups may increase cellular uptake of the nucleic acid. Pendantgroups can be linked to any portion of the nucleic acid but are commonlylinked to the end(s) of the oligonucleotide chain. Examples of pendantgroups include, but are not limited to: acridine derivatives (i.e.2-methoxy-6-chloro-9-ammoacridine); cross-linkers such as psoralenderivatives, azidophenacyl, proflavin, and azidoproflavin; artificialendonucleases; metal complexes such as EDTA-Fe(II),o-phenanthroline-Cu(I), and porphyrin-Fe(II); alkylating moieties;nucleases such as amino-1-hexanolstaphylococcal nuclease and alkalinephosphatase; terminal transferases; abzymes; cholesteryl moieties;lipophilic carriers; peptide conjugates; long chain alcohols; phosphateesters; amino; mercapto groups; radioactive markers; nonradioactivemarkers such as dyes; and polylysine or other polyamines. In oneexample, the nucleic acid is conjugated to a carbohydrate, sulfatedcarbohydrate, or glycan.

Kits

Any of the compositions described herein may be comprised in a kit. In anon-limiting example, individual miRNAs are included in a kit. The kitmay further include one or more negative control synthetic miRNAs thatcan be used to control for the effects of synthetic miRNA delivery. Thekit may further include water and hybridization buffer to facilitatehybridization of the two strands of the synthetic miRNAs. The kit mayalso include one or more transfection reagent(s) to facilitate deliveryof the miRNA to cells.

In another non-limiting example, multiple synthetic miRNAs are includedin a kit. The kit may further include one or more negative controlsynthetic miRNAs that can be used to control for the effects ofsynthetic miRNA delivery. The kit may also include one or moretransfection reagents to facilitate delivery into cells.

The components of the kits may be packaged either in aqueous media or inlyophilized form. The container means of the kits will generally includeat least one vial, test tube, flask, bottle, syringe or other containermeans, into which a component may be placed, and preferably, suitablyaliquoted. Where there is more than one component in the kit (labelingreagent and label may be packaged together), the kit also will generallycontain a second, third or other additional container into which theadditional components may be separately placed. However, variouscombinations of components may be comprised in a vial. The kits of thepresent invention also will typically include a means for containing thenucleic acids, and any other reagent containers in close confinement forcommercial sale. Such containers may include injection or blow-moldedplastic containers into which the desired vials are retained.

When the components of the kit are provided in one and/or more liquidsolutions, the liquid solution is an aqueous solution, with a sterileaqueous solution being particularly preferred.

However, the components of the kit may be provided as dried powder(s).When reagents and/or components are provided as a dry powder, the powdercan be reconstituted by the addition of a suitable solvent. It isenvisioned that the solvent may also be provided in another containermeans.

The container means will generally include at least one vial, test tube,flask, bottle, syringe and/or other container means, into which thenucleic acid formulations are placed, preferably, suitably allocated.The kits may also comprise a second container means for containing asterile, pharmaceutically acceptable buffer and/or other diluent. Thekits of the present invention will also typically include a means forcontaining the vials in close confinement for commercial sale, such as,e.g., injection and/or blow-molded plastic containers into which thedesired vials are retained.

Such kits may also include components that preserve or maintain themiRNA or that protect against its degradation. Such components may beRNAse-free or protect against RNAses. Such kits generally will comprise,in suitable means, distinct containers for each individual reagent orsolution.

A kit will also include instructions for employing the kit components aswell the use of any other reagent not included in the kit. Instructionsmay include variations that can be implemented.

Kits of the invention may also include one or more of the following:miRNA, library of miRNAs, combination library of miRNA, negative controlmiRNA, nuclease-free water; RNase-free containers, such as 1.5 ml tubes;hybridization buffer; and transfection reagent(s).

It is contemplated that such reagents are embodiments of kits of theinvention. Such kits, however, are not limited to the particular itemsidentified above and may include any reagent used for the manipulationor characterization of miRNA.

Sequence Identity

“Sequence identity” is herein defined as a relationship between two ormore nucleic acid (nucleotide, polynucleotide, RNA, DNA) sequences, asdetermined by comparing the sequences. In the art, “identity” also meansthe degree of sequence relatedness between nucleic acid sequences, asthe case may be, as determined by the match between strings of suchsequences. “Identity” and “similarity” can be readily calculated byknown methods, including but not limited to those described inComputational Molecular Biology, Lesk, A. M., ed., Oxford UniversityPress, New York, 1988; Biocomputing: Informatics and Genome Projects,Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis ofSequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., HumanaPress, New Jersey, 1994; Sequence Analysis in Molecular Biology, vonHeine, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov,M. and Devereux, J., eds., M Stockton Press, New York, 1991; andCarillo, H., and Lipman, D., SIAM J. Applied Math., 48:1073 (1988). Inan embodiment, identity is assessed on a whole length of a given SEQ IDNO.

Preferred methods to determine identity are designed to give the largestmatch between the sequences tested. Methods to determine identity andsimilarity are codified in publicly available computer programs.Preferred computer program methods to determine identity and similaritybetween two sequences include e.g. the GCG program package (Devereux,J., et al., Nucleic Acids Research 12 (1): 387 (1984)), BestFit, BLASTP,BLASTN, and FASTA (Altschul, S. F. et al., J. Mol. Biol. 215:403-410(1990). The BLAST X program is publicly available from NCBI and othersources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md.20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). Thewell-known Smith Waterman algorithm may also be used to determineidentity.

Preferred parameters for nucleic acid comparison include the following:Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970);Comparison matrix: matches=+10, mismatch=0; Gap Penalty: 50; Gap LengthPenalty: 3. Available as the Gap program from Genetics Computer Group,located in Madison, Wis. Given above are the default parameters fornucleic acid comparisons.

In this document and in its claims, the verb “to comprise” and itsconjugations is used in its non-limiting sense to mean that itemsfollowing the word are included, but items not specifically mentionedare not excluded. In addition the verb “to consist” may be replaced by“to consist essentially of” meaning that a miRNA, an equivalent, a mimicor a source or an antagomir thereof or a composition as defined hereinmay comprise additional component(s) than the ones specificallyidentified, said additional component(s) not altering the uniquecharacteristic of the invention. In addition, reference to an element bythe indefinite article “a” or “an” does not exclude the possibility thatmore than one of the element is present, unless the context clearlyrequires that there be one and only one of the elements. The indefinitearticle “a” or “an” thus usually means “at least one”.

All patent and literature references cited in the present specificationare hereby incorporated by reference in their entirety.

The following examples are offered for illustrative purposes only, andare not intended to limit the scope of the present invention in any way.

DESCRIPTION OF THE FIGURES

FIG. 1A and FIG. 1B provide a representative example of the transductionefficiency as a function of MOI and time after lentiviral transductionis shown for HUVEC cells with 8 μg/ml polybrene (FIG. 1A) and for RF24cells with 6 μg/ml polybrene (FIG. 1B). These examples show that thatboth HUVECs and RF24 cells are highly transducable (>95%) withlenti-copGFP. To assess the angiogenic potential of miRNAs inendothelial cells, functional screens were performed by transduction ofthe complete lentiviral miRNA library in human umbilical veinendothelial cells (HUVECs) and RF24 cells (immortalized endothelial cellline). The following parameters were optimized for optimal assayperformance using a control lentivirus with Green Fluorescent Protein(lenti-copGFP): cell number, lentivirus particle dose (MOI, forefficiency and optimal miRNA expression), time between lentiviraltransduction and readout of the MTS assay.

FIG. 2A and FIG. 2C show that the largest window between positive andnegative control is observed between MOI of 30 and 100 for both RF24cells (FIG. 2D) and HUVECs (FIG. 2B). The optimal assay conditions(assay-window; Z′ factor) were established using thepCDH-CMV-MCS-EF1-Puro vector expressing miR-92a (proliferation/survival)as a positive control, and an empty pCDH-CMV-MCS-EF1-Puro vector as anegative control.

FIG. 3A and FIG. 3B represent an example of the screenings results byshowing the average MTS absorbance data from plate 7. FIG. 3A representsthe average absorbance data of plate 7 with RF24 cells while FIG. 3Brepresents the average absorbance data with HUVEC cells. The hits thatwere selected for hit-confirmation are indicated by spheres.

FIG. 4: Transfection in HUVECs with mimics of miRNA-7 (miR-7) andmiRNA-574 (miR-574-5p) shows a dose-dependent decrease in cell viabilityas represented by a decrease in absorbance in the MTS read-out (n=3 percondition; +/−sd). Positive control is siRNA PLK1 (PLK1 is a kinase withanti-proliferation activity). Negative control is indicated by the mimiccontrol, a miRNA with scrambled nucleotide sequence.

FIG. 5: Transfection in HUVECs with mimics of miRNA-190b (miR-190b)shows a dose-dependent decrease in cell viability as represented by adecrease in absorbance in the MTS read-out (n=3 per condition; +/−sd).Positive control is siRNA PLK1 (PLK1 is a kinase with anti-proliferationactivity). Negative control is indicated by the mimic control, a miRNAwith scrambled nucleotide sequence.

FIG. 6: Transfection in HUVECs with mimics of miRNA-142-3p andmiR-142-5p show that miR-142-3p has a stronger dose-dependent decreasein cell viability compared to miR-142-5p as represented by a decrease inabsorbance in the MTS read-out (n=3 per condition; +/−sd). Positivecontrol is siRNA PLK1 (PLK1 is a kinase with anti-proliferationactivity). Negative control is indicated by the mimic control, a miRNAwith scrambled nucleotide sequence.

FIG. 7: In vitro endothelial tube formation assays employed Matrigel™ asa three-dimensional extracellular matrix. HUVEC in complete growthmedium (7.5×10⁴) were seeded onto 96-well plates containing Matrigel™ (5mg/ml). Naive HUVEC seeded in complete growth medium display robust tubeformation, as well as cells treated with lipofectamine andscrambled-siRNA. Cells transfected with siRNA-VEGFR2 and miRNA-190b showa markedly abrogated spontaneous tube formation of HUVEC seeded incomplete growth medium.

FIG. 8: In vitro endothelial tube formation assays employed Matrigel™ asa three-dimensional extracellular matrix. HUVEC in complete growthmedium (7.5×10⁴) were seeded onto 96-well plates containing Matrigel™ (5mg/ml). Naive HUVEC seeded in complete growth medium display robust tubeformation, as well as cells treated with lipofectamine andscrambled-siRNA. Cells transfected with siRNA-VEGFR2, miR-142-3p show aclearly abrogated spontaneous tube formation of HUVEC seeded in completegrowth medium. The inhibition of tube formation after transfection withmiR-142-3p shows a much stronger phenotypic effect compared tomiR-142-5p.

FIG. 9: In vitro endothelial tube formation assays employed Matrigel™ asa three-dimensional extracellular matrix. HUVEC in complete growthmedium (7.5×10⁴) were seeded onto 96-well plates containing Matrigel™ (5mg/ml). Naive HUVEC seeded in complete growth medium display robust tubeformation, as well as cells treated with X-tremeGene andscrambled-siRNA. Cells transfected with miR-9* show a markedly abrogatedspontaneous tube formation of HUVEC seeded in complete growth mediumcompared to cells treated only with X-tremeGene. The abrogation ofspontaneous tube formation by miR-9* is stronger than the abrogation oftube formation by siRNA-VEGFR2. Bar is 400 nm.

FIG. 10: Transfection in HUVECs with mimics of miRNA-9* (miR-9*) shows adose-dependent decrease in cell viability as represented by a decreasein absorbance in the MTS read-out (n=3 per condition; +/−sd). Positivecontrol is siRNA PLK1 (PLK1 is a kinase with anti-proliferationactivity). Negative control is indicated by the mimic control, a miRNAwith scrambled nucleotide sequence (miR-scrambled) and by the siRNAcontrol, a siRNA pool with scrambled nucleotide sequence)

FIG. 11A shows bFGF-induced in-vitro sprouting angiogenesis assayperformed with spheroids of HUVEC which are untreated or transfectedwith a mimic—From left to right and from top to bottom: phase-contrastimages of spheroids of untransfected HUVEC; untransfected HUVECstimulated with bFGF; untransfected HUVEC treated with Xtremegene andbFGF; miR-scrambled transfected HUVEC treated with bFGF; miR-7 HUVECtreated with bFGF; miR-27a transfected HUVEC treated with bFGF; andmiR-574-5p transfected HUVEC treated with bFGF. FIG. 11B shows thecumulative sprout length per spheroid from 10 spheroids per treatmentgroup as listed in FIG. 11A. FIG. 11C shows the mean number of sproutsper spheroid from 10 spheroids per treatment group as listed in FIG.11A. Error bars, SD; (*) P<0.001, ANOVA test.

FIG. 12A, FIG. 12B, FIG. 12C, FIG. 12D and FIG. 12E: Tumor growth curvesof Neuro2A tumor bearing mice treated locally with PBS(n=6) or withmiR-scrambled (n=6) or with synthetic anti-angiogenic miRNAs or withsiVEGFR2; FIG. 12A tumors treated with miR-7 (n=7); FIG. 12B tumorstreated with miR-574-5p (n=7); FIG. 12C tumors treated locally withmiR-27a (n=7); FIG. 12D tumors treated with the positive controlsiVEGFR-2 (n=7); FIG. 12E Tumors treated with miR-9* (n=8). The resultsdepicted in FIG. 12E originate from a different mice cohort than theresults depicted in FIGS. 12A-D. The PBS tumor growth curve wasgenerated with n=8 mice, while the miR-scrambled tumor growth curve wasgenerated with n=10 mice. Tumor volumes are depicted as mean±STDEV.

FIG. 13

Quantification of microvessel density (MVD) of CD31 stained Neuro2Atumors treated with PBS, miR-scrambled, miR-574-5p, miR-7, miR-27a orsiVEGFR2. Data are presented as mean±STDEV. **P<0.01 versusmiR-Scrambled. 1-way ANOVA test.

EXAMPLES Materials and Methods Cell Culture and Chemicals EC-RF24Vascular Endothelial Cells (ABM#T0003)

HUVECs (Human Umbilical Vein Endothelial Cells) P4 (Lonza#cc-2519) usedthroughout the examples unless otherwise indicated.M199 medium (Gibco#22340-087)

Fetal Bovine Serum (FBS) (Sigma#F7524, Lot#059K3395) Human Serum (HS)(Sigma#118K0494, Lot#H6914-100 ml) 10.000 U/ml Penicillin/Streptavidin(P/S) (Biochrom AG#A2213) 200 nM L-glutamin (Sigma#G7513, Lot#RNBB0722)

1% (m/V) gelatin (Sigma)

10×PBS (Gibco#14200-067) TrypLE Express (Gibco#12605) 0.4% Trypan BlueStain (Lonza#17-942E)

1 mg/ml polybrene (Sigma) in 1×PBSLentiviral-based microRNA (over)expressing library (14 plates)

CellTiter 96® AQUEOUS One Solution Cell Proliferation Assay (MTS)(Promega#G3580)

Multifuge X3R (Thermo scientific)

Multiskan FC (Thermo Scientific) Medium

Specific growth medium HUVECs: M199+100 U/ml P/S+2 mM L-glutamin+10%FBS+10% HS.Specific growth medium RF24 cells: M199+100 U/ml P/S+2 mM L-glutamin+10%FBS.

Example 1 Generation of the Lentiviral Library Encoding miRNAs

Human miRNAs were selected from both the public miRNA repository(www.mirbase.org) and proprietary small RNA deep sequencing data (see WO2007/081204). The miRNA sequences were amplified from their genomiclocation with amplicons containing the full-length pre-miRNA hairpin anda flanking sequence on both sides of 50-150 basepairs. The primers forthe amplicons were designed using a custom implementation of the Primer3software (www.geneious.com). If the primer design program could not findappropriate primers in the designated sequences, the requirements forthe flanking sequences were adjusted to 0-200 basepairs. The designedprimers were complemented with a 5′ GCGC overhang and a restriction sitefor directional cloning. As default the primer upstream of the miRNA wascomplemented with a BamHI restriction site (GGATCC) and the primerdownstream of the miRNA was complemented with an EcoRI restriction site(GAATTC). Primers of amplicons with internal BamHI or EcoRI restrictionsites (i.e. occurring in the genomic sequence) were complemented witheither a BglII site (AGATCT) or a XbaI site (TCTAGA) respectively. ThemiRNAs were amplified using the above-mentioned primers from humangenomic DNA of a single individual in the following PCR reaction:

constituent concentration volume supplier/cat # buffer 10X   1 μlStratagene/600159 dNTPs 10 mM each 0.2 μl GE Healthcare/27-18(58) 0-04fwd primer 10 μM 0.2 μl Integrated DNA Technologies rev primer 10 μM0.2μ lIntegrated DNA Technologie gDNA 100 ng/μl 0.1 μl private sourcePfu DNA pol 2.5 U/μl 0.1 μl Stratagene/600159 H₂O 8.2 μl

temp (° C.) time cycles 95 2 min — 95 15 s 40  59* 15 s 40 * −0.1°C./cycle 72 90 s 40 72 15 min  4 ∞

All miRNA loci were amplified in separate 10 μl PCR reactions. Theproducts were purified using the Qiagen PCR Clean-Up buffer set andWhatman Unifilter GF/C filter plates (cat #7700-1101). DNA was elutedwith 17 μl H₂0 per well. The separate eluates were used in the followingrestriction reaction:

Constituent concentration volume supplier/cat # buffer E 10X   2 μlPromega/R005A EcoRI* 12 U/μl 0.1 μl Promega/R6017 BamHI* 10 U/μl 0.1 μlPromega/R6025 eluate N/A  16 μl N/A H₂O N/A 1.8 μl N/A *Amplicons withinternal restriction sites for EcoRI or BamHI were cut with XbaI orBglII respectively instead. The EcoRI + BglII reaction was done withPromega buffer D. The BamHI + XbaI reaction was done with Promega bufferE.

constituent concentration volume supplier/cat # buffer 10X   2 μlPromega/C1263 T4 DNA ligase 1-3 U/μl   0.2 μl Promega/M1804 restrictedpCDH* 1 ng/μl 7.8 μl System Biosciences/ CD510B-1 eluate N/A  10 μl N/ALigation overnight at 4° C. *For directional cloning, pCDH was cut withboth EcoRI and BamHI. An alternate construct called pCDH- was made withreversed EcoRI and BamHI restriction sites so that the amplicons with 5′BamHI and 3′ EcoRI were cloned in the proper direction. The ampliconswith an internal EcoRI site were cut with XbaI and ligated into a pCDHvector that was restricted with XbaI and BamHI.

The resulting ligates were transformed separately into bacteria (PromegaSingle Step (KRX) competent cells, cat #L3002). 50 μl competent cellswas diluted with 950 μl transformation buffer II (10 mM MOPS, 75 mMCaCl₂, 10 mM RbCl, 15% glycerol, filter-sterilized). Per 20 μl ligate,20 μl diluted competent cells was added. The mix was incubated for 15minutes on ice, heat-shocked at 37° C. for 30 seconds, and put back onice. After 2 minutes the transformed bacteria were reconstituted in 150μl Luria broth (LB). The bacteria were allowed to recover for 20 minutesat 37° C. after which they were plated out separately onampicillin-containing (50 ug/mL) LB-agar plates and grown overnight at37° C.

Single colonies of each plate are picked and subcultured overnight in400 μl ampicillin-containing (50 ug/mL) LB. 1 μl of subculture is lysedin 100 μl water for sequencing purposes. Bacterial lysate is used in thefollowing PCR reaction:

constituent concentration volume supplier/cat # buffer 5X   1 μl privatesource dNTPs 10 mM each 0.1 μl GE Healthcare/27-18(5-8)0-04 pCDH-fwd 10uM 0.1 μl Integrated DANN Technologies pCDH-rev 10 uM 0.1 μl IntegratedDANN Technologies lysate 1:100   1 μl N/A Taq DNA pol unknown 0.02 μl private source H₂O N/A 2.68 μl  N/A

temp (° C.) time cycles 95 2 min — 95 15 s 40  59* 15 s 40 * −0.1°C./cycle 72 90 s 40 72 15 min  4 ∞

(SEQ ID NOs: 311 and 312) pCDH-fwd CACGCTGTTTTGACCTCCATAGA pCDH-revCACTGACGGGCACCGGAG

The PCR products were diluted 25×. 1 μl of diluted PCR product was usedin the following Sanger Sequencing reaction:

Constituent concentration volume supplier/cat # buffer N/A 1.9 μlprivate source BigDye v3.1 N/A 0.1 μl ABI/4336921 pCDH-seq 10 uM 0.1 μlIDT (Integrated DNA Technologies) PCR product 1:25   1 μl N/A H₂O N/A1.9 μl N/A

temp (° C.) time cycles 94 10 sec — 50 5 s 40 60 2 min 40 10 ∞

pCDH-seq (SEQ ID NO: 313) GACCTCCATAGAAGATTCTAGAGCTAGC

30 μl precipitation mix (80% ethanol, 50 mM sodium acetate pH 5.5) wasadded to each of the sequencing reaction products. The mixes werevortexed for 10 seconds and spun down at 5000 rcf (relative centrifugalforce) for 45 minutes at 4° C. Supernatant was aspirated and DNA pelletswere washed with 30 μl ice cold 80% ethanol and spun at 5000 rcf for 5minutes at 4° C. Supernatant was aspirated and the DNA pellet was driedon a heat block for 10 minutes. The dry DNA pellet was dissolved in 10μl H₂O. The resulting DNA solution was sequenced on an ABI 3730XL DNAAnalyzer. Sequences were compared to the expected genomic sequences.Correct clones were added to the library. For incorrect clones anadditional 4 bacterial colonies were picked, and analyzed for insertsequence.

Library constructs were subcultured overnight in 50 mLampicillin-containing (100 ug/mL) LB and isolated with the QiagenQIAfilter Plasmid Midi Kit (cat #12245) supplemented with the QiagenEndoFree Plasmid Buffer Set (cat #19048) according to the instructionsof the manufacturer. DNA was dissolved in the supplied TE buffer andbrought to a final concentration of 500 ng/μl.

We ordered constructs that we were not able to clone ourselves asminigenes from Integrated DNA Technologies. In these cases, thefull-length hairpin plus 20 basepairs flanking each site were clonedinto our vector as a service by IDT.

Packaging and virus production was performed by System Biosciences asdescribed in the user manual of CD-500B1-CD523-A1.

Example 2 Viral Transduction and Screening

Day-8: Start cell growth of RF24 cells and HUVECs in a T25 culture flaskCoat a T25 culture flask per cell type with 2 ml 1% gelatin for an hourat 37° C. Thaw cells (these cells were frozen in 95% correspondingmedium and 5% DMSO) obtained from the −80° C. deep freezer at 37° C. ina water bath. Clean the vial with 70% ethanol and transfer the cells inthe culture flasks with 5 ml of the appropriate growth medium and placeat 37° C., 95% humidity and 5% CO₂. 4 hours after seeding, the DMSOcontaining medium must be replaced by fresh warm culture medium. Thecells are subsequently incubated for three days at 37° C., 95% humidityand 5% CO₂.

Day-5: Transfer of RF24 cells and HUVECs to a T75 culture flask

Coat a T75 culture flask per cell line with 6 ml 1% gelatin for an hourat 37° C.Remove gelatin.Wash the T25 culture flask with cells once with 1×PBS.Spread 0.5 ml TrypLE Express evenly over the cell surface and remove theexcess.Incubate at room temperature until all cells have detached.Resuspend the cells in 15 ml cell specific growth medium (as donebefore) and incubate the cells in a T75 culture flask at 37° C., 95%humidity and 5% CO₂.Day-1: Seeding of RF24 cells and HUVECs in 96 well platesProtocol per plate (everything is performed in duplo):Coat the 96 well plates with 30 μl/well 1% gelatin for an hour at 37° C.Wash the T75 culture flask with cells once with 1×PBS.Spread 1.0 ml TrypLE Express evenly over the cell surface and remove theexcess.Incubate at room temperature until all cells have detached.Inactivate the trypsin process through addition of 5 ml/T75 freshspecific growth medium.

Add 20 μl 0.4% trypan blue solution to the same volume of cellsuspension and count the cells using the Fuchs-Rosenthal chamber. Thisis done by counting 3 of the 16 squares consisting of 16 squares each.To calculate the amount of cells (n) per ml the average cell number iscorrected for dilution and multiplied by 5000 (c/ml=n×2×5000).

To seed one 96 well plate with RF24 cells at a concentration of 1500cells/well, 1.8E+5 cells need to be suspended in an end volume of 18 ml.150 μl suspension is to be added to each well.

To seed one 96 well plate with HUVECs at a concentration of 2000cells/well, 2.4E+5 cells need to be suspended in an end volume of 18 ml.150 μl suspension is to be added to each well.

The plated cells will be incubated at 37° C., 95% humidity and 5% CO₂overnight.

Note: one seeded plate will be taken into the screen without transducingthe cells, to get a better understanding of plate effects.

Day 0: Transduction of RF24 cells and HUVECs in the morningFirst polybrene is added to the 96 well plates. HUVECs will be exposedto 6 μg/ml and RF24 cells to 8 μg/ml polybrene in PBS.Per plate:HUVECs: To 1270 μl PBS, 200 μl polybrene (1 mg/ml in PBS) is added toget 136 μg/ml polybrene. 10*136=170*8. End concentration: 8 μg/mlpolybrene in 170 μl.RF24 cells: To 1320 μl PBS, 150 μl polybrene (1 mg/ml in PBS) is addedto get 96 μg/ml polybrene. 10*102=170*6. End concentration: 6 μg/mlpolybrene in 170 μl. For every one of the 14 virus plates, depending onthe titer, a specific volume will be added to the cells. This differsper cell line due to difference in seeding concentration. Ideally theamount of virus added should be around a Multiplicity of infection (MOI)of no more than 100 and no less than 50 in both cell lines (see FIGS. 1and 2). Because every plate contains an array of totally differenttiters, the MOI should be no less than 50. All plates will be diluted 10times in 1×PBS before addition. This is done to minimize pipettingerrors. Because the polybrene concentration is set for a volume of 170μl, and the volume will differ slightly per well, slight polybreneconcentration differences will be unavoidable.

Add x μl virus to the cells (two plates per virus) to facilitate an MOIof 50 or higher and incubate at 37° C., 95% humidity and 5% CO₂ for 24hours.

After transduction disinfect the flow cabinet by means of UV radiationbefore handling cells again.

As a control for plate effects, two non-treated plates will be incubatedfor 8 days together with the transduced plates.

Day 1: Medium refreshment of RF24 cells and HUVECs 24 hours aftertransduction Remove all virus containing medium using a multichannel anddispose of it according to the MLII procedure.Add 150 μl fresh and warm (37° C.) medium to the cells and incubate at37° C., 95% humidity and 5% CO₂. Also refresh medium untransducedplate(s).Day 4: Medium refreshment of RF24 cells and HUVECs 96 hours aftertransduction Remove 100 μl virus containing medium using a multichanneland dispose of it according to the MLII protocols.Add 100 μl fresh and warm (37° C.) medium to the cells and incubate at37° C., 95% humidity and 5% CO₂.Also refresh medium untransduced plate(s).Day 7: Medium refreshment of RF24 cells and HUVECs 168 hours aftertransduction Remove all virus containing medium using a multichannel anddispose of it according to the MLII protocols.Add 150 μl fresh and warm (37° C.) medium to the cells and incubate at37° C., 95% humidity and 5% CO₂.Also refresh medium untransduced plate(s).Day 8: Cell viability assay, 8 days after transduction using MTSAdd 20 μl/well MTS solution to 150 μl medium.Incubate at 37° C., 95% humidity and 5% CO₂ for 4 hours. Shake theplates so that all non dissolved crystals dissolve and measure theabsorbance at 492 nm using the Multiskan FC.

Example 3 Hit Selection & Confirmation

To select the miRNAs that affect cell growth, the Z-score was chosen. Toevaluate the normal distribution per plate and of combined plates, adistribution plot was made with the calculated median and standarddeviation and with the actual values.

Several methods to calculate the Z-score were evaluated with differentcut-offs:

Method 1:

This method calculates the individual miRNA Z-score per plate. Thestandard Z-score uses the mean and the SD of the miRNA population.

Method 2:

This method calculates the individual miRNA Robust Z-score per plate.The Robust Z-score uses the median and instead of the SD the medianabsolute deviation (MAD) multiplied with a given number (1.48) tosimulate a normal population (Chung N. et al., J Biomol Screen13:149-58, 2008).

The abovementioned methods were used to select the significantinhibitors and significant stimulators for the MTS screen. To evaluatethe normal distribution per plate and of combined plates a distributionplot was made with the calculated median and standard deviation and withthe actual values. The correlation between the individual MTS results ofthe duplicate tests was 0.85 and hit selection was performed using theaverage value.

The library contains approximately 1120 miRNAs. All miRNAs were platedin fourteen 96-well plates, leaving the outer columns 1 and 12 vacantfor positive (miR-92a-1) and an empty pCDH-CMV-MCS-EF1-Puro vector as anegative control. The library was screened in-duplo with a threshold ofMOI 50 with HUVEC and RF24 endothelial cell line (FIG. 3). A total of110 hits were selected. The next step was performing the hitconfirmation with normalized titers per plate. This resulted in 39reconfirmed hits, of which 6 were pro-proliferative. These hits wereagain confirmed by normalizing the titers per miRNA (MOI 100 and 200) toexclude viral toxicity or dose-dependent effects of individual miRNA's.In this experiment we used a control group of different empty vectorpopulation and non-responsive miRNAs, in duplo and mirrored at plates,to further exclude plate effects. This resulted in the final miRNA hitswhich regulate proliferation in HUVEC and RF24 cells (Table 1).

TABLE 1 miRNA hits from normalized MTS assay depicted in deltaabsorbance. Population of Empty vector was used as control group. HUVECHUVEC RF24 RF24 Delta Delta Delta Delta Absorbance Absorbance AbsorbanceAbsorbance miRNA Effect MOI 100 MOI 200 MOI 100 MOI 200 hsa-mir-7-3Inhibitory −0.73 −0.79 −0.82 −0.90 hsa-mir-26b Inhibitory −0.53 −0.64−0.49 −0.68 hsa-mir-574 Inhibitory −0.52 −0.54 −0.13 −0.02 hsa-mir-27aInhibitory −0.07 −0.17 −0.21 −0.26 hsa-mir-92a-1 Inhibitory 0.36 −0.220.65 0.30 hsa-mir-190b Inhibitory −0.49 −0.56 −0.43 −0.45 hsa-mir-142Inhibitory −0.64 −0.72 −0.21 −0.30 hsa-mir-9-2 Inhibitory −0.52 −0.59−0.26 −0.56

Example 4 Total RNA Isolation

HUVEC and RF24 cells were seeded in a 24-well plate and were transducedat a MOI of 50 according to previous transduction protocols. At day 8cells, cells were washed with ice cold PBS, 1 ml of PBS was added andthe plate was put on ice. Cells were collected using a cell scraper andpipetted in an eppendorf tube. Cells were pelleted, PBS was aspiratedand cells were frozen at −80° C.

For RNA isolation, cells were thawed on ice, 200 μl Trizol (Invitrogen,15596-026) was added followed by a 5 minute incubation at roomtemperature. 40 μl Chloroform was added and tubes were shaken andincubated for 3 minutes. Samples were centrifuged at 12000×g for 15minutes at 4° C. and two thirds of the upper aqueous layer wastransferred to a non-stick RNAse free tube. The remaining aqueous layerwas transferred to a different tube as back up.

1 μl of Glycoblue (Applied Biosystems, AM9510) was added to all samplestogether with 100 μl RNAse free iso-propanol and the RNA wasprecipitated at −20° C. overnight for the first batch and for two weeksfor the backup batch. Samples were centrifuged at max speed forminimally 45 minutes at 4° C. and the pellet was washed with 200 μl 70%RNAse free ethanol. Samples were centrifuged at 7400×g for 5 minutes at4° C. and supernatant was removed. The pellet was dried and dissolved in25 μl H₂O for the first batch and 15 μl nuclease free H₂O for the backupbatch.

The RNA kit for the Qubit (Invitrogen) was used according to protocol tomeasure the final RNA concentration.

Example 5 Stem-Loop RT-PCR and qPCR

MicroRNA expression was determined by stem-loop RT-PCR as described(Chen, C. et al Nucleic Acids Res. 33: e179 (2005)). For the stem loopRT-PCR, stem loop primers were designed for each individual miRNAaccording to the mature sequences in mirBase 15 and 16 and if present anisoform thereof. For the qPCR individual forward primers were designedalso according to the mature miRNA sequence in mirBase 15 and 16 (seebelow). The universal reverse primer was designed for the stem-loopsequence (see below). As a household gene U6 was used.

SL-hsa-miR-7 (SEQ ID NO: 314)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAACAACA forward hsa-miR-7(SEQ ID NO: 315) GCCCGCTTGGAAGACTAGTGATTTTG SLhsa-miR-26b(SEQ ID NO: 316) GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACCTATforward hsa-miR-26b (SEQ ID NO: 317) TGCCAGTTCAAGTAATTCAGGATSLhsa-miR-26b* (SEQ ID NO: 318)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGAGCCA forward_hsa-miR-26b*(SEQ ID NO: 319) TGCCAGCCTGTTCTCCATTACTTG SLhsa-miR-574-5p(SEQ ID NO: 320) GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACACACforward_hsa-miR-574-5p (SEQ ID NO: 321) TGCCAGTGAGTGTGTGTGTGTGAGTSLhsa-miR-574-3p (SEQ ID NO: 322)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTGTGGG forwardhsa-miR-574-3p(SEQ ID NO: 323) TGCCAGCACGCTCATGCACACACC SLhsa-miR-27a (SEQ ID NO: 324)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGCGGAA forward hsa-miR-27a(SEQ ID NO: 325) TGCCAGTTCACAGTGGCTAAGTT SLhsa-miR-27a* (SEQ ID NO: 326)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTGCTCA forwardhsa-miR-27a*(SEQ ID NO: 327) TGCCAGAGGGCTTAGCTGCTTGTG SL hsa-miR-92a-1(SEQ ID NO: 328) GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAACAGGCforward hsa-miR-92a-1 (SEQ ID NO: 329) TGCCAGTATTGCACTTGTCCCGGCSLhsa-miR-190b (SEQ ID NO: 330)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAAACCCA forward hsa-miR-190b(SEQ ID NO: 331) GCCCGCTAAGCCCTTACCCCAAAAA SL_hsa-miR-142-5p(SEQ ID NO: 332) GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGTAGTforward_hsa-miR-142-5p (SEQ ID NO: 333) GCCCGCCATAAAGTAGAAAGCACSL_hsa-miR-142-3p (SEQ ID NO: 334)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCCATAforward_hsa-miR-142-3p (SEQ ID NO: 335) TGCCAGTGTAGTGTTTCCTACTTTASLhsa-miR-9 (SEQ ID NO: 336)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCATAC forward hsa-miR-9(SEQ ID NO: 337) TGCCAGTCTTTGGTTATCTAGCTGT SLhsa-miR-9* (SEQ ID NO: 338)GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACTTTC forward_hsa-miR-9*(SEQ ID NO: 339) TGCCAGATAAAGCTAGATAACCGA qPCR Reverse (SEQ ID NO: 340)GTGCAGGGTCCGAGGT U6 stem loop primer (SEQ ID NO: 341) GTCATCCTTGCGCAGGU6 forward primer (SEQ ID NO: 342) CGCTTCGGCAGCACATATACU6 reverse primer (SEQ ID NO: 343) AGGGGCCATGCTAATCTTCT

For the qPCR 1 μl of RT-PCR product was used in a reaction with 25 pmolforward en reverse primer, H₂0 and 2×iQ SYBR Green supermix (Bio-rad,170-8880). PCR reaction was done on a BioRad CFX96 with a initial 5minute step of 95° C., 45 cycli of 10 seconds 95° C., 20 seconds 60° C.and 10 seconds 72° C., after which a melting curve analysis waspreformed. Relative miRNA expression levels were calculated. CT valuesfor miRNA induced and empty vector samples were obtained and thecorresponding U6 CT value was subtracted. The difference between emptyvector miRNA levels and miRNA levels in transduced samples werecalculated as a measure for over-expression.

Calculations ΔCt:

1. The ΔCt=average Ct of miRNA−average Ct of U6 control gene.2. Calculate ΔΔCt (The ΔΔCt=ΔCt transduced−ΔCt untransduced)3. These calculations can produce negative or positive numbers.4. Calculate fold change: If ΔΔCt is negative, there is a fold changeincrease and the equation is: 2̂−[average ΔΔCt] OR if ΔΔCt is positive,there is a fold change decrease and the equation is: −(2̂[average ΔΔCt]).

The final hits were reconfirmed by qPCR. HUVECs were transduced withlenti-viral miRNA with a MOI of 50. RNA was isolated and stemloop RT andqPCR was performed. The results are depicted in Table 2.

TABLE 2 Final hits confirmed by qPCR in HUVEC. Results are depicted infold increase. HUVEC Fold Increase miR-7 248.46 Untransduced miR-7 1.00miR-26b 7.47 Untransduced miR-26 1.00 miR-26b* 0.00 UntransducedmiR-26b* 1.00 miR-142-5p 224.64 Untransduced miR-142-5p 1.00 miR-142-3p1727.70 Untransduced miR-142-3p 1.00 miR-574-5p 48.17 UntransducedmiR-574-5p 1.00 miR-574-3p 1.60 Untransduced miR-574-3p 1.00 miR-91048.5 Untransduced miR-9 1.00 miR-9* 2864.33 Untransduced miR-9* 1.00miR-92a-1 2.55 Untransduced miR-92a-1 1 miR-92a-1 VIAL 0.90 UntransducedmiR-92a-1 1 miR-27a 81.70 Untransduced miR-27a 1 hsa-miR-27a* 1.58Untransduced miR-27a* 1.00 miR-190b 694760 Untransduced miR-190b 1

Example 6 DNA Sequence Analysis

The sequence of the cloned miRNAs in the lentiviral vectors for the hitswas verified as follows. Proviral DNA was amplified by PCR on thefraction of genomic DNA in the RNA samples, using 1 μl RNA sample asinput, and pCDH 15 lentiviral vector-specific primers (forward:5′-CACGCTGTTTTGACCTCCATAGA-3′, reverse: 5′-CACTGACGGGCACCGGAG-3′, (SEQID NO's: 344, 345)) for 30 cycles at an annealing temperature of 58° C.DNA sequence analysis was performed using 0.1-1 μl of PCR product, 0.5ul of 10 uM pCDH-specific primer (5′-GACCTCCATAGAAGATTCTAGAGCTAGC-3′,(SEQ ID NO: 313)), and the Big Dye v3.1 kit (Applied Biosystems).Products were analyzed on a 3730 DNA Analyzers (Applied Biosystems).Data were collected using the Collection Software v3.0 and analyzedusing the Sequencing Analysis v5.3.1 program (Applied Biosystems). ThisSanger DNA sequence confirmed the sequence of the miRNA transduced intothe cells (Table 3).

TABLE 3 Sanger DNA sequence of lentivirus transduced in HUVEC. QueryQuery Subject Subject HUVEC Accession ID start end start end StrandScore Evalue hsa-mir-7-3 MI0000265 hsa-mir-7-3 30 139 1 110 + 5505.00E−39 hsa-mir-26b MI0000084 hsa-mir-26b 10 86 1 77 + 385 2.00E−25hsa-mir-574 MI0003581 hsa-mir-574 32 127 1 96 + 480 3.00E−33 hsa-mir-27aMI0000085 hsa-mir-27a 44 120 1 78 + 341 1.00E−21 hsa-mir-92a-1 MI0000093hsa-mir-92a-1 50 127 1 78 + 390 8.00E−26 hsa-mir-190b MI0005545hsa-mir-190b 10 88 1 79 + 395 3.00E−26 hsa-mir-142 MI0000458 hsa-mir-14255 141 1 87 + 435 2.00E−29 hsa-mir-9-2 MI0000467 hsa-mir-9-2 5 91 1 87 +435 1.00E−29

Example 7 Synthetic Mimic Transfection

To validate the selected miRNAs, transfection using a synthetic mimicwas performed using X-tremeGENE (Roche,04476093001) according tomanufacturers protocol (0.5 μl X-tremeGENE for each 96-well). Mimics(Pre-miR™ miRNA Precursors) and siRNA's (ON-TARGET plus SMARTpool) wereordered from respectively Ambion and Dharmacon and tested at differentconcentrations. Mimic sequences used are mature sequences ofcorresponding miRNA molecules as identified in Table 5. Cell viabilitywas determined with the MTS assay as described above.

Materials:

Ambion® Pre-miR™ miRNA Precursors hsa-miR-574-5p (PM13081)Ambion® Pre-miR™ miRNA Precursors hsa-miR-7 (PM10047)Ambion® Pre-miR™ miRNA Precursors hsa-miR-190b (PM13035)Ambion® Pre-miR™ miRNA Precursors hsa-miR-142-3p (PM10398)Ambion® Pre-miR™ miRNA Precursors hsa-miR-142-5p (PM10979)Pre-miR™ miRNA Precursor Negative Control #1 (AM17110)

PLK1 ON-TARGETplus SMARTpool (L-003290-00-0005)

To further validate the function of the selected miRNAs, a syntheticmimic molecule for miR-7, miR-574-5p, miR-190b, miR-142-3p andmiR-142-5p was used. In the same MTS assay, a synthetic mimic as well asa control miRNA and, as a positive control, a PLK1 siRNA was added toHUVEC cells in increasing concentrations (FIGS. 4, 5 and 6). Thenegative miRNA control showed no effect on cell growth. The siRNA forPLK1 showed an inhibition of cell viability in a dose dependent manner.Similarly, the mimic for miR-7, miR-574-5p, miR-190b, miR-142-3p andmiR-142-5p also showed a reduction of cell growth in a dose dependentmanner. Furthermore, the results for miR-190b, miR-142-3p and miR-142-5pare depicted in Table 9.

TABLE 9 HUVECs transfected with mimics in a MTS assay depicted inrelative absorbance to X-tremeGene. Average relative absorbance ±standard deviation. Concentration miRNA (nM) scrambled siRNA-PLKmiR-190b miR-142-3p miR-142-5p 10 0.90 ± 0.07 0.81 ± 0.05 0.52 ± 0.08 0.8 ± 0.03 0.82 ± 0.02 30 0.86 ± 0.04 0.66 ± 0.02 0.44 ± 0.02 0.66 ±0.01 0.71 ± 0.01 50 0.79 ± 0.04 0.56 ± 0.02 0.42 ± 0.01 0.57 ± 0.01 0.66± 0.03

Example 8 Tube Formation (Matrigel) Assay

To confirm the anti-angiogenic effect of miR-190b, miR-142-3p andmiR-142-5p, we performed a tube formation assay with HUVECs, sinceHUVECs form blood vessel-like capillaries on Matrigel. As shown in FIGS.7 and 8, miR-190b, miR-142-3p and miR-142-5p inhibit the capillary tubeformation by HUVECs compared to the control groups, Lipofectamine andscrambled-miRNA.

Materials & Methods:

BD Matrigel Matrix Basement Membrane; BD Bioscience Catalog Number356237

HUVECs were seeded in a 12 well plate (45000 cells per well) andtransfected the day after with XtremeGene and corresponding mimic. Cellswere incubated for 48 hours. While the Matrigel coated plate incubatesfor 30 minutes at 37° C., the transfected HUVECs were counted andprepared in a cell suspension of 7500 cells/100 μl in complete HUVECgrowth medium. 100 μl of cell suspension was added to each Matrigelcoated well of a 96-well. The plate was incubated in a humidified 37° C.with 5% CO2.

The plates were examined after 3 hours. The cultures were scored at thistime for capillary tube formation, and again after 16-20 hours. Data inFIGS. 7 and 8 represent tube formation after 16-20 hours.

Example 9 Tube Formation (Matrigel) Assay with HUVEC Transfected withSynthetic Mimic

To validate the selected miRNAs, transfection using a synthetic mimicwas performed using X-tremeGENE (Roche, 04476093001) according tomanufacturers protocol (6 μl X-tremeGENE for each 12-well). Mimics(Pre-miR™ miRNA Precursors) and siRNA's (ON-TARGET plus SMARTpool) wereordered from Ambion and Dharmacon, respectively. Mimic sequences usedare mature sequences of corresponding miRNA molecules as identified inTable 5.

To confirm the anti-angiogenic effect of a miR-9 such as a miR-9*, weperformed a tube formation assay with HUVECs, since they form bloodvessel-like capillaries on Matrigel. HUVECs were seeded in a 12 wellplate (45000 cells per well) and transfected the day after withX-tremeGene and corresponding MIMIC or siRNA. Cells were incubated for48 hours.

While the Matrigel coated plate incubates for 30 minutes at 37° C., thetransfected HUVECs were counted and prepared in a cell suspension of7500 cells/100 μl in complete HUVEC growth medium. 100 μl of cellsuspension was added to each Matrigel coated well of a 96-well. Theplate was incubated in a humidified 37° C. with 5% CO2 and after threehours it was examined. The cultures were scored at this time forcapillary tube formation, and again after 16-20 hours.

As shown in FIG. 9, miR-9* strongly inhibits the capillary tubeformation by HUVECs compared to the control groups, X-tremeGene andscrambled-siRNA. This assay shows that miR-9* shows a strong inhibitionof tube formation.

Materials & Methods:

BD Matrigel Matrix Basement Membrane; BD Bioscience Catalog Number356237

Ambion® Pre-miR™ miRNA Precursors hsa-miR-9* (PM13072)Custom made siRNA Negative Control (Ambion)

Sense: (SEQ ID NO: 346) CAUCGUCGAUCGUAGCGCAtt Antisense:(SEQ ID NO: 347) UGCGCUACGAUCGACGAUGtt

PLK1 ON-TARGETplus SMARTpool (L-003290-00-0005) Example 10 SyntheticMimic Transfection

To further confirm the results described in Example 9, showing thatmiR-9* inhibits tube formation in vitro, a MTS cell viability assay wasperformed.

Materials and Methods:

HUVECs cultured in EGM-2 medium were transfected with a synthetic mimicusing X-tremeGENE (Roche, 04476093001) according to manufacturersprotocol (0.5 μl X-tremeGENE for each 96-well). Mimics (Pre-miR™ miRNAPrecursors) and siRNA's (ON-TARGET plus SMARTpool) were ordered fromrespectively Ambion and Dharmacon and tested at differentconcentrations. Mimic sequences used are mature sequences ofcorresponding miRNA molecules as identified in Table 5. Cell viabilitywas determined with the MTS assay as described above.

Materials:

Ambion® Pre-miR™ miRNA Precursors hsa-miR-9* (PM13072)Pre-miR™ miRNA Precursor Negative Control #1 (AM17110)siRNA scrambled ON-TARGETplus SMARTpool (D-001810-10-05)

PLK1 ON-TARGETplus SMARTpool (L-003290-00-0005)

EGM-2 medium, Lonza (CC-3162)

Results:

FIG. 10 shows that the cell viability of HUVEC is dose dependentlyinhibited by miR-9*. In the same MTS assay, a synthetic mimic, a controlmiRNA and a positive control, a PLK1 siRNA was added to HUVEC cells inincreasing concentrations. The negative miRNA control and siRNA controlshowed no effect on cell growth up to a concentration of 15 nM.Treatment with siRNA for PLK1 inhibits cell viability in a dosedependent manner. Similarly, treatment with the mimic for miR-9* shows areduction of cell viability similar to the inhibition of cell viabilityby siPLK1.

Example 11 In Vitro Angiogenesis Assay: Sprouting Assay

The three-dimensional endothelial cell sprouting assay was used as amodel to investigate the role of miR-7 and miR-574-5p in endothelialcell proliferation and migration. We transfected HUVEC with mimics andharvested the cells four days after transfection to form spheroidsovernight with the hanging drop method. The spheroids were placed in agel and stimulated with bFGF to actively form capillary sprouts.

Materials and Methods:

HUVEC were transfected with 50 nM of mimics (see Example 7) and weresuspended in culture medium containing 20% (v/v) methocel and 10% heatinactivated human serum, at a final density of 40000 cells/ml. Themethocel was diluted from a stock solution obtained by dissolving 6 g ofcarboxymethylcellulose (viscosity 4000 cp; Sigma-Aldrich) in 500 ml ofmedium 199.

A single spheroid is prepared from 1000 endothelial cells. A drop of 25μl is pipetted on the inside of the inverted lid of a square 12×12 cmpetri-dish. The lid is carefully placed in its normal position over thedish containing 10 ml PBS and placed overnight in an incubator at 37° C.(5% CO2). Drops are pipetted with a multichannel pipette to ensure equalsize spheroids and a maximum of 100-120 spheroids are placed on theinside of one dish.

The spheroids were harvested by rinsing the lid gently with 2×5 ml PBScontaining 10% heat-inactivated FCS, collected in 15 ml tubes andcentrifuged at 300 g for 5 min. Medium is aspirated and the spheroidpellet is gently loosened by scraping over a rough surface.

Collagen gels for embedding of spheroids were prepared from PureColbovine type I collagen (Nutacon) in medium 199, pH 7.4, by combining, onice, 2/3 end volume Collagen and 1/12 end volume 10×M199, which isneutralized with ice-cold 0.2M NaOH (solution A). In another tube (B),NBCS (1/10 end volume) and Heparin (0.1% end volume) are mixed withmethocell stock (15% of end volume). Subsequently, A and B are gentlymixed and used to overlay the spheroids.

HUVEC spheroids were taken up in this complete mix. Then, 400 μl gel wasaliquoted into prewarmed μ-slides (Ibidi, Germany) and left to incubatefor 30 minutes at 37° C. (5% CO2) for the gels to polymerize. After thisstep, 100 μl overlay medium containing bFGF (100 ng/ml; 20 ng/ml endconcentration) was added for incubation overnight at 37° C. (5% CO2).Approximately 20 spheroids should be present in one well.

Phase-contrast images were captured using a camera (Hitachi GiGE, 1.4MB) linked to an inverted microscope (Leica DMI3000). In vitro capillarysprouting was quantified by measuring the cumulative sprout length andthe number of sprouts per spheroid using ImageJ software. For eachtreatment group the mean cumulative sprout length and the mean number ofsprouts was calculated by averaging these parameters over 10 speroids.

Results:

FIG. 11A shows an example of the images that were used for thequantification of the sprouting properties of HUVEC spheroid. The imagesshow that bFGF induced sprout formation. The images also show that HUVECspheroids generated from HUVEC that have been treated with miR-7,miR-574-5p and miR-27a form less and short sprouts as compared to thecontrol HUVEC treated with X-tremegene (mock) or miR-scrambled. FIGS.11B and C depict the quantification of the sprouts per treatment groupand shows that miR-7, miR-574-5p and miR-27a significantly inhibitsprout formation and sprout length (p<0.001 one-way Anova). miR-27a wasused as positive control since this miRNA has been described inliterature to be involved in the angiogenesis process.

Example 12 In Vivo Testing of miRNAs in the N2a Tumor Model Materialsand Methods:

To test the efficacy of the anti-proliferative miRNAs in vivo, we usedan in-vivo set up adapted from Vader et al. (Angiogenesis. 2011(4):457-66). Six to eight weeks old normal male A/J mice (Harlan, theNetherlands) were injected subcutaneously with 100 μl Neuro2A cells(1×10⁷ cells/ml). Tumor sizes were measured daily with a digital caliperand tumor volume was calculated by using the following formula:Length×width²×0.52. Treatment started with a tumor volume between 40-70mm³ by intratumoral injection of 10 μg of miRNA or siRNA on days 1, 3,5, 7, 9, 11 followed by electroporation at a setting of 200V/cm using anECM 830 electroporator (BTX, San Diego, Calif.) set to deliver 2×2pulses at perpendicular angles. On day 12 mice were scarified and thetumors were excised. miRNA mimics were ordered from Ambion based on thesequence listed in Table 5. miR-scrambled was ordered from Ambion asdescribed in Example 7. siVEGFR2 was ordered from Ambion and containedthe following sequence:

Sense: (SEQ ID NO: 397) 5′-CCGGAAAUCUGGAGAAUCAtt-3′ Anti-sense(SEQ ID NO: 398) 5′-UGAUUCUCCAGAUUUCCGGtt-3′MiRNAs and siRNA were dissolved in phosphate buffer (PBS).

Results:

FIG. 12 shows the tumor growth curves for animal groups that weretreated with phosphate buffer (PBS), miR-scrambled, miR-7, miR-574-5p,miR-9*, miR-27a or siVEGFR-2. The curves show that the tumor growthcurve of the miR-scrambled (n=6) treated animals is similar to that ofPBS treated animals (n=6), indicating low toxicity of non-functionalmiRNA. The curves also show that animals treated with miR-7 (n=7) show areduced tumor growth of approximately 50% compared to the miR-Scrambled(n=6) treated group (FIG. 12A). The same effect was observed between day6 and 10 for mice (n=7) treated with miR-574-5p mimic (FIG. 12B).Strikingly, animals treated with the reference anti-angiogenic miRNAmiR-27a (n=7, FIG. 12C), showed less reduction in tumor growth comparedto miR-7 and miR-574-5p. As a positive control within the in vivoexperiment animals were treated with siVEGFR-2 (n=7, FIG. 12D). Thisgroup showed a significant tumor growth repression from day 7 until theend of the experiment compared to PBS (n=6) and miR-Scrambled (n=6)groups. The tumor growth curves in FIG. 12E were generated using adifferent cohort of mice. Tumors treated with mimic miR-9* (n=8) show asignificant tumor growth repression from day 7 until the end of theexperiment compared to PBS (n=8) and miR-Scrambled (n=10) treated mice.

Example 13 Immunohistochemistry: CD31 Antibody Staining

To examine whether the inhibition of tumor growth (see Example 12) canbe ascribed to a decrease in tumor vasculature, tumors were stained withthe endothelial cell marker CD31. Microvascular density (MVD) wascalculated by quantification of the CD31 staining.

Materials and Methods:

Paraffin embedded tumor sections of 6 μm were immunostained for CD-31.The paraffin-embedded tumor sections were deparaffinized in xylene andhydrated in a graded series of alcohol baths. After washing the sectionsin demineralized water, the sections were boiled for 15 min in 10 mMCitrate buffer (pH 6). After reaching room temperature, the sectionswere washed with 1×PBS followed by incubating them in 5% normal goatserum (Dako x090710) in 1% BSA/PBS for 30 min at RT. Then the tissueswere incubated with primary antibody rabbit anti-mouse CD31 in 1%BSA/PBS at 4° C. overnight. Next day after reaching room temperature thetissues were washed 3× with PBS. To inactivate the endogenous peroxidasethe tumor tissues were incubated in 0.3% H₂O₂/PBS (1 part 30% H₂O₂ en 9parts PBS) for 30 min at RT. After washing 3× with PBS the sections wereincubated with Bright Vision polyHRP goat anti-rabbit (Immunologic) for30 min at RT. The slides were washed again and subsequently incubated inDAB (3,3′-diaminobenzidine) solution (500 μg/ml) for 1 min followed bywashing twice with demineralized water. The slides were transferred inHematoxylin (Mayers, J. T. Baker, the Netherlands) for 15 sec followedby another 2 washing steps with demineralized water and finally with tapwater. The slides were dehydrated again by transferring themsubsequently into 70%, 90%, 95%, and 100% ethanol and Xylene. Thesections were dried followed by addition of 3 drops of Pertex on theslide and covered with cover glass for further analysis.

Quantification of microvessel density (MVD) was done by counting thepositively stained luminal structures in four to five representativeimages per animal Four animals were analysed per treatment group.

Results:

CD31 staining of tumor tissues treated with miR-7 shows a significantreduction in MVD compared to miR-Scrambled treated tumors (FIG. 13). Thereduction in MVD is similar to that observed upon treatment withsiVEGFR2. This shows that miRNA-7 inhibits microvascularization and actsas an anti-angiogenic miRNA,

TABLE 4Precursor sequences of miRNAs identified in screening or referred to in the application List of miRNA precursor sequences (5′ to 3′direction). All sequences were obtained from miRBase (release 16: Sept 2010; www.mirbase.org). SEQID NO miRNA Precursor sequence  1 hsa-mir-7-1UUGGAUGUUGGCCUAGUUCUGUGUGGAAGACUAGUGAUUUUGUUGUUUUUAGAUAACUAAAUCGACAACAAAUCACAGUCUGCCAUAUGG CACAGGCCAUGCCUCUACAG  2hsa-mir-7-2 CUGGAUACAGAGUGGACCGGCUGGCCCCAUCUGGAAGACUAGUGAUUUUGUUGUUGUCUUACUGCGCUCAACAACAAAUCCCAGUCUACCU AAUGGUGCCAGCCAUCGCA  3hsa-mir-7-3 AGAUUAGAGUGGCUGUGGUCUAGUGCUGUGUGGAAGACUAGUGAUUUUGUUGUUCUGAUGUACUACGACAACAAGUCACAGCCGGCCUCAU AGCGCAGACUCCCUUCGAC  4hsa-mir-26b CCGGGACCCAGUUCAAGUAAUUCAGGAUAGGUUGUGUGCUGUCCAGCCUGUUCUCCAUUACUUGGCUCGGGGACCGG  5 hsa-mir-574GGGACCUGCGUGGGUGCGGGCGUGUGAGUGUGUGUGUGUGAGUGUGUGUCGCUCCGGGUCCACGCUCAUGCACACACCCACACGCCCACAC UCAGG  6 hsa-mir-27aCUGAGGAGCAGGGCUUAGCUGCUUGUGAGCAGGGUCCACACCAAGUCGUGUUCACAGUGGCUAAGUUCCGCCCCCCAG  7 hsa-mir-92a-1CUUUCUACACAGGUUGGGAUCGGUUGCAAUGCUGUGUUUCUGUAUGGUAUUGCACUUGUCCCGGCCUGUUGAGUUUGG  8 hsa-mir-132CCGCCCCCGCGUCUCCAGGGCAACCGUGGCUUUCGAUUGUUACUGUGGGAACUGGAGGUAACAGUCUACAGCCAUGGUCGCCCCGCAGCACG CCCACGCGC  9 hsa-mir-126CGCUGGCGACGGGACAUUAUUACUUUUGGUACGCGCUGUGACACUUCAAACUCGUACCGUGAGUAAUAAUGCGCCGUCCACGGCA 10 hsa-mir-21UGUCGGGUAGCUUAUCAGACUGAUGUUGACUGUUGAAUCUCAUGGCAACACCAGUCGAUGGGCUGUCUGACA 11 hsa-mir-145CACCUUGUCCUCACGGUCCAGUUUUCCCAGGAAUCCCUUAGAUGCUAAGAUGGGGAUUCCUGGAAAUACUGUUCUUGAGGUCAUGGUU 12 hsa-let-7a-1UGGGAUGAGGUAGUAGGUUGUAUAGUUUUAGGGUCACACCCACCACUGGGAGAUAACUAUACAAUCUACUGUCUUUCCUA 13 hsa-let-7a-2AGGUUGAGGUAGUAGGUUGUAUAGUUUAGAAUUACAUCAAGGGAGAUAACUGUACAGCCUCCUAGCUUUCCU 14 hsa-let-7a-3GGGUGAGGUAGUAGGUUGUAUAGUUUGGGGCUCUGCCCUGCUAUGGGAUAACUAUACAAUCUACUGUCUUUCCU 15 hsa-mir-221UGAACAUCCAGGUCUGGGGCAUGAACCUGGCAUACAAUGUAGAUUUCUGUGUUCGUUAGGCAACAGCUACAUUGUCUGCUGGGUUUCAGG CUACCUGGAAACAUGUUCUC 16hsa-mir-222 GCUGCUGGAAGGUGUAGGUACCCUCAAUGGCUCAGUAGCCAGUGUAGAUCCUGUCUUUCGUAAUCAGCAGCUACAUCUGGCUACUGGGUCU CUGAUGGCAUCUUCUAGCU 17hsa-mir-190b UGCUUCUGUGUGAUAUGUUUGAUAUUGGGUUGUUUAAUUAGGAACCAACUAAAUGUCAAACAUAUUCUUACAGCAGCAG 18 hsa-mir-142GACAGUGCAGUCACCCAUAAAGUAGAAAGCACUACUAACAGCACUGGAGGGUGUAGUGUUUCCUACUUUAUGGAUGAGUGUACUGUG 19 hsa-mir-9-1CGGGGUUGGUUGUUAUCUUUGGUUAUCUAGCUGUAUGAGUGGUGUGGAGUCUUCAUAAAGCUAGAUAACCGAAAGUAAAAAUAACCCCA 20 hsa-mir-9-2GGAAGCGAGUUGUUAUCUUUGGUUAUCUAGCUGUAUGAGUGUAUUGGUCUUCAUAAAGCUAGAUAACCGAAAGUAAAAACUCCUUCA 21 hsa-mir-9-3GGAGGCCCGUUUCUCUCUUUGGUUAUCUAGCUGUAUGAGUGCCACAGAGCCGUCAUAAAGCUAGAUAACCGAAAGUAGAAAUGAUUCUCA

TABLE 5 Mature and mimic sequences of miRNAs identified in screening orreferred to in the application List of mature miRNA sequences (5′ to 3′direction). All sequences were obtained from miRBase (release 16: Sept 2010; www.mirbase.org).Seed (SEQ microRNA mature miRNA ID NO) SEQ mature miRNA (SEQ ID)hsa-mir-7-1 hsa-miR-7 GGAAGAC UGGAAGACUAGUGAUUUUGUUGU (22) hsa-mir-7-2(348) hsa-mir-7-3 hsa-mir-7-1 hsa-miR-7-1* AACAAAUCAACAAAUCACAGUCUGCCAUA (23) (349) hsa-mir-7-2 hsa-miR-7-2* AACAAAUCAACAAAUCCCAGUCUACCUAA (24) (350) hsa-mir-26b hsa-miR-26b UCAAGUAUUCAAGUAAUUCAGGAUAGGU (25) (351) hsa-mir-26b hsa-miR-26b* CUGUUCUCCUGUUCUCCAUUACUUGGCUC (26) (352) hsa-mir-574 hsa-miR-574-5p GAGUGUGUGAGUGUGUGUGUGUGAGUGUGU (27) (353) hsa-mir-574 hsa-miR-574-3p ACGCUCACACGCUCAUGCACACACCCACA (28) (354) hsa-mir-27a hsa-miR-27a UCACAGUUUCACAGUGGCUAAGUUCCGC (29) (355) hsa-mir-27a hsa-miR-27a* GGGCUUAAGGGCUUAGCUGCUUGUGAGCA (30) (356) hsa-mir-92a-1 hsa-miR-92a AUUGCACUAUUGCACUUGUCCCGGCCUGU (31) hsa-mir-92a-2 (357) hsa-mir-92a-1hsa-miR-92a-1* GGUUGGG AGGUUGGGAUCGGUUGCAAUGCU (32) (358) hsa-mir-132hsa-miR-132 AACAGUC UAACAGUCUACAGCCAUGGUCG (33) (359) hsa-mir-132hsa-miR-132* CCGUGGC ACCGUGGCUUUCGAUUGUUACU (34) (360) hsa-mir-126hsa-miR-126 CGUACCG UCGUACCGUGAGUAAUAAUGCG (35) (361) hsa-mir-126hsa-miR-126* AUUAUUA CAUUAUUACUUUUGGUACGCG (36) (362) hsa-mir-21hsa-miR-21 AGCUUAU UAGCUUAUCAGACUGAUGUUGA (37) (363) hsa-mir-21hsa-miR-21* AACACCA CAACACCAGUCGAUGGGCUGU (38) (364) hsa-mir-145hsa-miR-145 UCCAGUU GUCCAGUUUUCCCAGGAAUCCCU (39) (365) hsa-mir-145hsa-miR-145* GAUUCCU GGAUUCCUGGAAAUACUGUUCU (40) (366) hsa-let-7a-1hsa-let-7a GAGGUAG UGAGGUAGUAGGUUGUAUAGUU (41) hsa-let-7a-2 (367)hsa-let-7a-3 hsa-let-7a-1 hsa-let-7a* UAUACAA CUAUACAAUCUACUGUCUUUC (42)hsa-let-7a-3 (368) hsa-let-7a-2 hsa-let-7a-2* UGUACAGCUGUACAGCCUCCUAGCUUUCC (43) (369) hsa-mir-221 hsa-miR-221 GCUACAUAGCUACAUUGUCUGCUGGGUUUC (44) (370) hsa-mir-221 hsa-miR-221* CCUGGCAACCUGGCAUACAAUGUAGAUUU (45) (371) hsa-mir-222 hsa-miR-222 GCUACAUAGCUACAUCUGGCUACUGGGU (46) (372) hsa-mir-222 hsa-miR-222* UCAGUAGCUCAGUAGCCAGUGUAGAUCCU (47) (373) hsa-mir-190b hsa-miR-190b GAUAUGUUGAUAUGUUUGAUAUUGGGUU (48) (374) hsa-mir-142 hsa-miR-142-5p AUAAAGUCAUAAAGUAGAAAGCACUACU (49) (375) hsa-mir-142 hsa-miR-142-3p GUAGUGUUGUAGUGUUUCCUACUUUAUGGA (50) (376) hsa-mir-9-1 hsa-miR-9 CUUUGGUUCUUUGGUUAUCUAGCUGUAUGA (51) hsa-mir-9-2 (377) hsa-mir-9-3 hsa-mir-9-1hsa-miR-9* UAAAGCU AUAAAGCUAGAUAACCGAAAGU (52) hsa-mir-9-2 (378)hsa-mir-9-3

TABLE 6 DNA Sequences of miRNAs identified in screening (see Table 1)Seq ID miRNA Cloned sequence in lentiviral vector 53 hsa-mir-7-3TCATAGCTTGGCTCAGGTGAGAAGGAGGAGCTGGGCAGGGGTCTCAGACATGGGGCAGAGGGTGGTGAAGAAGATTAGAGTGGCTGTGGTCTAGTGCTGTGTGGAAGACTAGTGATTTTGTTGTTCTGATGTACTACGACAACAAGTCACAGCCGGCCTCATAGCGCAGACTCCCTTCGACCTTCGCCTTCAATGGGCTGGCCAGTGGGGGAGAACCGGGGAGGTCGGGGAAGAATCGCTTCCACTCGGAGTGGGGGGGCTGGCTCACTCCAGGCGATACAG 54 hsa-mir-26bGGGCTCCTCCTCTAGGCTCCCCCGTGCTGTGCTCCCTCGCCCCACCCTGCCCGGGACCCAGTTCAAGTAATTCAGGATAGGTTGTGTGCTGTCCAGCCTGTTCTCCATTACTTGGCTCGGGGACCGGTGCCCTGCAGCCTTGGGGTGAGGGGGCTGCCCCTGGATTCCTGCACTAGGCTGAGGTTGAGGCAGGGGAAGGGATTGGGAATTAGGGACCTC 55 hsa-mir-574TCTGCGTTAGTGAGAAGCAGTGGTCAGGGAGGACCCGGCTCTGGGGTGAGGGTCTGGGGCGGCGCGGCCGAGGGACCTGCGTGGGTGCGGGCGTGTGAGTGTGTGTGTGTGAGTGTGTGTCGCTCCGGGTCCACGCTCATGCACACACCCACACGCCCACACTCAGGGTCTGCCCCCTCGGCCTGCGTGAACCTCCGCGGAGCCTGCCTGGATCTCCCAAAGTATCC 56 hsa-mir-27aCCTGTCACAAATCACATTGCCAGGGATTTCCAACCGACCCTGAGCTCTGCCACCGAGGATGCTGCCCGGGGACGGGGTGGCAGAGAGGCCCCGAAGCCTGTGCCTGGCCTGAGGAGCAGGGCTTAGCTGCTTGTGAGCAGGGTCCACACCAAGTCGTGTTCACAGTGGCTAAGTTCCGCCCCCCAGGCCCTCACCTCCTCTGGCCTTGCCGCCTGTCCCCTGCTGCCGCCTGTCTGCCTGCCATCCTGCTGCCTGGCCTCCCTGGGCTCTGCCTCCCGTGCCTACTGAGCTG AAACACA 57hsa-mir-92a-1 CCAGCTGTGTGATATTCTGCTGTGCAAATCCATGCAAAACTGACTGTGGTAGTGAAAAGTCTGTAGAAAAGTAAGGGAAACTCAAACCCCTTTCTACACAGGTTGGGATCGGTTGCAATGCTGTGTTTCTGTATGGTATTGCACTTGTCCCGGCCTGTTGAGTTTGGTGGGGATTGTGACCAGAAGATTTTGAAAATTAAATATTACTGAAGATTTCGACTTCCACT 58 hsa-mir-190bTCTTTGCAACTGGAAGGAAGGCAGATGACCCCCAAAGCTCTCCTGCCTGCTTCTGTGTGATATGTTTGATATTGGGTTGTTTAATTAGGAACCAACTAAATGTCAAACATATTCTTACAGCAGCAGGTGATTCAGCACCACCCTCTTTCATACTTCAATCTCTGGGGCTCCTGTCTCTTTTACTGAACCTCTTCTC TCCAGG 59 hsa-mir-142TCTTAGGAAGCCACAAGGAGGGCTGGGGGGCTCTTGGAGCAGGAGTCAGGAGGCCTGGGCAGCCTGAAGAGTACACGCCGACGGACAGACAGACAGTGCAGTCACCCATAAAGTAGAAAGCACTACTAACAGCACTGGAGGGTGTAGTGTTTCCTACTTTATGGATGAGTGTACTGTGGGCTTCGGAGATCACGCCACTGCTGCCGCCCGCTGCCCGCCACCATCTTCCTCGGCGCTCGGG GACCTCGTGTGACAGGTGA 60hsa-mir-9-2 ATCAGGACCTGGAGTCTGGCAAGAGGAAGACAGAGGCCTGTGTGGGAAGCGAGTTGTTATCTTTGGTTATCTAGCTGTATGAGTGTATTGGTCTTCATAAAGCTAGATAACCGAAAGTAAAAACTCCTTCAAGATCGCCGGGGAGCGTGTGAGAATGAAAGACTACAGCCG

TABLE 7 IsomiR and seed sequences of miRNAs identified in screening (see Table 1) or referred to in the application.These isomiR sequences have been derived from small RNA  high-throughput deep sequencing analyses, and were obtained  after combining the data of 87 human tissue samples. Mature miRNASeed (SEQ ID NO) IsomiR sequence (SEQ ID NO) hsa-miR-7 GGAAGAC (61)UGGAAGACUAGUGAUUUUGUUGUU (116) GAAGACU (62) UGGAAGACUAGUGAUUUUGUUG (117)AAGACUA (63) UGGAAGACUAGUGAUUUUGU (118) AGACUAG (64)UGGAAGACUAGUGAUUUUGUUGUUU (119) GACUAGU (65) UGGAAGACUAGUGAUUUUGUU (120)ACUAGUG (66) GGAAGACUAGUGAUUUUGUUGUU (121) CUAGUGA (67)GGAAGACUAGUGAUUUUGUUGU (122) UGGAAGA (68) UGGAAGACUAGUGAUUUUG (123)GUGGAAG (69) UGGAAGACUAGUGAUUUUGUUGUUC (124) UGGAAGACUAGUGAUUUU (125)GAAGACUAGUGAUUUUGUUGUU (126) GAAGACUAGUGAUUUUGUUGU (127)UGGAAGACUAGUGAUUUUGUUGUUUU (128) GGAAGACUAGUGAUUUUGUUGUUU (129)GAAGACUAGUGAUUUUGUUGUUG (130) AAGACUAGUGAUUUUGUUGUU (131)AGACUAGUGAUUUUGUUGUU (132) AAGACUAGUGAUUUUGUUGU (133)GACUAGUGAUUUUGUUGUUUUU (134) GACUAGUGAUUUUGUUGUU (135)GGAAGACUAGUGAUUUUGUUG (136) UGGAAGACUAGUGAUUUUGUUGUUGU (137)UGGAAGACUAGUGAUUUUGUUGUUCUG (138) UGGAAGACUAGUGAUUUUGUUGUUCUGA (139)AGACUAGUGAUUUUGUUGU (140) GGAAGACUAGUGAUUUUGUU (141)GACUAGUGAUUUUGUUGUUUUUA (142) GACUAGUGAUUUUGUUGU (143)GACUAGUGAUUUUGUUGUUU (144) GUGGAAGACUAGUGAUUUUGUU (145)GAAGACUAGUGAUUUUGUUGUUU (146) GUGGAAGACUAGUGAUUUUGUUGUU (147)GACUAGUGAUUUUGUUGUUUU (148) AAGACUAGUGAUUUUGUUGUUU (149)AACAAAUCACAGUCUGCCAU (150) GUGGAAGACUAGUGAUUUUGUUGU (151)UGGAAGACUAGUGAUUUUGUUGUUUUU (152) AAGACUAGUGAUUUUGUUGUUUU (153)ACUAGUGAUUUUGUUGUU (154) GGAAGACUAGUGAUUUUGUUGUUG (155)GAAGACUAGUGAUUUUGUUG (156) AAGACUAGUGAUUUUGUUGUUG (157)UGUGGAAGACUAGUGAUUUUGUUGU (158) UGUGGAAGACUAGUGAUUUUGU (159)CUGGAAGACUAGUGAUUUUGUUGU (160) GGAAGACUAGUGAUUUUGUUGUUUU (161)GGAAGACUAGUGAUUUUGU (162) GAAGACUAGUGAUUUUGUUGUUUU (163)AGACUAGUGAUUUUGUUG (164) AAGACUAGUGAUUUUGUUGUUUUU (165)AGACUAGUGAUUUUGUUGUUU (166) hsa-miR-7-1* AACAAAU (70)AACAAAUCACAGUCUGCCAUA (167) CAAAUCA (71) CAACAAAUCACAGUCUGCCAU (168)ACAAAUC (72) CAACAAGUCACAGCCGGCCUCA (169) AACAAGU (73)CAACAAAUCACAGUCUGCCA (170) ACAAGUC (74) AACAAAUCACAGUCUGCCAUAU (171)AACAAAUCACAGUCUGCCAU (172) CAACAAGUCACAGCCGGCCUCAU (173)CAACAAAUCACAGUCUGCCAUAU (174) ACAAAUCACAGUCUGCCAUAU (175)CAACAAGUCACAGCCGGCCUC (176) AACAAGUCACAGCCGGCCUCA (177) hsa-miR-26bUCAAGUA (75) UUCAAGUAAUUCAGGAUAGGUU (178) CAAGUAA (76)UCAAGUAAUUCAGGAUAGGUU (179) UUCAAGUAAUUCAGGAUAGG (180) hsa-miR-574-5pGAGUGUG (77) UGAGUGUGUGUGUGUGAGUGU (181) AGUGUGU (78)UGAGUGUGUGUGUGUGAGUGUGUGU (182) UGAGUGU (79)UGAGUGUGUGUGUGUGAGUGUG (183) UGCGUGG (80) UGAGUGUGUGUGUGUGAGUGUGUG (184)UGAGUGUGUGUGUGUGAGUG (185) UGAGUGUGUGUGUGUGAGU (186)GAGUGUGUGUGUGUGAGUGUGU (187) GAGUGUGUGUGUGUGAGUGU (188)GUGAGUGUGUGUGUGUGAGUGU (189) GAGUGUGUGUGUGUGAGUGUGUGU (190)GAGUGUGUGUGUGUGAGUGUG (191) GUGAGUGUGUGUGUGUGAGUGUGU (192)GAGUGUGUGUGUGUGAGUGUGUG (193) UGAGUGUGUGUGUGUGAG (194)CUGCGUGGGUGCGGGCGUG (195) GAGUGUGUGUGUGUGAGU (196) hsa-miR-574-3pACGCUCA (81) CACGCUCAUGCACACACCCAC (197) CGCUCAU (82)CACGCUCAUGCACACACCCA (198) GCUCAUG (83) ACGCUCAUGCACACACCCACA (199)CACGCUC (84) CACGCUCAUGCACACACCC (200) CACGCUCAUGCACACACCCACAC (201)CACGCUCAUGCACACACC (202) CGCUCAUGCACACACCCACA (203)ACGCUCAUGCACACACCCAC (204) CCACGCUCAUGCACACACCCAC (205) hsa-miR-27aUCACAGU (85) UUCACAGUGGCUAAGUUCCG (206) UUCACAGUGGCUAAGUUCC (207UUCACAGUGGCUAAGUUC (208) UUCACAGUGGCUAAGUU (209) hsa-miR-92aAUUGCAC (86) UAUUGCACUUGUCCCGGCCUG (210) UAUUGCACUUGUCCCGGCCU (211)hsa-miR-132 AACAGUC (87) UAACAGUCUACAGCCAUGGUC (212) ACAGUCU (88)UAACAGUCUACAGCCAUGGU (213) AACAGUCUACAGCCAUGGUCG (214)UAACAGUCUACAGCCAUGG (215) hsa-miR-126 GUACCGU (89)CGUACCGUGAGUAAUAAUGCG (216) hsa-miR-21 AGCUUAU (90)UAGCUUAUCAGACUGAUGUUGAC (217) UAGCUUAUCAGACUGAUGUUG (218) hsa-miR-145UCCAGUU (91) GUCCAGUUUUCCCAGGAAUCCC (219) GUCCAGUUUUCCCAGGAAUCC (220)GUCCAGUUUUCCCAGGAAUC (221) GUCCAGUUUUCCCAGGAAU (222) hsa-miR-221GCUACAU (92) AGCUACAUUGUCUGCUGGGUUU (223) AGCUACAUUGUCUGCUGGGUU (224)AGCUACAUUGUCUGCUGGG (225) hsa-miR-222 GCUACAU (93)AGCUACAUCUGGCUACUGGGUCU (226) AGCUACAUCUGGCUACUGGGUCUC (227)AGCUACAUCUGGCUACUGGGUCUCU (228) AGCUACAUCUGGCUACUGGG (229)AGCUACAUCUGGCUACUGGGUC (230) Let-7a GAGGUAG (94)UGAGGUAGUAGGUUGUAUAGU (231) UGAGGUAGUAGGUUGUAUAG (232)UGAGGUAGUAGGUUGUAUAGUUU (233) hsa-miR-190b GAUAUGU (95)UGAUAUGUUUGAUAUUGGGUUG (234) AUAUGUU (96) UGAUAUGUUUGAUAUUGGGUUGU (235)UGAUAUGUUUGAUAUUGGGU (236) GAUAUGUUUGAUAUUGGGUUG (237)UGAUAUGUUUGAUAUUGGG (238) GAUAUGUUUGAUAUUGGGUUGU (239)GAUAUGUUUGAUAUUGGGUU (240) hsa-miR-142-5p CCAUAAA (97)CCCAUAAAGUAGAAAGCACUA (241) AUAAAGU (98) CCCAUAAAGUAGAAAGCACU (242)UAAAGUA (99) CAUAAAGUAGAAAGCACUA (243) CAUAAAG (100)CAUAAAGUAGAAAGCACUACUA (244) AAAGUAG (101) CCCAUAAAGUAGAAAGCACUAC (245)CCCAUAA (102) AUAAAGUAGAAAGCACUACUAA (246) AGUAGAA (103)CAUAAAGUAGAAAGCACUAC (247) AAGUAGA (104) CAUAAAGUAGAAAGCACUACUAA (248)AUAAAGUAGAAAGCACUACUA (249) CCCAUAAAGUAGAAAGCAC (250)CCCAUAAAGUAGAAAGCA (251) CAUAAAGUAGAAAGCACU (252)AUAAAGUAGAAAGCACUACU (253) UAAAGUAGAAAGCACUACUAA (254)CCAUAAAGUAGAAAGCACUA (255) CCAUAAAGUAGAAAGCACUAC (256)AUAAAGUAGAAAGCACUA (257) CCAUAAAGUAGAAAGCACU (258)ACCCAUAAAGUAGAAAGCACUA (259) UAAAGUAGAAAGCACUACUA (260)CCCAUAAAGUAGAAAGCACUACU (261) AUAAAGUAGAAAGCACUAC (262)ACCCAUAAAGUAGAAAGCACU (263) UAAAGUAGAAAGCACUACU (264)CAUAAAGUAGAAAGCACUACUAAC (265) AAAGUAGAAAGCACUACUAA (266)AUAAAGUAGAAAGCACUACUAAC (267) AAGUAGAAAGCACUACUA (268) hsa-miR-142-3pUAGUGUU (105) GUAGUGUUUCCUACUUUAUGGA (269) AGUGUUU (106)UGUAGUGUUUCCUACUUUAUGG (270) GUGUUUC (107) GUAGUGUUUCCUACUUUAUGG (271)GAGUGUA (108) UGUAGUGUUUCCUACUUUAUG (272) UGAGUGU (109)UGUAGUGUUUCCUACUUUAU (273) UGUAGUG (110) GUAGUGUUUCCUACUUUAUG (274)GUAGUGU (111) UAGUGUUUCCUACUUUAUGGA (275) UGUAGUGUUUCCUACUUU (276)UGUAGUGUUUCCUACUUUA (277) UAGUGUUUCCUACUUUAUGG (278)GUAGUGUUUCCUACUUUAUGGAU (279) UGAGUGUACUGUGGGCUUCGG (280)GUAGUGUUUCCUACUUUAU (281) AGUGUUUCCUACUUUAUGGAU (282)AGUGUUUCCUACUUUAUGGA (283) UGAGUGUACUGUGGGCUUCGGA (284)GUGUAGUGUUUCCUACUUUAUG (285) AUGAGUGUACUGUGGGCUUCGGA (286)UAGUGUUUCCUACUUUAUG (287) AGUGUUUCCUACUUUAUGGAUGA (288)AGUGUUUCCUACUUUAUGGAUG (289) hsa-miR-9 CUUUGGU (112)UCUUUGGUUAUCUAGCUGUAUG (290) UUUGGUU (379) UCUUUGGUUAUCUAGCUGUA (291)UUGGUUA (380) UCUUUGGUUAUCUAGCUGUAU (292) UCUUUGG (381)UCUUUGGUUAUCUAGCUGU (382) CUUUGGUUAUCUAGCUGUAUGA (383)UCUUUGGUUAUCUAGCUG (384) UCUUUGGUUAUCUAGCUGUAUGAG (385)CUUUGGUUAUCUAGCUGUAUG (386) UUUGGUUAUCUAGCUGUAUGA (387)CUUUGGUUAUCUAGCUGUAU (388) CUUUGGUUAUCUAGCUGUA (389)CUUUGGUUAUCUAGCUGUAUGAG (390) AUCUUUGGUUAUCUAGCUGUAUG (391)UUUGGUUAUCUAGCUGUAUGAG (392) AUCUUUGGUUAUCUAGCUGUAUGA (393)CUUUGGUUAUCUAGCUGU (394) UCUUUGGUUAUCUAGCUGUAUGAGU (395)AUCUUUGGUUAUCUAGCUGUA (396) hsa-miR- 9* UAAAGCU (113)UAAAGCUAGAUAACCGAAAGUA (293) AAAGCUA (114) UAAAGCUAGAUAACCGAAAGU (294)AAGCUAG (115) UAAAGCUAGAUAACCGAAAGUAA (295)AUAAAGCUAGAUAACCGAAAGUA (296) AUAAAGCUAGAUAACCGAAAG (297)AUAAAGCUAGAUAACCGAAA (298) AUAAAGCUAGAUAACCGAAAGUAA (299)UAAAGCUAGAUAACCGAAAG (300) UAAAGCUAGAUAACCGAAAGUAAA (301)UAAAGCUAGAUAACCGAAA (302) UAAAGCUAGAUAACCGAAAGUAG (303)AAAGCUAGAUAACCGAAAGU (304)

TABLE 8 Sequences of Anti-miRNAs (5′ to 3′ direction) based on mature miRNA sequences (5′ to 3′ direction) obtained from  miRBase (release 16: Sept 2010; www.mirbase.org). microRNA mature miRNASEQ ID NO SEQ Anti-miRNA (5′-3′) hsa-mir-132 hsa-miR-132 305CGACCAUGGCUGUAGACUGUUA hsa-mir-132 hsa-miR-132* 306AGUAACAAUCGAAAGCCACGGU hsa-mir-126 hsa-miR-126 307CGCAUUAUUACUCACGGUACGA hsa-mir-126 hsa-miR-126* 308CGCGUACCAAAAGUAAUAAUG hsa-mir-21 hsa-miR-21 309 UCAACAUCAGUCUGAUAAGCUAhsa-mir-21 hsa-miR-21* 310 ACAGCCCAUCGACUGGUGUUG

REFERENCE LIST

-   Adams R. H. and Alitalo K. Molecular regulation of angiogenesis and    lymphangiogenesis. Nat Rev Mol Cell Biol 8(6):464-478, 2007.-   Anand S., Majeti B. K., Acevedo L. M., Murphy E. A., Mukthavaram R.,    Scheppke L., Huang M., Shields D. J., Lindquist J. N., Lapinski P.    E., King P. D., Weis S. M. and Cheresh D. A. MicroRNA-132-mediated    loss of p120RasGAP activates the endothelium to facilitate    pathological angiogenesis. Nat Med 16(8):909-914, 2010.-   Aravin, A. & Tuschl, T. Identification and characterization of small    RNAs involved in RNA silencing. FEBS Lett 579:5830-40, 2005.-   Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver    M., Kearne M., Magner M. and Isner J. M. Bone marrow origin of    endothelial progenitor cells responsible for postnatal    vasculogenesis in physiological and pathological neovascularization.    Circ Res 85(3):221-228, 1999.-   Beijnum, J. R., Rousch, M., Castermans, K., van der Linden, E &    Griffioen, A W. Isolation of endothelial cells from fresh tissues,    Nature Protocols 3(6):1085-1091, 2008.-   Berezikov, E., Cuppen, E., and Plasterk, R. H. Approaches to    microRNA discovery, Nat Genet. 38 Suppl, S2-7, 2006.-   Berezikov, E., Liu, N., Flynt, A. S., Hodges, E., Rooks, M.,    Hannon, G. J., and Lai, E. C. Evolutionary flux of canonical    microRNAs and mirtrons in Drosophila, Nat Genet. 42,:6-9; author    reply 9-10, 2010.-   Berezikov, E., Robine, N., Samsonova, A., Westholm, J. O., Naqvi,    A., Hung, J. H., Okamura, K., Dai, Q., Bortolamiol-Becet, D.,    Martin, R., Zhao, Y., Zamore, P. D., Hannon, G. J., Marra, M. A.,    Weng, Z., Perrimon, N., and Lai, E. C. Deep annotation of Drosophila    melanogaster microRNAs yields insights into their processing,    modification, and emergence, Genome Res 21:203-215, 2011.-   Bodles-Brakhop A M, Heller R and Draghia-Akli R. Electroporation for    the Delivery of DNA-based Vaccines and Immunotherapeutics: Current    Clinical Developments. Molecular Therapy vol. 17 no. 4:585-592,    April 2009-   Bonnet, E., Wuyts, J., Rouze, P. and Van De, P. e. Y. Evidence that    microRNA precursors, unlike other non-coding RNAs, have lower    folding free energies than random sequences. Bioinformatics    20:2911-2917, 2004.-   Carmeliet P. Angiogenesis in life, disease and medicine. Nature    438(7070):932-936, 2005.-   Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med    6(4):389-395, 2000.-   Carmeliet P. and Jain R. K. Angiogenesis in cancer and other    diseases. Nature 407(6801):249-257, 2000.-   Chang T. C. and Mendell J. T. microRNAs in vertebrate physiology and    human disease. Annu Rev Genomics Hum Genet. 8:215-239, 2007.-   Chen C. Z., Li L., Lodish H. F. and Bartel D. P. MicroRNAs modulate    hematopoietic lineage differentiation. Science 303(5654):83-86,    2004.-   Creighton, C J., Reid, J G. and Gunaratne, P H. Expression profiling    of microRNAs by deep sequencing. Briefings in Bioinformatics.    VOL 10. NO 5:490-497, 2009.-   Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I.,    Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E.,    Messina, J. L. and Heller, R. Phase I Trial of Interleukin-12    Plasmid Electroporation in Patients With Metastatic Melanoma.    Journal of clinical oncology 26(36):5896-903, 2008.-   Fish J. E., Santoro M. M., Morton S. U., Yu S., Yeh R. F., Wythe J.    D., Ivey K. N., Bruneau B. G., Stainier D. Y. and Srivastava D.    miR-126 regulates angiogenic signaling and vascular integrity. Dev    Cell 15(2):272-284, 2008.-   Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J.    Med. 285, 21:1182-1186, 1971.-   Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other    disease. Nat Med 1(1):27-31, 1995.-   Folkman J. Angiogenesis: an organizing principle for drug discovery?    Nat Rev Drug Discov 6(4):273-286, 2007.-   Folkman J. Role of angiogenesis in tumor growth and metastasis.    Semin Oncol 29(6 Suppl 16):15-18, 2002.-   Griffioen A. W. and Molema G. Angiogenesis: potentials for    pharmacologic intervention in the treatment of cancer,    cardiovascular diseases, and chronic inflammation. Pharmacol Rev    52(2):237-268, 2000.-   Hanahan D. and Folkman J. Patterns and emerging mechanisms of the    angiogenic switch during tumorigenesis. Cell 86(3):353-364, 1996.-   Harris T. A., Yamakuchi M., Ferlito M., Mendell J. T. and    Lowenstein C. J. MicroRNA-126 regulates endothelial expression of    vascular cell adhesion molecule 1. Proc Natl Acad Sci USA    105(5):1516-1521, 2008.-   Helisch A. and Schaper W. Arteriogenesis: the development and growth    of collateral arteries. Microcirculation 10(1):83-97, 2003.-   Heusschen R, van Gink M, Griffioen A W, Thijssen V L. MicroRNAs in    the tumor endothelium: novel controls on the angioregulatory    switchboard. Biochim Biophys Acta. 1805, 1:87-96, 2010-   Hofacker, I. L. Vienna RNA secondary structure server. Nucleic Acids    Res 31:3429-31, 2003. Kuehbacher A., Urbich C., Zeiher A. M. and    Dimmeler S. Role of Dicer and Drosha for endothelial microRNA    expression and angiogenesis. Circ Res 101(1):59-68, 2007.-   le Sage C., Nagel R., Egan D. A., Schrier M., Mesman E., Mangiola    A., Anile C., Maira G., Mercatelli N., Clafre S. A., Farace M. G.    and Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221    and miR-222 promotes cancer cell proliferation. EMBO J.    26(15):3699-3708, 2007.-   Linsen, S E V., de Wit, E., de Bruijn, E.& Cuppen, E. Small RNA    expression and strain specificity in the rat. BMC Genomics 11:249,    2010.-   Miki K., Miki A., Matsuoka M., Muramatsu D., Hackett S. F.,    Campochiaro P. A. Effects of Intraocular Ranibizumab and Bevacizumab    in Transgenic Mice Expressing Human Vascular Endothelial Growth    Factor. Ophthalmology 116(9):1748-1754, September 2009.-   Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, 0.,    Ruse, C., Fu, C., Lindow, M., Stenvang, M., Straarup, E. M.,    Frydenlund Hansen, F., Koch, T., Pappin, D., Hannon, G. J., and    Kauppinen, S. Silencing of microRNA families by seed-targeting tiny    LNAs. Nature Genetics 43,371-378, 2011.-   Poliseno L., Tuccoli A., Mariani L., Evangelista M., Citti L., Woods    K., Mercatanti A., Hammond S, and Rainaldi G. MicroRNAs modulate the    angiogenic properties of HUVECs. Blood 108(9):3068-3071, 2006.-   Poy M. N., Eliasson L., Krutzfeldt J., Kuwajima S., Ma X.,    Macdonald P. E., Pfeffer S., Tuschl T., Rajewsky N., Rorsman P. and    Stoffel M. A pancreatic islet-specific microRNA regulates insulin    secretion. Nature 432(7014):226-230, 2004.-   Ribatti D., Vacca A. and Presta M. The discovery of angiogenic    factors: a historical review. Gen Pharmacol 35(5):227-231, 2000.-   van Rooij E., Sutherland L. B., Qi X., Richardson J. A., Hill J. and    Olson E. N. Control of stress-dependent cardiac growth and gene    expression by a microRNA. Science 316(5824):575-579, 2007.-   Shen et al. Suppression of ocular neovascularization with siRNA    targeting VEGF receptor 1. Gene therapy 13:225-234, 2006.-   Steffen P., Voss B., Rehmsmeier M., Reeder J., Giegerich R.    RNAshapes: an integrated RNA analysis package based on abstract    shapes. Bioinformatics, 22:500-503, 2006-   Suarez Y., Fernandez-Hernando C., Pober J. S, and Sessa W. C. Dicer    dependent microRNAs regulate gene expression and functions in human    endothelial cells. Circ Res 100(8):1164-1173, 2007.-   Vader P, van der Meel R, Symons M H, Fens M H, Pieters E, Wilschut K    J, Storm G, Jarzabek M, Gallagher W M, Schiffelers R M, Byrne A T.    Examining the role of Rac1 in tumor angiogenesis and growth: a    clinically relevant RNAi-mediated approach. Angiogenesis. 2011    December; 14(4):457-66, 2011.-   Wang S., Aurora A. B., Johnson B. A., Qi X., McAnally J., Hill J.    A., Richardson J. A., Bassel-Duby R. and Olson E. N. The    endothelial-specific microRNA miR-126 governs vascular integrity and    angiogenesis. Dev Cell 15(2):261-271, 2008.-   de Wit, E., Linsen, S. E., Cuppen, E., and Berezikov, E. Repertoire    and evolution of miRNA genes in four divergent nematode species,    Genome Res 19:2064-2074, 2009.

1. A miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule,an equivalent such as a mimic, an isomiR or a source thereof or acomposition comprising said miRNA-9, miRNA-574, miRNA-7, miRNA-190band/or miRNA-142 molecule, equivalent or source thereof for use as amedicament for preventing, treating, reverting, curing and/or delayingneo-angiogenesis or a disease or a condition associated withneo-angiogenesis.
 2. A miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/ormiRNA-142 molecule, an equivalent such as a mimic, an isomiR or a sourcethereof or a composition comprising said miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 equivalent or source thereof according toclaim 1, wherein the disease or condition associated withneo-angiogenesis is a cancer.
 3. A miRNA-9 molecule, an equivalent or asource thereof or a composition comprising said miRNA-9, equivalent orsource thereof according to claim 1, which is a miRNA-9* molecule, anequivalent or a source thereof or a composition comprising said miRNA-9*molecule, equivalent or source thereof.
 4. A composition according toclaim 1, further comprising another miRNA molecule, equivalent such as amimic, an isomiR or source thererof selected from: a) a miRNA-9, amiRNA-190b, a miRNA-7, a miRNA-574 and/or a miRNA-142 molecule, and/orequivalent of such as a mimic or an isomiR and/or a source thereof, b)optionally at least one of miRNA-26b, miRNA-27a, miRNA-92a, miRNA-221,miRNA-222, miRNA-145 and a let7a1 molecule, and/or an equivalent of suchas a mimic or an isomiR and/or a source thereof, c) and optionally atleast one antagomir of a miRNA-132, miRNA-126 and miRNA-21 and/or anequivalent and/or a source thereof.
 5. A method for preventing,treating, reverting and/or delaying neo-angiogenesis or a condition ordisease associated with neo-angiogenesis by administering a miRNA, anequivalent or a source thereof or composition as defined in claim 1 to asubject in the need thereof.
 6. A method for diagnosing neo-angiogenesisor a disease or condition associated with neo-angiogenesis in a subject,the method comprising the steps of: (a) determining the expression levelof a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule,an equivalent or a source thereof in a subject, and optionally (b)comparing the expression level of said molecule equivalent or sourcethereof as defined in (a) with a reference value for the expressionlevel of said molecule, equivalent or source thereof, the referencevalue preferably being the average value for the expression level ofsaid molecule, equivalent or source thereof in a healthy subject.
 7. Amethod according to claim 6, comprising in step (a) determining theexpression level of another miRNA molecule, equivalent or source thereofas identified in claim
 4. 8. A method according to claim 7, whereinneo-angiogenesis or a disease or condition associated withneo-angiogenesis is diagnosed when the comparison leads to the findingof a decrease of the expression level of said miRNA-9, miRNA-574,miRNA-7, miRNA-190b and/or miRNA-142 molecule, equivalent or a sourcethereof.
 9. A method according to claim 7, wherein neo-angiogenesis or adisease or condition associated with neo-angiogenesis is diagnosed whenthe comparison leads to the finding of a decrease of the expressionlevel of said miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142molecule, equivalent or a source thereof and a decrease of theexpression level of at least one of another miRNA molecule, equivalentor a source thereof as identified in claim 4 a) and/or b) and/or anincrease of the expression level of at least one of another miRNAmolecule, equivalent or a source thereof as identified in claim 4 c).10. A method according to claim 6, wherein the expression level of saidmiRNA is determined indirectly by quantifying the amount of thenucleotide sequence.
 11. A method according to claim 6, wherein theexpression level is determined ex vivo in a sample obtained from thesubject.
 12. A method for identification of a substance capable ofpreventing, treating, reverting and/or delaying neo-angiogenesis or acondition or disease associated with neo-angiogenesis in a subject, themethod comprising the steps of: (a) providing a test cell populationcapable of expressing a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/ormiRNA-142 molecule or equivalent thereof, preferably the test populationcomprises bladder cells, more preferably the test cell populationcomprises mammalian cells, even more preferably human cells; (b)contacting or incubating the test cell population with the substance;(c) determining the expression level of said miRNA-9, miRNA-574,miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent thereof orthe activity or steady state level of said miRNA-9, miRNA-574, miRNA-7,miRNA-190b and/or miRNA-142 molecule or equivalent thereof in the testcell population contacted or incubated with the substance; (d) comparingthe expression, activity or steady state level determined in (c) withthe expression, activity or steady state level of said miRNA-9,miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalentin a test cell population that is not contacted with the substance; and,(e) identifying a substance that produces a difference in expressionlevel, activity or steady state level of said miRNA-9, miRNA-574,miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent, between thetest cell population that is contacted with the substance and the testcell population that is not contacted with the substance.
 13. A methodaccording to claim 12, whereby the expression levels, activities orsteady state levels of at least another one miRNA molecule, equivalentor source thereof is compared, preferably wherein the other miRNAmolecule, equivalent or source thereof is as identified in claim 4.